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Abstract 
Breast Cancer Risk Factors and Associations with Breast Cancer Tumor Characteristics in 
High Risk Populations 
Meghan E. Work 
Background: Estrogen receptor (ER)- and progesterone receptor (PR)-negative (ER-PR-) breast 
cancer is associated with higher grade and poorer prognosis compared with other breast cancer 
subtypes. High parity, coupled with lack of breastfeeding, has been associated with an increased 
risk of ER-PR- cancer. The mechanism of this etiology is unclear, and may be obfuscated by ER 
and PR correlation with each other as well as other prognostic tumor characteristics. 
Methods: Using population-based and clinic-based ascertained cases and controls from the 
Breast Cancer Family Registry, I examined reproductive risk factors, including parity, 
breastfeeding, and oral contraceptive  (OC) use, in relation to ER and PR status, using 
polytomous logistic regression (for the population-based data) and the method of generalized 
estimating equations (GEE) (for the clinic-based data) as well as the pseudo-conditional 
likelihood approach, which accounts for correlated outcome variables. 
Results: High parity (≥ 3 live births) combined with lack of breastfeeding, was positively 
associated with ER-PR- tumors (odds ratio [OR]=1.57, 95% confidence interval [CI] 1.10-2.24, 
population-based cases vs. controls) relative to nulliparity. There was no association with ER-
PR- tumors and parity in women who breastfed (OR=0.93, 95%CI 0.71-1.22) relative to 
nulliparous women. Associations with ER-PR- cancer were higher across all races/ethnicities 
among women who did not breastfeed compared with women who did. Population-based and 
clinic-based data were generally in agreement (OR=2.07, 95% CI 1.09-3.91, clinic-based cases 
vs. controls, relative to nulliparity). When adjusted for the correlation of PR-status and grade, to 
ER-status, the association between high parity +lack of breastfeeding and ER- status, was 
maintained. OC use before year 1975 was associated with an increased risk of ER-PR- tumors 
(OR=1.32, 95% CI 1.04-1.67, population-based data, cases vs. controls) relative to never use of 
OCs. For women who began OC use in 1975 or later there was no increased risk.  Analysis of 
OC use in clinic-based data agreed with the findings of the population-based data.  
Conclusions: My findings support that there are modifiable factors for ER-PR- breast cancer, 
and that breastfeeding in particular may mitigate the increased risk of ER-PR-cancers seen from 
multiparity. The mechanism of both risk and risk mitigation may operate primarily through the 
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Chapter 1—Risk Factors and Breast Cancer Tumor Characteristics: A Review  
 
1A. INTRODUCTION 
It is estimated that nearly 237,000 women in the United States were diagnosed with breast cancer 
in 2014 (the most recent year numbers were available) and more than 42,000 women died from 
the disease (source: U.S. Centers for Disease Control and Prevention). While age-specific rates 
of invasive breast cancer in women 45 and above decreased between 1999 and 2003 [1], these 
rates stabilized by 2008, and the rate in 2016 was expected to be similar to 2008 [2]. Meanwhile, 
rates among women under the age of 40 have increased slightly [3]. Mortality from breast cancer 
has been reduced in recent years, with increases in screening leading to early detection and 
treatment, and innovations in treatments for the disease resulting in longer survival times. 
Despite overall reductions in mortality, disparities in mortality among African-American and 
Caucasian breast cancer patients have persisted and even increased, such that African-American 
women are more likely to die from their breast cancer than Caucasians [4]. Studies have 
indicated that this disparity may partly occur due to different incidence of breast cancer 
“subtypes” among African Americans and Caucasians, such that African-Americans have higher 
rates of breast cancer subtypes that are more resistant to treatment and are associated with poorer 
prognosis [5-8]. In addition, the increasing incidence of breast cancer among younger women is 
of concern because these women more commonly present with tumor characteristics, such as 
high tumor grade and ER- and/or PR-negativity, which render the tumor less amenable to 
currently available treatments and are associated with poorer prognosis [9-11].  
Previous research into breast cancer etiology has identified a host of breast cancer risk factors, 
some of which are strong predictors of breast cancer but are of low prevalence in both the 
general and breast cancer population (including genetic factors such as BRCA1 and BRCA2 
mutation and first-degree family history), and others that may be considered intermediate, but 
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modifiable, markers of breast cancer risk, such as breast density. In addition to these stronger 
factors, which confer greater than 2-fold risk, there are a number of established risk factors of 
high population prevalence that appear to have modest individual effects on breast cancer risk, 
including reproductive factors such as nulliparity, early age at menarche and late age at first 
birth, lack of breastfeeding, and use of exogenous hormones, including oral contraceptives and 
hormone replacement therapies [12, 13]. Because these latter breast cancer risk factors are 
typically found to be modest in effect (conferring <2 fold increased risk), it can be difficult to 
rule out bias as an explanation for associations, and findings are often inconsistent across studies. 
This may be because, rather than being a singular entity, breast cancer is a heterogeneous 
disease, with different etiologic factors contributing to disease causation to a greater or lesser 
degree depending on breast cancer type.  
Due to greater understanding of tumor biology and of the importance of tumor markers, breast 
cancer, like many other cancers, is rarely regarded as a single homogenous disease, not only in 
terms of treatment and prognosis, but also when understanding cancer risk. The current paradigm 
for many cancers, including breast cancer, is to examine risk factors for cancer subdivided by 
tumor characteristics or biomarkers, rather than as a single entity. In breast cancer, most such 
studies have focused on defining breast cancer by the tumor characteristics of estrogen-receptor 
(ER) and progesterone receptor (PR) expression, and, beginning in the early 2000s, by human 
epidermal growth factor receptor 2 (HER2) expression, as these tumor characteristics are 
relevant for determining treatment options and cancer prognosis and proliferation rate. Tumor 
grade is a characteristic that is less commonly examined according to risk factor; however it is an 
important prognostic characteristic that has been demonstrated in some studies to differ 
according to risk factor [5, 14]. High tumor grade has been associated with self-reported family 
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history of breast cancer [15], and in breast cancers occurring among those with BRCA1 or 
BRCA2 positivity [16]. 
1B. BACKGROUND 
1.B.1 Overview of Breast Cancer Subtypes  
In the past 20 years, an increasingly abundant literature has surfaced to describe how known risk 
factors for breast cancer may differ among the different “subtypes” of breast cancer as defined 
by ER and PR status, by grade, and by molecular subtype. If risk factors differ among subtypes, 
then breast cancer should not be considered as a single disease entity whose development is a 
result of the same set of causal partners, but rather should be considered a heterogeneous 
condition. Indeed, from a treatment perspective, this division is already accepted: women who 
are both ER and PR negative are not treated with adjuvant hormonal therapies such as tamoxifen, 
which are ineffective in such women, while women of any ER/PR status who have breast cancer 
that presents as HER2+ are successfully treated with trastuzumab [17, 18].  
1.B.2 Breast Cancer Subtypes by Hormone Receptor Expression  
ER and PR status are the most widely studied markers in breast tissue [19]. While clinical and 
pathologic differences between breast cancers defined by ER and PR status are established, 
epidemiologic studies that have compared risk factors for receptor positive vs. receptor negative 
tumors have had ambivalent findings for some individual risk factors. However, they have 
established that risk factors for ER and PR status do differ by subtype, indicating the 
heterogeneous nature of breast cancer. Previous studies, the majority of which are case-control, 
typically compare ER+ breast cancer cases, and ER- cases, to controls, or consider ER and PR 
status jointly to arrive at four ER/PR- defined classifications, ER+PR+, ER+PR-, ER-PR+, and 
ER-PR-, which are typically compared to a control group that serves as a common referent 
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group. Less commonly, a case-only analysis is conducted, where ER+PR+ will serve as the 
reference group to which the other categories are compared. Because ER+PR- and ER-PR+ cases 
are less common, analyses are often underpowered to find statistically significant findings in 
these classifications. Some clinicians believe that any hormone positivity (ER+, PR+, or positive 
for both) should be analyzed as a group against those who are both ER and PR negative, however 
data have indicated that those who are positive for both markers have better treatment outcomes 
than those positive for only one marker [20, 21]. 
1.B.3 Breast Cancer “Molecular” Subtypes   
The understanding of HER2 as an important tumor marker that aids in determining optimal 
patient treatment, and the combination of this marker with the presence of ER and PR 
biomarkers, has resulted in the designation of four “molecular subtypes”, originally determined 
by intrinsic expression, but correlated with ER, PR, and HER2 status as follows: Luminal A (ER 
and/or PR+, HER2-), which typically comprises over 60% of the population; Luminal B (ER 
and/or PR+, HER2+),  which accounts for about 12% of the population, HER2+ (ER and PR-, 
HER2+), which accounts for less than 10% of the population, and triple-negative (ER-, PR-, and 
HER2-) types, which accounts for about 15% of the population [5, 22]. Although sometimes the 
term “basal-like” is used interchangeably with triple-negative cancer, whether a tumor is basal-
like is determined through tissue microarray or its IHC surrogate of CK5/6 CK14 and or EGFR 
expression, while determination of ER, PR, and HER2 negativity occurs through 
immunohistochemistry [23]. While there is overlap, not all triple-negative tumors are basal-like; 
the correlation between triple-negative and basal-like breast cancers is 70-80% according to 
studies [24, 25]. The term “triple-negative” will be used throughout this dissertation to connote 
that the subtype is determined immunohistochemically. The respective importance of various 
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risk factors, treatment effectiveness, and cancer outcome differ across these types [5, 6, 22, 26-
30]. Figure 1-1 represents the categorization of breast cancer into molecular subtypes.  
1.B.4 Other options for classifying tumors  
Although used less frequently, there are other appropriate sub-classifications of breast cancer for 
the purposes of examining risk factors by subtype. Tumors can be classified by histologic type 
[31-34], or by other intrinsic features that are associated with prognosis, such as tumor grade or 
tumor size, or features of the cancer, such as presence of positive nodes or cancer stage. 
However, these latter two features are largely predicated on when the tumor is diagnosed, rather 
than features that are intrinsic to the tumor, so examining risk factor associations with a 
characteristic such as stage may be complicated by factors associated with when the tumor is 
diagnosed (such as healthcare-seeking behavior) rather than an intrinsic function of the tumor. 
Lymph node status is positively correlated with grade and tumor size, however the relationship 
with ER and PR status is less clear; one study indicated that 46% of ER and PR positive tumors 
had positive nodes, while 53% of tumors that were ER and PR negative had positive nodes, 
indicating any correlation between ER and PR and nodal may be weak or nonexistent [35]. 
Additionally, expression of other receptors on tumor tissue may be of value for classification; 
expression of cell-cycle proteins, for example, is associated with poorer prognosis, and risk 
factors for cancers that do and do not express these proteins may differ [36].  
1.B.5 Tumor Grade  
In this dissertation, I will examine tumor grade, an important prognostic feature of breast cancer.  
Grade has been demonstrated to independently affect prognosis, regardless of tumor size or 
number of positive nodes (which represent other prognostic indicators) [37]. Tumor grade 
classifies cancer cells according to their appearance under a microscope (how abnormal they 
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look compared to normal breast tissue) and how quickly the tumor is likely to grow and spread. 
The Scarff-Bloom-Richardson system is the most common type of classification system used, 
and will be used for the data in this dissertation. In this scoring system, pathologists observe 
three features of the cancer cells to determine tumor grade: (1) the frequency of cell mitosis, (2) 
tubule formation (the percentage of cancer composed of tubular structures) and (3) nuclear 
pleomorphism (also known as nuclear grade), which describes the change in cell size and 
uniformity. Each of these features is assigned a score ranging from 1 to 3 (with 1 indicating a 
more normative situation, e.g., slower mitosis, fewer tubular structures, more uniform cells, and 
3 indicating a more radical situation). The scores of each the cell’s features are then added 
together for a final sum that ranges from 3 to 9. A tumor with a final sum of 3, 4, or 5 is 
considered to have a tumor grade of 1 (i.e., well-differentiated). A sum of 6 or 7 is Grade 2, or 
moderately differentiated, and a sum of 8 or 9 is Grade 3, considered poorly differentiated. Table 
1-1 describes the components of tumor grade. 
1.B.6 Breast Cancer Subtypes: The Role of Family History 
Family history is a well-established breast cancer risk factor, typically conferring a two-fold 
increased risk of breast cancer for women with one affected first-degree relative [38, 39]; this 
association can increase to a four-fold risk for women with 3 or more affected relatives [38]. 
Family history has been associated with all subtypes of breast cancer defined by hormone 
receptor status, both ER+ and ER-, PR+ and PR- [15, 40-47]. Therefore, family history appears 
to be a consistent risk factor for breast cancer across subtypes.  
There has been little exploration of how family history may modify the effect of risk factors on 
different tumor subtypes. This may partially result from the fact that, in average risk populations, 
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only 5-10% of cancer patients will have a positive first-degree family history of breast cancer, 
limiting the power to conduct sub-analyses on persons with family history.  
Familial breast cancer (FBC) is defined as either breast cancer that occurs among patients 
carrying mutations in the two known breast cancer susceptibility genes: BRCA1 and BRCA2, or 
that which occurs in cases with family history of the disease, that do not carry a known 
susceptibility gene (typically in a first or 2nd degree relative). While as many as 90% of persons 
carrying BRCA mutations will ultimately be diagnosed with breast or a related cancer [48], most 
FBC patients do not carry mutations in these genes. Examination of how breast cancer subtypes 
and other tumor characteristics associate with family history, particularly among those who are 
not BRCA1 or 2 positive, has been limited, and available studies have taken different approaches 
to examine this issue (See Table 1-2). 
Perhaps a more important question regarding the role of family history on breast cancer risk is 
what role environmental risk factors play in breast cancer risk in the presence or absence of 
family history. In my comprehensive review (see below), I have separated studies of “high-risk” 
women and risk factors for breast cancer defined by tumor subtype, from studies of “average-
risk” women. Included within the higher-risk group are studies that examine risk factors by 
tumor subtype among women with a first-degree family history of breast cancer. If we can 
understand how breast cancer risk factors affect risk in the presence of family history, women 
may be better able to make decisions that allow for reduction in overall risk. If, in addition, we 
can understand the role that these risk factors play in the etiology of subtypes with prognostic 
ramifications, in the presence or absence of family history, we could further tailor behavioral 
modifications to reduce the risk of those types of breast cancer associated with poorer survival, 
such as ER-PR- or triple-negative breast cancers. 
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Previous studies that have examined environmental breast cancer risk factors among women with 
a family history of BC include the Minnesota Breast Cancer Family Study, a study of 544 case 
families that found evidence that family history modifies the association between adolescent 
obesity, alcohol consumption, and OC use, and breast cancer risk. However, this study did not 
examine hormone-receptor defined subtypes of breast cancer. Other studies have compared 
strengths of associations between risk factors and breast cancer for women with a family history 
compared to those for women with no family history [49], but again, these associations have 
been examined using the outcome of invasive breast cancer as one homogenous condition, rather 
than via receptor-defined subtypes.  
This review will separate studies that examine women at high risk of breast cancer based on 
factors such as family history, age at diagnosis, and BRCA1 or BRCA2 status from studies that 
examine risk factors in average-risk populations. A population will be considered to be “high 
risk” if the examined population is premenopausal or consists entirely of women age 55 or 
younger, consists of a BRCA1 or BRCA2 positive population, or has a first-degree family history 
prevalence of breast cancer of 20% or more of the population (the 20% mark is similar to the 
first-degree family history proportion within the population-based sites of the Breast Cancer 
Family Registry, the population examined in this dissertation). The review will primarily cover 




1C. COMPREHENSIVE REVIEW OF CURRENT LITERATURE ON RISK FACTORS 
AND BREAST CANCER TUMOR CHARACTERISTICS 
1.C.1 Literature Search Criteria of Risk Factor Associations with Tumor Characteristics 
1.C.1.a  Literature Search for reproductive and hormonal risk factors associated with molecular 
subtype or similar 
To date, there has been one systematic review of reproductive risk factor associations with 
“molecular” subtypes, defined immunohistochemically by ER, PR, and HER2 status [30], as well 
as a review that included the association with reproductive risk factors and HR+, HER2+ and 
triple negative cancer subtypes [50] and some reviews (covering etiology, genetics, treatment, 
prognosis) specifically of the triple-negative subtype [23, 51-53]. 
For the purposes of this dissertation, I conducted a literature review of all publications examining 
risk factor relationships with the molecular subtypes Luminal A, Luminal B, HER2+, and Triple-
Negative breast cancer. Because the term “triple-negative” breast cancer did not appear until 
October of 2005 [23], this comprehensive review primarily covers literature published between 
October 1, 2005, and September 1, 2017. Prior to this date, there were a few publications that 
examined risk factors in relation to HER2 expression independent of ER/PR status [26, 54, 55], 
and these publications are included in the review.  
 A PubMed search using the terms: 
“molecular subtype” [Title/Abstract] OR (“molecular” [Title/Abstract] AND “subtype”[Title]) 
AND ("breast neoplasms"[Title] OR ("breast"[Title] AND "neoplasms"[Title]) OR 
("breast"[Title] AND "cancer" [Title]) OR "breast cancer" [Title]) AND ("women"[MeSH 
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Terms] OR "women"[Title/Abstract] OR "female"[Title/Abstract]) AND (“risk” [Title/Abstract] 
or “odds”[Title/Abstract] or “rate”[Title/Abstract]) AND “English”[lang] 
yielded 63 studies. After excluding clinical trials and studies that dealt with prognosis, treatment, 
survival, recurrence, genetic factors/polymorphisms, and studies that examined risk factors 
outside of the scope of this dissertation (e.g. mammographic density, diet, non-steroidal anti-
inflammatory use), or publications that were comments or letters, 13 studies remained for 
inclusion in the literature review. I then replaced the term “molecular subtype” in the above 
search with “triple-negative” and limited the search to title, which yielded 8 additional pertinent 
studies, then changed triple-negative to “basal-like” which yielded 2 additional pertinent studies. 
Replacing “triple-negative” with ER-PR-HER2- yielded no additional pertinent studies, and 
replacing “triple-negative” with “luminal” yielded no additional pertinent studies. Finally, I 
conducted a search that incorporated each risk factor of interest separately, to capture any 
remaining studies that had been missed, for example: 
“triple-negative” [Title/Abstract] OR (“molecular” [Title/Abstract] AND “subtype”[Title]) AND 
("breast neoplasms"[Title] OR ("breast"[Title] AND "neoplasms"[Title]) OR ("breast"[Title] 
AND "cancer" [Title]) OR "breast cancer" [Title]) AND ("women"[MeSH Terms] OR 
"women"[Title/Abstract] OR "female"[Title/Abstract]) AND (“parity”[MeSH Terms] or 
“parity”[Title/Abstract]) AND “English”[lang] 
For each search, the relevant risk factor, such as “parity” (the bolded term in the search string 
above) was inserted, and “luminal” was substituted for “triple-negative” such that 2 searches 
were conducted for each risk factor. This process yielded a total of 11 additional relevant papers. 
In total, I found 13+8+2+11=34 studies that met the initial criteria for review. The References 
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section of each study was examined to yield additional studies for review, however no additional 
studies were found. I additionally limited the review to those studies with a total sample size 
(cases and controls, where relevant) of 500 or more subjects, as studies with a smaller overall 
sample size are likely to be underpowered to detect associations in rarer subtypes (are likely to 
have fewer than 50 cases of HER2+, for example). This criterion eliminated 4/34 studies, 
yielding a body of 30 studies for review. 
1.C.1.b Literature Search for reproductive and hormonal risk factors associated with ER and/or 
PR Status 
The 30 studies ascertained above are the basis of information on risk factor associations with 
breast cancer classified by ER, PR, and HER2 status into the molecular subtypes denoted in 
Figure 1-1. I additionally reviewed the literature to ascertain papers on risk factors associated 
with breast cancer defined by ER, PR, or joint ER/PR status. 
A comprehensive review on this topic was published in 2004 by M. Althuis et al, in the journal 
Cancer Epidemiology Biomarkers and Prevention [19]. An additional review, specifically for 
breastfeeding, was published in 2015 by F. Islami et al, in Annals of Oncology. Finally, a review 
of reproductive risk factors for HR+ tumors as well as HER2+ and triple negative tumors was 
published in 2014 (Anderson et al, Breast Cancer Research and Treatment). A summary of these 
reviews, and an additional literature review of all publications examining risk factor relationships 
with ER status, PR status, and joint ER/PR status published between Feb. 1, 2004 (the last date 
of inclusion for the Althuis review) and September 1, 2017 was combined with the review of 
molecular subtypes. Specifically for breastfeeding, since a recent review has been published, a 
review is included only for articles published after the last date of paper inclusion for the Islami 
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review (8/27/14). In order to identify articles published on ER/PR, or joint ER/PR status between 
the dates specified, a PubMed search using the terms: 
(estrogen[Title/Abstract] OR progesterone[Title/Abstract] AND receptor[Title/Abstract] AND 
breast[Title/Abstract] AND cancer[Title/Abstract] AND parity[Title/Abstract]) AND 
(risk[Title/Abstract] OR odds[Title/Abstract] OR rate[Title/Abstract]) AND (English[lang] AND 
("2004/02/01"[PDAT]: "2017/09/01"[PDAT])) 
was conducted. The bolded term (“parity” in the example above) was replaced with each risk 
factor of interest, and a separate search run for each risk factor (parity, breastfeeding/lactation, 
age at first birth, age at menarche, oral contraceptive use, hormone replacement therapy) of 
interest, as well as for factors that may additionally be examined or adjusted for in the model 
(age, race, menopausal status, education, body mass index [BMI], smoking, alcohol use). Papers 
that classified breast cancer using the “molecular subtypes” rather than just ER and PR status 
were examined separately and reviewed using the criteria noted in section 1.C.1.a above. This 
method yielded 102 studies for “parity”, 42 studies for “breastfeeding” or “lactation”, 47 studies 
for “contraceptive”, 85 studies for “menarche”, 29 studies for “age at first birth” and 150 studies 
for “exogenous hormone” or “hormone replacement therapy”. After excluding studies that dealt 
with prognosis, treatment, survival, recurrence, genetic factor/polymorphisms, studies that 
examined risk factors outside of the scope of this dissertation (e.g. mammographic density, diet, 
non-steroidal anti-inflammatory use), studies that were redundant across searches, and comments 
or letters, the search terms above yielded a total of 56 pertinent studies (including reviews). 
These 56 studies are distinct from those found using the molecular subtype search terms. 
 13 
 
Papers meeting these criteria were then examined to determine if they consisted of a sample of at 
least 500 subjects, and bibliographies examined to yield additional studies. Five of fifty-six 
papers included fewer than 500 subjects, however two of these papers (Largent et al, 2005 and 
Jia et al, 2015) examined risk factors and ER status in women 35 years of age or younger. Thus, 
I did not exclude these papers because they examined a high risk population. Examination of 
bibliographies yielded two additional pertinent references. Thus, 55 papers on ER/PR status 
published since the Althuis review are included in the comprehensive review. 
1.C.1.c  Literature Search for reproductive and hormonal risk factors associated with tumor 
grade 
Tumor grade is under-examined in terms of its relation to typical breast cancer risk factors. No 
previous review of risk factor associations with tumor grade exists. To search for literature 
associating risk factors of interest with tumor grade, I conducted a literature search in PubMed 
using the following search terms: 
Breast [Title/Abstract] AND cancer [Title/Abstract] AND “parity” [Title/Abstract] AND grade 
[Title/Abstract]  
“Parity” was replaced in consecutive searches with the other risk factors of interest, as was done 
for the previous searches. Thirteen total pertinent studies examining tumor grade were found. 
The bibliographies of these studies were examined to yield additional references, revealing one 
other pertinent reference, for a total of 14 studies. Because of the overall paucity of papers in this 
field, I did not limit the sample size for inclusion of papers examining the association with 
relevant risk factors and grade.  
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1.C.2 Findings of Review 
The results of the review of hormonal and reproductive risk factors for average-risk populations 
are summarized by risk factor of interest in Table 1-3. The results of the comprehensive review 
for high-risk population are summarized in Table 1-4. While the table of study findings of 
average-risk populations includes summary across multiple studies, Table 1-4, of high-risk 
populations, describes results of individual studies. To my knowledge, the below review is the 
first to review the literature regarding breast cancer risk factors and tumor characteristics, 
specifically within higher-risk populations, as well as the first review of risk factors on tumor 
grade. 
1.C.2.a  Risk Factor: Parity 
ER, PR, and joint ER/PR status: The results of the Althuis et al review found that any parity, 
compared with nulliparity, reduced risk of ER positive, but not ER negative, tumors in most 
instances, with risk estimates ranging from 0.5-0.8 (compared with controls), and the greatest 
reduction in risk found for multiparous women [19]. The review’s findings regarding whether PR 
status is affected by parity appear to indicate that PR+ women are more likely to be nulliparous 
[19]. Of the studies in average-risk populations published since Althuis that examine ER status, 
ten have supported that parity reduces ER+, but not ER- breast cancer when compared to a 
control group [56-65]. The review of HR+ cancers found that an inverse association between 
parity and HR+ breast cancer was present in 19 of 22 studies [50]. Only Iwasaki et al examined 
PR status alone, and found it unrelated to parity [66]. Four studies, by Nichols et al, 
(premenopausal women), Jia et al (women under age 36), Largent et al (women under age 35) 
and Bertrand et al (African-American women under age 45) examined parity and ER status in a 
 15 
 
high-risk category of women [55, 67-69] . Nichols and Bertrand found results regarding ER- 
status similar to those found in average risk populations, while Jia found increased likelihood of 
ER+ tumors, with higher parity, and Largent found no association between parity and ER status 
(Table 1-3 and Table 1-4). 
Regarding joint ER/PR status, Althuis et al found equivocal results in regards to parity, however, 
some of the differences in findings may have been attributable to differences in age distribution 
of the population studied, or selection bias associated with missing receptor status [63]. Since 
2004, the additional studies that have examined the relation between parity and joint ER/PR 
status, including one meta-analysis [70], have usually found that parity is associated with 
reduced risk of ER+/PR+, but not ER-/PR- cancer (See Table 1-3). In three studies, higher parity 
was associated with an elevated risk of ER-PR- cancer, when compared with controls [71] and 
compared with ER+PR+ cases [65, 72], while a few studies indicated that parity did not differ by 
joint ER/PR status [41, 73]. One study examined a high risk population, women <50 years of age 
[27]. In this population, the protective effect of parity was confined to ER+/PR+ cancers 
(compared with controls), and increased with each additional pregnancy.  
Molecular subtype: The first published paper to examine the association between parity and 
“molecular subtype”, by Millikan et al in 2007, found that “basal-like” breast cancer, often used 
synonymously with “triple-negative” cancer, was positively associated with parity, in contrast to 
the findings for Luminal A cancer, where parity was protective [6]. Since Millikan’s publication, 
many additional studies have confirmed or supported these findings [28, 59, 65, 74-80], while 
several studies have found no overall differential association with parity and molecular subtype 
[80-84]. A review article was published in 2016, which indicated that parity was protective 
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against developing the Luminal breast cancer subtypes, across 12 studies, of 15 evaluated [30]. 
For the HER2 subtype, one study indicated no association with parity [30]; however a case-only 
analysis indicated increased risk of HER2+ cancer, with increased parity, compared with 
Luminal A cancer [85]. While Kwan et al found no overall association between parity and 
molecular subtype, case-only analysis found that women who had three or more children and 
never breastfed were at increased risk for triple-negative or HER2+ cancers [81].  
Only one study examined the association between parity and molecular subtype in a high risk 
population, although others limited their analyses to certain ethnicities that are at higher risk for 
triple-negative cancer specifically [6, 76, 79]. The study of high-risk women (younger than age 
45) only examined triple-negative cancer compared to non-triple negative cancer; there was no 
association between parity and triple-negative cancer [68]. 
Grade: I found five studies that examined the association of parity and tumor grade [54, 86-88], 
all of which had slightly different findings. In Butt et al, nulliparity was more strongly associated 
with grade 3 tumors, compared with grade 1,2 tumors, while Albrektsen et al and Somasegar et 
al found no overall association between parity (vs. nulliparity) and tumor grade, but Albrektsen 
found that among parous women, higher parity was associated with more undifferentiated 
tumors, a component of tumor grade. In the two studies conducted in a high risk population, 
Largent et al and Jia et al found no association between parity and grade in women diagnosed 
with breast cancer prior to age 35 [54, 69]. 
1.C.2.b Risk Factor: Age at first birth 
ER, PR, and joint ER/PR status: The results of the Althuis et al review found that a later age at 
first live birth was more consistently observed for ER-positive rather than ER-negative tumors, 
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with older ages in ER+ women associated with risk estimates ranging from 1.4 to 2.6 (Table 1-
3). Another review in 2014 confirmed these findings, for HR+ tumors [50]. Of the studies 
published since the Althuis review, five studies found a positive association with late age at first 
birth and ER+, but not ER- breast cancer, while three studies found no such association. Althuis 
et al found no elevated risk specifically associated with PR expression [19]. Additional studies 
examining PR status have not found any association with PR status and age at first birth [65, 89]. 
In the review by Althuis, among studies that assessed joint ER/PR expression, there was a 
modest increase in hormone-receptor (HR) positive but not HR negative tumors among women 
with an older age at first birth. Most studies published since the review support this finding. A 
meta-analysis published in 2006, which used many of the same studies reviewed in the Althuis et 
al paper, found that women in the oldest age at first birth category were on average at 27% 
increased risk of ER+PR+ cancer, but age at first birth was not associated with ER-PR- cancer 
[70]. Five additional studies support this finding, including one in a case-only analysis of a high 
risk population [27]. However, other studies found positive associations with ER-PR- cancer [63, 
71, 90] or with ER+ PR- cancer [73] and late age at first birth. Studies of high-risk populations 
have been inconsistent in regard to age at first birth and ER/PR status (Table 1-4). 
Molecular subtype: Millikan et al in 2007, found that “basal-like” breast cancer was positively 
associated with a younger age at first full-term pregnancy, while Luminal A cancer was 
associated with older age at first full-term pregnancy [6]. Since Millikan’s publication, three 
additional studies and a meta-analysis have confirmed these findings [30, 59, 74, 80], however 
four studies have either not found an association between age at first birth and molecular subtype 
[81-83] or found an association with late age at birth and HER2+, but not ER+, breast cancer 
[75]. Of two studies that examined the association between age at first birth and molecular 
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subtype in a high risk population, one found an inverse association between age at first birth and 
triple-negative breast cancer, and one found no association between age at first birth and subtype 
[68, 91]. Given the lack of agreement in findings, the relation between age at first birth and 
molecular subtype is unclear. 
Grade: In Butt et al, there was a statistically significant positive association between late age at 
first live birth and grade 3 tumors. In Albrektsen et al, later age at first birth was associated with 
fewer high grade tumors, compared to earlier age at first birth. In the study of women <age 35, 
Largent et al found that early age (<20 years) at first full-term pregnancy was positively 
associated with tumors of higher grade, refuting the findings by Butt in an average risk 
population [54], while Jia et al found no association between grade and age at first birth [69].  
1.C.2.c  Risk Factor: Age at menarche 
ER, PR, and joint ER/PR status: Older age at menarche was not associated with individual ER or 
PR status in the studies reviewed by Althuis in 2004, and age at menarche was not related to 
breast cancer risk at all, in a higher-risk population. However in case-only analysis, PR 
negativity was inversely associated with early age at menarche, compared to PR+ status [65]. 
Where ER and PR status were defined jointly, ER+/PR+ cancer was inversely associated with 
older age at menarche, with risk estimates ranging from 0.5 to 0.8, compared with menarche at 
younger ages, but was not associated with any hormone negative cancers (ER-PR+, ER+PR, ER-
PR-)[19]. Since the Althuis review, a meta-analysis and 3 additional studies, including one that 
studied women under the age of 50, found that late age at menarche was not differentially 
associated in hormone-receptor positive cancers, although late age at menarche was associated 
with decreased breast cancer risk overall [27, 63, 70, 73, 92, 93]. In contrast, Cui et al found late 
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age at menarche was inversely associated with ER+, but not ER- tumors[57], Rosenberg et al 
found that earlier menarche (< age 12 years) was associated with ER-PR- cancer [41] and 
Setiawan et al, in the Multi-Ethnic Cohort study, found that late age at menarche (≥15) was 
associated with a protective effect against ER+PR+, but not ER-PR- cancers [40], as did Ritte et 
al, in their cohort study [61]. 
Molecular subtype: Millikan et al found no association between age at menarche and molecular 
subtype of breast cancer, in case-only analyses [6]. Additional studies have confirmed the 
Millikan findings [74], found a positive association between early age at menarche and the 
HER2 subtype [82] and a positive association between early age at menarche and Luminal 
subtype, but not other subtypes [72, 80]. A 2014 review indicated that younger age at menarche 
increased risk for HR+ breast cancer in about ½ of studies reviewed, but was rarely associated 
with HER2+ or Triple-negative breast cancer [50]. 
Grade: In the only study of an average-risk population, early age at menarche (≤11) was 
associated with a two-fold increased risk of medium or high grade tumors, compared to low 
grade tumors [94]. In the study of the high risk population of incident cases ≤ 35, age at 
menarche was not associated with grade [54].  
1.C.2.d Risk Factor: Breastfeeding 
ER, PR, and Joint ER/PR status: Althuis found that ER or PR expression was not differentially 
associated with breastfeeding [19], rather, in most studies breastfeeding has been associated with 
a decreased risk of all types of breast cancer. Since Althuis, a recent review and meta-analysis, 
by Islami et al, covering 27 studies, demonstrated that breastfeeding was inversely associated 
 20 
 
with ER-PR- breast cancer, but not consistently inversely associated with ER+PR+ breast cancer 
[95]. 
Molecular subtype: The initial study of risk factors in relation to molecular subtypes, by Millikan 
et al found an important interaction between breastfeeding and parity in relation to molecular 
subtypes, namely, that women who were multiparous but did not breastfeed were at increased 
risk of triple-negative cancer [6]. Probably as a result of this finding, most studies that followed 
Millikan’s have included breastfeeding as a risk factor of interest, and have sometimes included 
an interaction term that pairs breastfeeding and parity. A cohort study confirmed Millikan’s 
findings [81], as did a case-control study in a high-risk population [96], and the review and meta-
analysis by Islami et al demonstrated an inverse association between breastfeeding and triple-
negative cancer [95]. However other studies have failed to find a differential association between 
breastfeeding and molecular subtypes (some did find an overall inverse association between 
breastfeeding and breast cancer) although these studies did not examine breastfeeding and parity 
jointly [29, 59, 74, 83]. In a pooled analysis, one study found that breastfeeding reduced risk of 
both Triple-negative and Luminal A subtypes, but only in African-American women [79], while 
a case-only study among a racially diverse group of women found that longer breastfeeding 
duration was positively associated with Luminal B, compared to Luminal A, breast cancer, and 
not associated with HER2+ or Triple-negative breast cancer, compared to Luminal A cancer 
[85]. A recent meta-analysis found that breastfeeding was strongly inversely associated with 
luminal breast cancer, not associated with the HER2+ subtype, and significantly inversely 
associated with triple-negative breast cancer [30]. A study in high-risk women, age 20-44, also 
indicated that breastfeeding was associated with inverse risk of luminal and triple-negative breast 
cancer, but not HER2+ breast cancer [91]. 
 21 
 
Grade: Only two studies have examined breastfeeding in relation to tumor grade. In these studies 
breastfeeding was not associated with tumor grade [54, 97]. 
1.C.2.e  Risk factor: Oral contraceptive use  
ER, PR and Joint ER/PR status: The Althuis review found modest evidence of a positive 
association with oral contraceptive use and ER- tumor subtypes, while a more recent cohort 
study found an inverse association of OC use and ER+ cancer [74]. However, studies examining 
OC and joint expression of ER and PR were inconclusive in the Althuis review [19]. In studies 
published more recently:  OC use has not been associated with estrogen receptor status or joint 
estrogen/progesterone receptor status in two studies published since Althuis [27, 41] while other 
studies have demonstrated a borderline protective effect against ER+PR+ cancer in an Asian 
population [98], and a positive association for OC use on ER-PR- cancer in African American 
women [99]. Among high risk populations, Beaber et al found that recent OC use was positively 
associated with ER+ breast cancer [100] , while Bertrand et al found no association between OC 
use and ER+ or ER- cancer, among young African American women [67]. 
Molecular subtype: Millikan found no association with oral contraceptive use and molecular 
subtype, a finding confirmed in more recent analyses [74, 96]. In a detailed examination of OCs, 
that examined not only use but duration, time since use, and age at first use, Ma et al also found 
no associations between OCs and molecular subtype [59]. Studies of OC use and molecular 
subtype that yielded findings, demonstrated that ever use was protective against Luminal B, 
compared with Luminal A, cancer [81], and among young women age 20-44, that long duration 
of OC use (≥15 years) was associated with increased risk of triple-negative, but not HER2+, 
breast cancer [101]. 
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Grade: In the only two studies known to examine OC use and tumor grade, one found that 
“never-users” of OCs had higher grade tumors than “ever-users” but also that each additional 
year of OC use conferred increased risk [102], while the in the other, which was conducted 
among women <35 years old, OC use was not associated with tumor grade [54]. 
1.C.2.f  Risk factor: Hormone replacement therapy 
ER, PR and Joint ER/PR status: The Althuis review found among older studies included in the 
review, there was no association with hormone replacement therapy and breast cancer risk [19]. 
However, among more recent studies in the review, including the Nurses’ Health study, 
previous, but not current use of combined HRT was associated with increased risk of ER+, but 
not ER- tumors [42], and increased risk of ER+PR+ tumors, but not hormone negative tumors 
[103]. Among studies published since the Althuis et al review, hormone replacement therapy has 
been almost exclusively associated with ER+, or ER+PR+ tumors, but not ER- or ER-PR- 
tumors [40, 41, 104-106]. 
Molecular subtype: Few studies have examined HRT use in relation to molecular subtype. In two 
studies [82, 106], combined HRT therapy was associated with Luminal A and B types, as would 
be expected given these types are also ER/PR positive. Two studies using case-only analyses 
where Luminal A was the reference population showed differing results, with one having null 
findings [6] and the other demonstrating an inverse association between HRT use and Luminal B 
and HER2+ cancer types, compared to Luminal A types [81].  
Grade: In one study, current, but not former use of HRT, was positively associated with low 
grade tumors; findings did not vary by regimen [105]. 
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There are few studies of high risk populations and HRT use, primarily because HRT use 
generally occurs among a postmenopausal (and thus older and less high-risk) population. 
1.C.3  Summary of Literature on other Factors:  Age, Race, Menopausal Status, Body Mass 
Index, Smoking and Alcohol Use 
For this dissertation, I will primarily concentrate on hormonal and reproductive risk factors. 
However, other factors that are known or suspected to be associated with breast cancer, and 
which differ in prevalence according to breast cancer subtype, will need to be examined and/or 
adjusted for.  
The following is a brief summary of the literature to date on the associations between age, race, 
menopausal status, smoking, and alcohol use, and breast cancer tumor subtypes. 
1.C.3.a  Age at Breast Cancer Diagnosis and Tumor Subtype 
ER- and PR- tumors, and higher grade tumors, are associated with a younger age at diagnosis. 
This association can somewhat be explained by the stronger association of ER-, PR- and high 
grade with BRCA1 or 2 positivity, which is associated with early age at cancer onset, as well as 
the fact that, even without BRCA1 or 2 positivity, breast cancers that occur in younger women 
are often of a more aggressive type, which corresponds to ER and PR negativity, HER2 
positivity, and high grade [107]. Additionally, women in younger ages may have had less 
exposure to factors positively associated with ER+PR+ cancer, such as hormone replacement 
therapy, which is typically not prescribed to premenopausal (younger) women, thus a greater 




1.C.3.b  Race and Tumor Subtype 
Many studies have examined racial differences in incidence of tumor subtypes, and this topic in 
itself would qualify for a systematic review. Most such studies have demonstrated that African- 
American women tend to have a higher incidence of ER-PR- breast cancer, and the first studies 
that elucidated triple-negative breast cancer demonstrated that African-Americans experience 
higher incidence of triple-negative breast cancer that do white women [5-7, 108, 109]. However, 
it is less clear whether this is an intrinsic association with race, or rather reflects different 
distributions of risk factors that are associated with triple-negative breast cancer, among African-
Americans compared to other races [56, 110]. Among other races and ethnicities examined for 
this review, there does not appear to be differential incidence of any hormone-defined tumor 
subtype by race.1.C.3.c  Menopausal Status and Tumor Subtype 
Certain risk factors for breast cancer are differentially important depending on a woman’s 
menopausal status. For example, hormone replacement therapy, which is almost exclusively used 
among women in peri- and post-menopause, can typically only be examined among a 
postmenopausal population. HRT use is associated with ER+ and PR+ tumors, and with low 
grade, and postmenopausal women are also more likely to have ER+, PR+ and lower grade 
tumors than premenopausal women. BMI also acts differently depending on a woman’s 
menopausal status. Postmenopausal obesity is positively associated with breast cancer, and 
appears to be most associated with ER+/PR+ cancer, while premenopausal obesity does not 




1.C.3.d  BMI and Associated Characteristics and Tumor Subtype 
As just noted, the role of obesity in breast cancer etiology differs depending on whether the 
cancer occurs pre- or post-menopause. Obesity measured at the time of diagnosis (i.e. current 
BMI) may also not reflect the role of excess weight in the development of cancer. Various 
studies have examined not only current BMI (BMI at the time of cancer diagnosis) but also 
weight at age 20, weight gain in adulthood, and factors with which obesity is associated, such as 
metabolic syndrome [40-42, 112-115]. Studies reviewed by Althuis et al did not find any 
association with premenopausal obesity and cancer defined by hormone receptor status [19]. 
High body mass index has been associated with ER+/PR+ tumors, but not ER-/PR- tumors [40-
42, 116], particularly among women who gained a significant amount of weight in adulthood 
compared with women who gained little weight [41, 113]. High BMI was found to be associated 
with triple-negative breast cancer in one population [114], but not another [109], and metabolic 
syndrome, but not obesity alone (which is a component of metabolic syndrome) was associated 
with triple-negative breast cancer in another study [115]. One study that examined the 
association between BMI and grade found that BMI is positively associated with higher grade 
tumors in a premenopausal population [117]. High BMI and obesity has also been described 
consistently as a risk factor in male breast cancer, which is predominantly of the “Luminal” 
subtype [118]. 
1.C.3.e  Smoking and Breast Cancer Tumor Subtypes 
Smoking is not consistently associated with breast cancer, and has been looked at in a very 
limited fashion in regards to breast cancer defined by tumor characteristics. In such studies, 
smoking has not been differentially associated with any specific subtype defined by tumor 
 26 
 
characteristic. Studies reviewed by Althuis et al did not find any differential association with 
smoking and cancer defined by ER or PR expression [19]. One other recent study that examined 
this association also did not find any differential relation between smoking and breast cancer 
defined by ER or PR subtype [116]. A study of postmenopausal women found no association 
between smoking and triple-negative breast cancer [119]. Only one study has examined the 
relation between smoking and grade, and found that smoking was associated with tumors of 
higher grade in a postmenopausal population [120].  
1.C.3.f  Alcohol and Breast Cancer Tumor Subtypes 
It is acknowledged that there is an association between alcohol and overall breast cancer risk, 
and many, but not all, papers support an association between this risk and ER+ status. Papers 
differ in regard the importance of PR status. Althuis et al found that there was no consistent 
association between alcohol use and hormone-defined subtypes of breast cancer [19]. Since the 
Althuis review, additional publications have not clarified the relationship. A 2005 cohort study 
demonstrated a positive association between alcohol use and ER, but not PR, status [121]. A 
meta-analysis published in 2008 demonstrated an association between alcohol consumption and 
all ER/PR defined subtypes except ER-PR- [122]. In postmenopausal populations, alcohol was 
positively associated with ER+PR+ cancer, but not ER+PR- or ER-PR- cancer [123, 124]. A 
study of women with triple negative breast cancer showed a reduced risk for drinkers compared 
with non-drinkers [119]. No known studies have examined the association between alcohol use 





1.C.4 Literature regarding Risk Factors and Correlation of Tumor Characteristics 
Most previous research regarding risk factor and breast cancer tumor characteristics has been via 
case-control design, and the examination of the association between the risk factor(s) of interest 
and the outcome of breast cancer performed using polytomous logistic regression, where the 
outcome of breast cancer is divided into several sub-outcomes defined, for example, by ER or 
PR status. However, because ER status is correlated with PR status, along with other 
characteristics of the tumor, such as tumor grade, it may be unclear whether the risk factor 
associations found with ER or PR status are etiologically related to development of ER+ or ER- 
cancers, PR+ or PR- cancers, or whether these risk factors are etiologically related to a factor 
correlated to ER or PR status, such as tumor grade.   
Therefore, an alternative analytic technique has emerged for examining the association of 
multiple tumor subtypes by specific risk factors. This technique is known as the pseudo-
conditional likelihood method, and it is an offshoot of polytomous logistic regression [125, 126]. 
This type of regression allows for the adjustment of correlated tumor characteristics, when 
examining a risk factor’s association with a cancer outcome more specifically defined by the 
presence or absence of a tumor marker. Additional details on this method are described in 
Appendix 1. To date, few publications have utilized this method in examining breast cancer [14, 
127], however a number of publications have used the method as a platform for examining 
colorectal cancer [128-130].  
Among the breast cancer studies, in a study published in 2006, Garcia-Closas and colleagues 
examined the relation among various tumor characteristics (though not defined by ER/PR status) 
and several risk factors of interest. The relation between the risk factors and tumor characteristics 
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such as grade, tumor size, and nodal status was more clearly elucidated when the correlated 
tumor characteristics were adjusted for using the novel extension of polytomous logistic 
regression that can account for multiple disease outcomes [125]. These case-only analyses 
demonstrated, for example, that late age at first birth was associated with larger tumor size (> 2 
cm) vs. small tumor size, and this finding remained significant even after adjustment for tumor 
grade and nodal status. While late age at first birth was also associated with positive (compared 
with negative) nodal status, the association did not hold after accounting for tumor grade and 
tumor size, indicating that the unadjusted findings were likely due to the correlation between 
large tumor size and positive nodes [14]. In another previous study that utilized the pseudo-
conditional likelihood method, the investigators determined that ER-α levels (e.g., ER positivity) 
were inversely associated with BMI among premenopausal women, but this relationship was not 
maintained when adjusting for ER-β levels, PR levels, and HER2 levels; however, high PR 
levels (i.e., PR positivity) were positively associated with high BMI among post-menopausal 
women, and this relationship was maintained when adjusting for the other marker levels [127]. 
High HER2 levels were associated with high BMI among premenopausal women, however this 
trend became significant only after the other markers (ER-α, ER-β, PR) were adjusted for [127]. 
These studies indicate that risk factors may have an apparent association with a specific tumor 
characteristic, such as ER status, but in reality are associated with a different, but correlated 
characteristic, such as tumor grade or HER2 status. 
1.C.5. Literature Review: Summary and Conclusion 
While we have made great strides improving treatment of and reducing mortality from breast 
cancer, there is still much that is not understood about the etiology of breast cancer, how 
different subtypes of breast cancer develop and what patterns of biomarker expression exist. 
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Understanding more about why some cancers develop certain characteristics or express certain 
biomarkers, which have major implications for breast cancer treatment and prognosis, is 
important in quantifying breast cancer risk, especially among family members of those with 
breast cancer, and modifying behaviors that may increase a person’s risk of developing a high-
mortality or difficult to treat tumor. Among familial as well as sporadic breast cancer, better 
understanding of risk factors that lead to certain cancer subtypes may allow for behavior 
modifications that reduce risks, or for enhanced preventive behaviors.  
1.D. RESEARCH GAPS AND DESCRIPTION OF AIMS 
While the literature on risk factor associations with breast cancer tumors defined by ER- and PR-
status is abundant, several gaps in research remain. First, few of these studies have been 
performed in a higher breast-cancer risk population, such as among younger women, women 
with a family history of breast cancer or women positive for BRCA1 or BRCA2. Second, despite 
a preponderance of literature on risk factors and breast cancer hormone receptor status, some risk 
factors remain under-examined, and do not account for how various risk factors, such as oral 
contraceptive use or breastfeeding prevalence, may have changed over time. Third, almost no 
studies have accounted for the fact that hormone-receptor status correlates with other tumor 
characteristics, such as tumor grade, obfuscating the causal pathway through which risk factors 
may function to cause specific subtypes of disease. Finally, no studies to date have explored the 
relationship between risk factors and tumor characteristics in the context of a family-based 
design. 
Analyses as part of this dissertation examine the following specific Aims, intended to address the 
current gaps in knowledge. This dissertation addresses these gaps by analyzing data by subtype 
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in a large high-risk breast cancer population, the Breast Cancer Family Registry, that includes 
both population-based and sibling controls. The analysis will primarily concentrate on the 
hormonal and reproductive factors of parity, breastfeeding, and oral contraceptive use, and will 
explore potential cohort effects for OC use, parity, and breastfeeding behavior, and cancer 
subtype. Analysis will also be performed in both a traditional case-control as well as a family-
based design, using women who have personal or familial experience with breast cancer, to 
examine within family differences. Risk factors will be examined by both joint ER/PR status and 
molecular subtype, and by the important prognostic factor of tumor grade, and tumor 
characteristics will be adjusted for one another via a two-stage regression approach, to account 
for the correlation among ER status, PR status, and grade, or ER status, PR status, and HER2 
status. 
Specific Aim 1: To understand the role of select reproductive and hormonal risk factors in a 
high-risk breast cancer population with significant family history of breast cancer, using 
population-based data from the BCFR, by evaluating the associations among selected breast 
cancer risk factors, and estrogen and progesterone receptor status, in breast cancer cases versus 
unrelated controls, using polytomous logistic regression, and considering role of family history 
and age cohort effects. 
Main analyses and findings for Specific Aim 1 are included in Chapter 2. 
Specific Aim 2: To evaluate the associations among select reproductive and hormonal breast 
cancer risk factors and breast cancer estrogen and progesterone receptor status, using clinic-
based data from the BCFR, by comparing the risk factor proportions in breast cancer cases 
versus related controls, utilizing the methods of polytomous logistic regression, as well as 
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generalized estimating equations that account for the correlation between cases and familial 
controls; while considering the role of family history and BRCA1/2 status, in terms of risk factor 
effect on outcome. 
Main analyses and findings for Specific Aim 1 are included in Chapter 3. 
Specific Aim 3 To evaluate the associations among breast cancer risk factors and breast cancer 
tumor characteristics, including ER and PR status, HER2 status and tumor grade, using 
population-based and clinic-based data from the BCFR, by comparing risk factor proportions 
among cases who do and do not exhibit various tumor characteristics (case-only analysis), using 
binomial logistic regression as well as a regression approach (pseudo-conditional likelihood 
approach) that accounts for the correlation among tumor characteristics. 
Main analyses and findings for Specific Aim 3 are included in Chapters 2 and 3. 
A comparison of the findings in the population-based and clinic-based data sets is included in 
Chapter 4. 




Figure 1-1: Classification of invasive breast cancer subtypes according to 
immunohistochemistry marker profile, using ER, PR and HER2 status  
(Adapted from: Blows F, et al, 2010)[131] 
  
 65-68% 11-12% 6-7% 13-15% 
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Table 1-1: Components of Tumor Grade 
Total Feature Score* Tumor Grade Features of Cells 
3-5 Grade 1 Well-differentiated (appear normal, growing 
slowly, not aggressive) 
6-7 Grade 2 Moderately-differentiated (semi-normal, 
growing moderately fast) 
8-9 Grade 3 Poorly-differentiated (abnormal, growing 
quickly, aggressive) 
*The total feature score is summed from 3 components: (a) Tubule Formation (score range 1-3), (b) Tumor Mitotic 




Table 1-2: Breast Cancer Subtypes among those with Family History of Breast Cancer: 
Summary of Literature 
Study Topic Findings 
Allen-Brady K, et al, 
IJC 2005 
Ductal or lobular breast 
cancer and risk of BC in 
relatives 
Morphology-specific relative risks showed that relatives of 
probands with lobular breast cancer had an increased risk of 
lobular cancer (FRR=4.51), as well as an increased risk of 
any breast cancer (FRR=2.47), compared to first degree 
relatives of cases with any histology (FRR=1.83) [132] 
Melchor, L et al, 
Oncogene 2008 
BRCA status and molecular 
subtype among those with 
familial BC 
Patients with BRCA1 positivity most often present with a 
“basal-like” pathology (associated with ER, PR and HER2 
negativity); familial patients that are not BRCA1 or 2 positive 
most often present with a “Luminal A” pathology (associated 
with ER or PR positivity and HER2 negativity)[45] 
Welsh ML et al, 
Breast Can Res Treat, 
2009 
Degree of family history 
and ER/PR status 
Women with a first-degree family history of breast cancer 
are more likely to have ER+/PR+ and ER+/PR- tumors (but 
not ER-/PR-) tumors, compared with women with no family 
history, while women with a 2nd degree family history only 
are not at increased risk for any ER/PR -defined tumor 
subtype.[47] 
Mavaddat N, et al, 
Breast Cancer Res, 
2010 
ER status and familial 
relative risk (FRR) in 
relatives 
In a study that computed familial relative risk (FRR) for 
breast cancer by subtypes (defined by ER, PR, and HER2 
status), there was no difference between breast cancer FRR 
for relatives of patients with ER- breast cancer or ER+ breast 
cancer [133].  
Phipps, et al, Breast 
Cancer Res Treat 
2011 
Family history of breast 
cancer in first degree 
relative and risk of triple 
negative BC 
Having a first-degree family history of breast cancer was 
associated with an increased risk of triple-negative breast 
cancer [46] 
Jiang X, et al, PloS 
One 2012 
Family history and breast 
cancer hormone receptor 
status 
In a Spanish cohort, women with a family history of breast 
cancer were non-significantly more likely to have ER-PR- 
tumors than women without family history, but only if 
diagnosed prior to age 50 [44]  
Ricks L, et al, J. 
Community Genet 
2014 
Family history of cancer 
and BC clinicopathological 
features 
Self-reported family history of any cancer was associated 





Table 1-3. Reproductive and Hormonal Risk Factor Associations with Breast Cancer Tumor 
Characteristics in Average risk populations: Summary of Studies by Risk Factor 




Summary of Findings References 
Parity 
ER Status 





2005-2014 Parity vs. nulliparity reduced risk of ER+, but not ER- BC 
 [56, 57, 59, 60, 
62, 63, 65] 
2006, 2007 
Risks associated with parity and number 
of births did not significantly differ by 
hormone receptor status 
[41, 66] 
PR Status 




Research 2007 PR status not associated with parity 
[66] 




Review 2004 Consensus finding not reached [19] 
Meta-analysis 2006 
Each additional live birth further 






Parity (vs. nulliparity) inversely 
associated with ER+/PR+, but not ER-
/PR- cancer 
[40, 58, 63, 65, 
71, 90, 98] 
2011, 2013 Higher parity associated with elevated 
risk of ER-PR- cancer 
[65, 71, 72] 








Increasing parity positively associated 
with triple-negative breast cancer, 
protective against Luminal A cancer 
[5,40,45-48] 
2008-2010 No differential association between parity and molecular subtype 
[21,49,50] 
Meta-analyses 2016 
Nulliparity associated with increased 
risk of Luminal subtype in Asian 
populations; parity protective against 
Luminal subtype 
[30, 80] 
Review 2014, 2016 Increased parity positively associated 




2009 Nulliparity more strongly associated 
with Grade 3 vs. Grade 1, 2 tumors 
[86] 
2010, 2016 Parity not associated with tumor grade [87, 88] 
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Age at First Birth 
ER Status 
 
Review 2004, 2014 
Later age at first live birth more 
consistently observed for ER-positive 
than ER-negative tumors; with risk 






Later age at first birth positively 
associated with ER+, but not ER-, breast 
cancer 





Later age at first birth not differentially 
associated with ER+ vs. ER- breast 
cancer 










Modest increase in HR positive but not 
HR negative tumors among women with 





Women with older age at first birth were 
at increased risk of ER+PR+ cancer, but 
age at first birth was not associated with 
ER-PR- cancer 




2008 Positive association between late age at 
first birth and ER-PR- cancer [90] 
Original 
research 
2013 No association between age at first birth 





2007-2011 Positive association between late age at 
first birth and Luminal A breast cancer, 
positive association between early age at 
first birth and triple-negative breast 
cancer 
[6, 59, 74] 
Original 
research 
2008-2011 No differential association between 
molecular subtype and age at first birth [75, 81-83] 
Meta-analysis 
2016 Positive association between late age at 
first birth and Luminal A breast cancer, 






2009 Late age at first birth associated with 
higher grade tumors [86] 
Original 
research 
2010 Earlier age at first birth associated with 
higher grade tumors [87] 
Age at Menarche 
ER Status 
Review 2004 Age at menarche not differentially 
associated with ER status [19] 
Original 
research 2008, 2011 
Age at menarche not associated with ER 
status [65, 94] 
Original 
research 2014 
Early age at menarche positively 
associated with ER+, but not ER- cancer [57] 
PR Status Review 2004 Age at menarche not differentially 




research 2007, 2011 
Late age at menarche inversely 




ER+/PR+ cancer inversely associated 
with older age at menarche, with risk 
estimates ranging from 0.5 to 0.8, 
compared with menarche at younger 




Late age at menarche decreased risk of 
all subtypes of breast cancer, but 
protective effect statistically 





2005-2015 Late age at menarche not differentially 
associated with ER/PR status 
[63, 73, 92, 93, 
98] 
2009, 2013 Late age at menarche inversely 





2007, 2011 No relation between molecular subtype 
and age at menarche [6, 74] 
2008 Early age at menarche was positively 
associated with HER2+ disease [82] 
Grade Original 
research 2008 
Early age at menarche was associated 
with a two-fold increased risk of 




Review 2004 Breastfeeding associated with reduced 
risks of all types of breast cancer [11] 
Meta-analysis 2005 Breastfeeding associated with reduced 
risks of all types of breast cancer [70] 
ER Status Original 
research 2008 
Breastfeeding inversely associated with 
ER+, but not ER- cancer [62] 
PR Status Review 2004 Breastfeeding not differentially 
associated with PR status [11] 
Joint ER/PR 
status 
Review 2015 Breastfeeding inversely associated with ER-PR- breast cancer [95] 
Original 
research 2005-2011 
Breastfeeding associated with reduced 
risk of all cancer subtypes, no 
differential association 
[58, 63, 90, 98] 
Original 
research 2005, 2011 
No association between breastfeeding 





Breastfeeding inversely associated with 
multiple molecular subtypes [59, 83] 
Original 
research 2007, 2009 
Having multiple children and not 
breastfeeding associated with increased 





2016, 2017 Breastfeeding reduced risk of both Luminal A and triple-negative cancer [30, 79] 
Review 2015 Breastfeeding inversely associated with triple-negative subtype [95] 
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Grade Original Research 2014 Breastfeeding not associated with grade [97] 
Oral Contraceptive Use 
ER Status 
Review 2004 
OCs positively associated with ER- 
cancer in earlier studies, no association 




OC use of >10 years associated with 
reduced risk of ER+ cancer [74] 
PR Status No studies of average risk populations  
Joint ER/PR 
status 
Review 2004 OCs not differentially associated with joint ER/PR status [19] 
Original 
research 2010 
OC use positively associated with ER-





OC use not differentially associated with 
molecular subtype [6, 59, 74] 
Original 
research 2009 
OC use associated with reduced 
incidence of Luminal B compared with 




Never OC use positively associated with 
higher grade tumors (case-only 
analysis); long duration of use also 
associated 
[102] 
Hormone Replacement Therapy 
ER Status Review 2004 
Past use of combined HRT associated 
with increased risk of ER+, but not ER- 
tumors 
[19] 
PR Status Original 
research 2009 
Current HRT use associated with PR+ 





Past use of combined HRT associated 
with increased risk of ER+PR+ tumors, 




Use of combined HRT associated more 
strongly with ER+PR+ subtypes 





research 2007, 2008 
Combined HRT associated with 
Luminal A and B subtypes [6, 82] 
Original 
research 2009 
Combined HRT associated with reduced 





Current use of HRT positively  





Table 1-4. Reproductive and Hormonal Risk Factor Associations with Breast Cancer Tumor 
Characteristics in high risk populations: Summary of Studies by Risk Factor 
 Parity  
Study Outcome 
Studied 
Population Studied Publication 
Date(s) 
Summary of Findings 
Nichols, HB et al 




2005 Parity vs. nulliparity reduced risk of 
ER+, but not ER- BC 
Largent, JA et al 
[54] ER Status 
Women <35 years 
old 
2005 Parity not associated with ER+ or ER- 
cancer 
Jia, X et al [69] ER Status Women ≤35 years 
old 2015 
Parity positively associated with ER+ 
cancer 
Bertrand, KA et 
al[67] ER Status 
African-American 
women <45 years 
old 
2016 
Nonsignificant (NS) trend for inverse 
association between high parity and 
ER+, NS trend for positive association 
between high parity and ER- 
Ma, H et al [27] 
Joint ER/PR 
Status 
Women <50 years 
old 2006 
parity association was confined to 
ER+/PR+ cancers (compared with 
controls) , and increased with each 
additional pregnancy 
Dolle JM et al 
[68] Molecular 
s\Subtype 
Women <45 years 
old 2009 
No association between parity and 
TNBC; inverse association between 
high parity and non-TNBC 
Gaudet, MM et al 
[96] Molecular Subtype 
Women ≤56 years 
old 2012 
Nulliparous women at 3-fold risk of 
Luminal A and B cancer, no increased 
risk of triple-negative or HER2 
Li, CI et al [91] Molecular 
Subtype Women age 20-44 2013 
Parity similarly associated with ER+, 
HER2+, and triple-negative breast 
cancer 
Largent, JA et al 
[54] Grade Women <35 years old 2005 Parity not associated with tumor grade 
Nagatsuma AK et 
al [135] Grade Premenopausal women 2013 
Recent parity (but not overall parity) 
associated with higher tumor grade 
Jia, X et al [69] 
Grade Women ≤35 years 
old 2015 Parity not associated with tumor grade 
Age at first Birth 
Nichols, HB et al 






Late age at first birth associated with 
both ER+ and ER- tumors 
 
Largent, JA et al 
[54] ER Status Women <35 years old 2005 
Age at first birth not associated with 
ER+ or ER- tumors 
Bertrand, KA et 
al [67] ER Status 
African-American 
women <45 years 
old 
2016 
Positive association between later age 
at first birth and ER- cancer; NS 
inverse association between late age at 
first birth and ER- tumors 
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Ma H et al [27] Joint ER/PR 
status 
Women <50 years 
old 
 
2006 Age at first birth only associated with ER+PR+ tumors 
Dolle, JM et al 
[68] Molecular Subtype 
Women <45 years 
old 2009 
No association between age at first 
birth and TNBC or non-TNBC 
Li, CI et al [91] Molecular 
Subtype Women age 20-44 2013 
Age at first birth inversely associated 
with triple-negative breast cancer, not 
associated with HER2+ 
Largent, JA et al 
[54] Grade Women <35 years old 2005 
Early age at first birth associated with 
higher grade tumors 
Age at Menarche 
Nichols, HB et al 




2005 Age at menarche not associated with breast cancer 
Bertrand, KA et 
al, [67] ER Status 
African-American 
women <45 years 
old 
2016 
NS trend to inverse association 
between later age at menarche and both 
ER- and ER+ cancer. 
Ma H, et al [27] Joint ER/PR 
Status 
Women <50 years 
old 2006 
Late age at menarche not differentially 
associated with hormone-receptor 
positive cancers 
Gaudet, MM et al 
[96] Molecular Subtype 
Women ≤56 years 
old 2012 
Age at menarche associated with 
reduced risk of Luminal B cancer 
Largent, JA et al 
[54] Grade Women <35 years old 2005 
Age at menarche not associated with 
tumor grade 
Breastfeeding 
Largent, JA et al 
[54] ER Status Women <35 years old 2005 
Breastfeeding associated with ER- 
cancer only  
Bertrand, KA et 
al, [67] ER Status 
African-American 
women <45 years 
old 
2016 Ever breastfeeding inversely associated 
with ER-, but not ER+, breast cancer 
Nichols HB et al 
[55] 






2005 Breastfeeding not associated with ER-, PR-, or HER2- cancer  
Ma H, et al [27] Joint ER/PR 
Status 
Women <50 years 
old 2006 
Breastfeeding inversely associated with 
both ER+PR+ and ER-PR- cancer 
Gaudet, MM et al 
[96] Molecular Subtype 
Women ≤56 years 
old 2012 
Breastfeeding inversely associated with 
Luminal B, TNBC, HER2+ subtypes 
Li, CI et al [91] Molecular 
Subtype Women age 20-44 2013 
Breastfeeding inversely associated with 
Luminal and TNBC, but not HER2 
cancer 
Largent, JA et al 
[54] Grade Women <35 years old 2005 Breastfeeding not associated with grade 
Oral Contraceptive Use 
Bertrand, KA et 
al, [67] ER Status 
African-American 
women <45 years 
old 
2016 Ever use of OCs and recency of use not 
associated with ER+ or ER- cancer 
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Beaber ER, et al 
[100] ER Status Women aged 20-49 2014 Recent OC use positively associated with ER+ risk 
Ma H, et al [27] Joint ER/PR 
Status 
Women <50 years 
old 2006 
OC use not associated with ER+PR+ or 
ER-PR- cancer 
Gaudet, MM et al 
[96] Molecular Subtype 
Women ≤56 years 
old 2012 
Oral contraceptive use not associated 
with molecular subtype 
Beaber, EF et al 
[101] Molecular 
Subtype Women aged 20-44 2014 
Lifetime duration of OC use for ≥15 
years associated with increased risk of 
all BC, risk magnitude greater in 
TNBC subtype 
Largent, JA et al 
[54] Grade Women <35 years old 2005 
Oral contraceptive use not associated 
with grade 
HRT Use 






Select Reproductive Risk Factors and Risk of Estrogen and Progesterone Receptor-Defined 
Breast Cancer in Population-Based sites of the Breast Cancer Family Registry 
 
2.A. INTRODUCTION 
Breast cancer is a heterogeneous disease, with different etiologic factors contributing to disease 
causation to a greater or lesser degree depending upon breast cancer type. In the past 20 years, an 
increasingly abundant literature has surfaced to describe how known risk factors for breast 
cancer may differ among the different subtypes of breast cancer defined by estrogen-receptor 
(ER) and progesterone receptor (PR) expression [14, 19, 40-43, 54, 63, 65, 70, 73, 81, 90, 121-
123, 127, 136-149]. The bulk of literature has associated most reproductive factors and hormonal 
risk factors, such as parity, age at first birth, and exogenous hormone use, with hormone positive 
(ER+ and/or PR+) cancers. For example high parity, lower age at first birth, and higher age at 
menarche have been associated with reduced risk of ER+ and PR+ cancers [19, 27, 40, 55, 58, 
63, 65, 70, 71, 90, 98], and postmenopausal exogenous hormone use (hormone replacement 
therapy, or HRT) is positively associated with ER+ and PR+ breast cancer [19, 40, 98, 104, 105]. 
By contrast, ER and PR negative breast cancer (ER-PR-), which is positively associated with 
African American race, younger age at onset, high tumor grade, and poor prognosis compared 
with ER+PR+ cancer [3, 5, 108, 109, 146, 150], has not demonstrated the same associations with 
reproductive and hormonal risk factors. For example, age at first birth appears to be unrelated to 
ER-PR- cancer, and high parity has been associated with increased, rather than decreased risk, in 
many studies [6, 27, 40, 41, 65, 70, 71, 73, 81, 98]. Breastfeeding is one of the few factors 
consistently associated with a reduction in both hormone receptor positive and negative breast 
cancer by a majority of studies [19, 27, 58, 70, 90, 98]. For ER-PR- or triple-negative (ER-PR-
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HER2-) cancer, in particular, breastfeeding may mitigate the increased risk of ER-PR- cancer 
associated with multiparity [6, 71, 81, 151].  
Many studies that have previously examined the relation between reproductive and hormonal 
risk factors have failed to consider secular trends in these factors, and how changes over time 
may subsequently affect assessment of risk. For example, usage of oral contraceptives (OCs) has 
changed dramatically over time due to both historical events and changes in women’s 
reproductive practices. Because OCs did not become widely available until 1961, women in 
older cohorts likely did not have access to OCs either at all, or prior to childbearing, whereas 
younger cohorts had access upon reaching reproductive age, and were more likely to use OCs 
prior to first full-term pregnancy. Prior to 1975, OCs contained a higher dosage of both estrogens 
and progestins, leading to concerns about increased risk for female cancers [152, 153]. In 1975, 
estrogen and progestin content in OCs was reduced in most industrialized countries, including 
the United States, Canada, and Australia. Therefore, older cohorts using OCs would primarily 
have received higher doses of exogenous hormones, while later cohorts received primarily the 
low-estrogen/progestin doses. The overall proportion of women using oral contraception, and 
average duration of use, has also increased over time.  
Previous studies have supported that year of OC use (before or after 1975) is an important 
variable in assessing breast cancer risk, however these studies have not examined year of use by 
ER or PR status, or whether changes in duration or timing of use before or after pregnancy by 
successive cohorts affect risk [153, 154].  
While literature examining reproductive risk factors and breast cancer subtypes defined by ER 
and PR status is abundant, relatively few studies have reported risk of oral contraceptives in a 
high breast cancer risk population. Potential risk factors may be different for younger, higher risk 
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populations, and understanding how risk factors interact in these populations has potential for 
risk prediction. Whether risk factor associations found in average-risk populations extend to 
women to women at high risk of breast cancer is also critical for prevention, as there are few 
prevention options available to these women apart from risk-reducing surgeries and 
chemoprevention; options that are particularly difficult to consider during childbearing age. This 
is especially true in the case of ER-PR- cancer, where few modifiable risk factors are known. 
Additionally, few studies have examined whether reproductive and hormonal risk factors differ 
according to tumor grade [54, 86-88, 94]. Tumor grade classifies cancer cells according to their 
appearance under a microscope (how abnormal they look compared to normal breast tissue) and 
how quickly the tumor is likely to grow and spread. Poorly differentiated tumors are more 
aggressive, are often less amenable to treatment and have poorer prognosis compared with well 
differentiated tumors, even after accounting for stage and nodal status, thus it is of value to 
understand if modifiable risk factors are associated with high grade tumors. One study has found 
nulliparity to be more strongly associated with higher grade tumors [86]. In the only study 
conducted in a high risk population, Largent et al found no association between parity, 
breastfeeding, or oral contraceptive use and grade in women diagnosed with breast cancer prior 
to age 35 [54].  
In this chapter, I evaluate associations between known and suspected reproductive and hormonal 
breast cancer risk factors and breast cancer, categorized by ER and PR status, using population-
based data from the Breast Cancer Family Registry, specifically concentrating on parity, 
breastfeeding, and oral contraceptive use, to evaluate whether the reduction in risk from 
breastfeeding in the presence of high parity, which has been described in the literature, extends 
to higher risk women, and to potentially clarify the role of OCs on breast cancer risk, where the 
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literature to date has been ambivalent. I consider possible age-cohort effects by examining year 
of birth in relation to OC use, parity, and breastfeeding, to understand whether possible age 
cohort effects can explain previous equivocal findings. I also evaluate the data by race, to 
evaluate whether higher prevalence of ER-PR- cancers in specific races (particularly among 
African American women) could be partially explained by environmental factors that may differ 
by race (such as breastfeeding). I also examine the association of these factors with breast cancer 
risk in women with a first-degree family history, to determine how risk factors may change in the 
face of a strong genetic predetermination for breast cancer. Finally, I use a statistical method that 
accounts for correlated outcomes, to assess the effect of risk factors on individual breast cancer 
tumor characteristics that are correlated with one another, in order to better understand the 
possible etiology of risk factors on ER- and PR-defined subtypes, and their relation to correlated 
tumor characteristics such as grade. 
2.B. MATERIALS AND METHODS 
Study Population 
In 1995, the National Cancer Institute funded six international sites establishing the Breast 
Cancer Family Registry (BCFR), a resource for genetic studies of breast cancer. Six participating 
sites from the United States, Canada, and Australia ascertained families either from population-
based cancer registries (in the San Francisco Bay, CA area, Ontario, Canada, and Melbourne and 
Sydney, Australia) or from clinical and community settings (producing clinic-based families in 
New York, NY, Philadelphia, PA, and Salt Lake City, UT) [155, 156]. 
Most families were enrolled in the BCFR from 1996-2000. During the period 2001-2005, several 
sites continued to recruit (1) families known to segregate BRCA1 or BRCA2 mutations, (2) 
families with multiple cases of breast or ovarian cancer, (3) selected relatives of previously 
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enrolled families, (4) families of Ashkenazi Jewish ancestry and (5) families from specific racial 
and ethnic groups [155]. The recruiting criteria for each population-based site are detailed in a 
previous publication, [155], and summarized in Appendix Table A1-1.  
A total of 5,732 women with a first primary invasive breast cancer (2,038 from San Francisco, 
2,553 from Ontario, and 1,141 from Australia), have been enrolled in the population-based sites, 
5,087 of whom completed the epidemiology questionnaire. Of those recruited, questionnaire data 
were obtained for 76%, 72%, and 75% of eligible cases from Northern California, Ontario, and 
Australia, respectively. In addition, 3,013 population-based controls (634 in San Francisco, 1711 
in Ontario, and 668 in Australia), have been enrolled, and 2,997 have completed the 
epidemiology questionnaire. The overall population-based study sample size is 5,087 female 
cases with a first primary breast cancer, and 2,997 unrelated controls.  
Of the 5,087 cases, 4,011 (79%) of women have ER/PR information available and were therefore 
eligible for analysis, including 1,994 cases from Northern California, 1,088 from Ontario, and 
929 from Australia. I used data from all 2,997 population-based controls that completed the 
epidemiology questionnaire. For the majority of the data collection period, pathologists did not 
ascertain HER2 status of breast tumors, because HER2 was not recognized as an important 
prognostic marker, nor was there targeted therapy available for HER2+ patients. As a result, only 
a subsample of the BCFR population had HER2 data available for analysis. Minority cases were 
targeted for HER2 examination in California, and a subset of women (both white and minority) 
had HER2 data available from the Ontario site. HER2 status was not available for cases from the 
Australia site of the BCFR. Data are thus available on HER2 status for a subgroup of women 
from Northern California and Ontario (N=798). Appendix Figure A1-2 depicts cases who did and 




At each of the three study sites, incident breast cancer cases were identified through population-
based cancer registries. In San Francisco area and Ontario, women likely to be at increased 
genetic risk of breast cancer were oversampled; all cases from local population-based cancer 
registries with specific indicators of genetic risk and a random sample of cases without these 
indicators were invited to participate. In Northern California, cases aged 18-64 years between 
January 1, 1995 and December 30, 2000 were recruited if they met one or more of the following 
criteria: diagnosis before age 35, bilateral breast cancer with diagnosis before age 50, prior 
ovarian or childhood cancer, or a history of breast, ovarian, or childhood cancer in ≥ 1 first 
degree relative. Cases not meeting these criteria were randomly sampled at 5% for non-Hispanic 
whites and 20% for cases of other race/ethnicity. Enrollment of cases diagnosed between 
October 1, 1998 and December 30, 2000 was limited to those who self-identified as African-
American, Hispanic, Chinese, Japanese or Filipina.  
In the Ontario site, cases aged 18-69 years between January 1, 1996 and December 31, 1998 
were included if they met one or more of the following criteria: Ashkenazi Jewish heritage, 
diagnosis before age 36, prior breast or ovarian cancer, first- or second- degree relative(s) with 
breast or ovarian cancer, first- second- or third-degree relative(s) with early age at diagnosis for 
breast or ovarian cancer (before age 36), multiple primary breast cancers, or male breast cancer; 
or 3 or more first degree relatives with any combination of breast, ovarian, colon, prostate, 
pancreatic cancers and/or sarcoma. Cases not meeting these criteria were randomly sampled at 
25%.  
In the Australia sites, all women diagnosed with invasive breast cancer from 1996-1999, aged 
18-39 years, and residing in Melbourne or Sydney at the time of diagnosis, were identified. In 
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Melbourne, women aged 40-49 years and 50-59 years were randomly sampled at 41% and 25%, 
respectively, while in Sydney, both age groups were randomly sampled at 28%.  
Control Ascertainment 
The study investigators randomly sampled unrelated controls from the general population living 
in the catchment area of each of the regional cancer registries, and controls were frequency 
matched to cases by 5-year age groups; in Northern California, they were additionally frequency 
matched by race/ethnicity. In Ontario and Northern California, controls were identified through 
lists of randomly selected residential telephone numbers. In Ontario, of 2,688 eligible population 
controls, 1,706 (64%) completed the risk factor and family history questionnaires and comprise 
the Ontario control group. In Northern California, 67% (623) of 930 eligible controls completed 
the family history and risk factor questionnaires, and comprise the Northern California control 
group. In Melbourne and Sydney the population controls were randomly selected from electoral 
rolls (for which registration is compulsory for adults in Australia) by use of proportional random 
sampling based on expected age distribution of the cases. Of 898 controls selected, 668 (74%) 
completed the family history and risk factor questionnaires and comprise the Australia control 
group. 
Risk Factor Data Collection 
Cases and controls completed structured questionnaires assessing breast cancer risk factors and 
family history of cancer (family history was assessed through a telephone questionnaire, and 
breast cancer risk factor information was ascertained through an in-person interview for the 
cases, while breast cancer risk factors and family history were ascertained through a mailed 
questionnaire for the controls). In addition to detailed family history of cancer, information was 
collected on established and suspected breast cancer risk factors, including oral contraceptive 
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use, menopausal hormone therapy use, age at menarche, parity, age at first childbirth, 
breastfeeding history, smoking history, alcohol use, education, body mass index (BMI), and 
menopausal status.  
Tumor Marker Data Collection 
For 2351 cases, BCFR study pathologists ascertained ER and PR status from patient tumor tissue 
using immunohistochemistry and/or pathology reports using a standardized protocol and 
pathology reporting forms. For the remaining cases (N=1660), ER and PR status were provided 
by the relevant Cancer Registry for that population, or through patient medical records. For 
California cases with HER2 status available (N=798), the information on HER2 status was 
provided by the California Cancer Registry (N=639), or patient medical records (N=159). The 
distribution of risk factors did not differ between cases that did or did not have ER/PR data 
available for review (data not shown). 
Where tissue samples were available, BCFR pathologists examined sections from histologic 
slides and/or paraffin tumor blocks and categorized tumors as ER or PR positive if ≥10% of 
tumor cells stained positive. This cutoff for positivity was typical for samples collected and 
examined at the time of data collection, although current practice classifies positivity at greater 
than 1% tumor cells stained positive. Where tissue samples were not obtained, pathologists 
reviewed pathology reports and medical records and recorded the ER and PR status listed on the 
report, or, if information existed on the percent of cells staining positive, employed the same 
requirements that ≥10% of cells staining positive resulted in a definition of ER or PR positive. 
For ascertaining HER2 status, pathology reports or medical records were used to ascertain status, 
and when tissue was available, study pathologists also examined histologic slides or paraffin 
tumor blocks and characterized tumors as HER2 positive or negative. Immunostaining for HER2 
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was considered positive when strong intensity of membranous staining was present in the 
majority (>50%) of cancer cells. Current procedure more commonly defines breast cancer as 
HER2+ when strong intensity of membranous staining is positive in >30% of cancer cells. 
Of the cases, 2486 were ER+PR+, 920 were ER-PR-, 397 were ER+PR-, and 208 were ER-PR+, 
using the classification methods described above. Of the sub-population for whom HER2 data 
are available, 470 are classified as Luminal A (ER+ and/or PR+, HER2-), 119 as Luminal B 
(ER+ and/or PR+, HER2+), 67 as HER2+ (ER- and PR-, HER2+) and 142 as Triple-negative 
(ER-, PR-, and HER2-). 
Statistical Analysis  
I conducted a case-control analysis using ER and PR status to define the cases, using unordered 
polytomous logistic regression, resulting in 4 ER- and PR-defined groups (ER+PR+, ER+PR-, 
ER-PR+, ER-PR-) which were each compared to the control group. I additionally used binary 
logistic regression to examine case/case differences, comparing ER-PR- cases to ER+PR+ cases. 
To determine whether risk factor associations differed by age cohort, for risk factors of interest 
(parity, breastfeeding, oral contraceptive use) I stratified women on the basis of birth year into 
four age cohorts: birth year 1926-1939, 1940-49, 1950-59, and 1960-1981. To examine role of 
family history, I conducted stratified analyses based on first-degree family history. For the sub-
population where HER2 status was available, I conducted case-only analysis comparing Luminal 
B, HER2+ and Triple-negative cases to the referent of Luminal A cases. 
Using multivariable unordered polytomous regression, adjusted for age, race/ethnicity, and study 
site, I compared known or suspected breast cancer risk factors, including OC use (never, ≤ 5 
years, > 5 years), starting date of OC use (never, any use prior to 1975, all use in 1975 or later); 
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age at menarche (≤11, 12, ≥ 13 years); parity (nulliparous, 1-2 live births, ≥3 live births); age at 
first birth (continuous); lifetime breastfeeding duration (never, <12 months, ≥ 12 months); 
combined parity and breastfeeding (nulliparous, 1-2 children never breastfed, 1-2 children ever 
breastfed, ≥ 3 children never breastfed, ≥ 3 children ever breastfed); smoking history (never 
smoker, former smoker, current smoker), BMI (continuous), education (< high school, high 
school or higher), alcohol consumption (< 7 drinks per week, ≥ 7 drinks per week, current non-
drinker), history of ≥ 1 first-degree relative with breast cancer (yes, no), and menopausal status 
(pre- or postmenopausal).  
The key variables of interest were parity, oral contraceptive use, breastfeeding, and a combined 
breastfeeding/parity variable. The multivariable model included these variables and was adjusted 
for age, site, race, and any of the variables noted in the previous paragraph that was found to be 
significant in at least one ER/PR grouping (ER+PR+, ER+PR-, ER-PR+, ER-PR-) compared 
with a control group, was strongly associated with a risk factor of interest, such that it 
confounded the association between that factor and the outcome when added to a regression, or 
for which there was strong evidence in previous literature of an association between the risk 
factor and breast cancer. I considered a risk factor to be a confounder if the suspected confounder 
changed the effect measure [β] of the risk factor of interest on the outcome by 10% or greater, or 
if a preponderance of previous literature supported an association. A risk factor was considered 
significantly related to the outcome if the 95% confidence interval did not include the value of 
“1”. All statistical tests were two-sided.  
Because the nature of various reproductive and hormonal risk factors has changed over time, I 
examined effects using four “cohorts” defined by birth year, to identify whether associations 
with oral contraceptive use, parity, and breastfeeding behavior, demonstrated in the overall 
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sample remained when examined within birth cohort. To examine the significance of this 
change, I created in interaction term between year of birth and the risk factor of interest (i.e. oral 
contraceptives) and tested whether the interaction terms was significant (p-value 0.05). For all 
cohorts, the interaction term for oral contraceptive use was significant in a polytomous logistic 
regression (data not shown). I then conducted polytomous logistic regression with two case 
groups (Any ER or PR positivity, designated HR+, and ER-PR-) and one control group, stratified 
by age cohort. 
To examine these tumor characteristics after accounting for their correlation with one another, I 
examined ER, PR, and the additional tumor characteristic of grade in case-only analyses using 
binary logistic regression, comparing ER- tumors to ER+ tumors, PR- tumors to PR+ tumors, 
and high-grade tumors to low-grade tumors (where high grade was considered grade 3, and low-
grade was considered grade 1,2). I then accounted for the correlation between these factors by 
simultaneously adjusting for the correlation of ER status to PR status, for example, to see how 
findings changed. 
All statistical analyses used SAS Version 9.2 Software (SAS Institute, Cary, NC) or MATLAB. 
 
2.C. RESULTS 
Table 2-1 summarizes frequencies of demographic characteristics, risk factors and (for the cases) 
tumor characteristics, for controls and breast cancer cases categorized by joint ER/PR status. The 
distribution of ER and PR status was very similar across sites (ER+PR+: 64%, 60% and 61%, 
ER+PR-: 9%, 10%, and 11%, ER-PR+: 5%, 8%, and 4%, and ER-PR-: 22%, 21%, and 24% for 
Ontario, Australia, and California, respectively. Due primarily to oversampling for non-white 
race and positive family history among the cases, cases consist of a higher proportion of non-
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whites, and are much more likely to have a family history of breast cancer, than controls. Cases 
regardless of hormone status had a higher rate of nulliparity and were less likely to breastfeed 
than controls, reflecting differences in known breast cancer risk factors. 
Appendix Table A1-2 summarizes demographic, risk factor and tumor characteristic frequencies, 
for cases categorized separately according to independent ER status, PR status, and grade. ER-, 
PR-, and high grade cases were more often younger and premenopausal, and were much for 
likely to be BRCA1+. ER- and high grade cases were more likely to have used OCs for more 
than 5 years, and less likely to have used HRT.  
Parity & Breastfeeding 
Table 2-2 presents the multivariable adjusted ORs for the association of parity and breastfeeding, 
and a combined parity/breastfeeding variable on each breast cancer subtype, categorized as either 
ER+PR+, ER+PR-, ER-PR+, or ER-PR-, compared with the control group, and also includes the 
findings for parity and breastfeeding from case-only analyses comparing ER-PR- cases to 
ER+PR+ cases. 
High parity (≥3 live births) was associated with an increased risk of ER-PR- cancer (OR=1.59, 
95% CI 1.15-2.18, vs. nulliparity) and 1-2 live births was associated with a borderline increased 
risk (OR=1.33, 95% CI 1.00-1.76). When stratified by menopausal status, high parity was 
associated with increased risk of ER-PR- cancer in premenopausal women only (OR=1.50, 95% 
CI 1.04-2.17, 1-2 live births; OR=1.68, 95% CI 1.10-2.56, ≥3 live births, vs. nulliparity). 
Breastfeeding was associated with a reduced risk of all breast cancer subtypes, but most strongly 
with ER-PR- cancer (OR=0.72, 95% CI 0.57-0.91 <12 months of breastfeeding vs. never; 
OR=0.52, 95% CI 0.40-0.68, ≥12 months of breastfeeding vs. never), with even greater risk 
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reduction found in postmenopausal women (OR=0.34, 95% CI 0.21-0.54, ≥12 months of 
breastfeeding vs. never). Breastfeeding >3 months was non-significantly inversely associated 
with ER-PR- cancer, and a breastfeeding variable defined continuously was significant, 
indicating that additional months of breastfeeding may confer additional benefit (data not 
shown).  
When combined with breastfeeding behavior, the increased risk of ER-PR- breast cancer 
associated with high parity was only found in women who had children but did not breastfeed 
(OR=1.57, 95% CI 1.10-2.24, ≥3  live births, no breastfeeding, vs. nulliparity). Case-only 
comparisons (with ER+PR+ tumors as the referent) also showed increased risk of ER-PR- 
tumors for parity combined with a lack of breastfeeding (OR=1.59, 95% CI 1.19-2.13, 1-2 live 
births, and OR=1.69, 95% CI 1.20-2.38, ≥3 live births vs. nulliparity). 
Oral Contraceptive Use 
Table 2-3 presents the multivariable adjusted ORs for each breast cancer subtype, compared with 
the control group, for OC use and OC start date, and also includes the findings for OC use for the 
case-only comparisons comparing ER-PR- cases to ER+PR+ cases.  
Oral contraceptive use was not associated with ER-PR- breast cancer (OR=1.13, 95% CI 0.89-
1.44 for use >5 years vs. none). However, first use of OCs prior to 1975 was positively 
associated with ER-PR- cancer (OR=1.32, 95% CI 1.04-1.67), but not with hormone receptor 
positive cancers. First use in 1975 or later was not associated with ER-PR- cancer. 
OC use was inversely associated with ER+PR+, ER+PR-, and ER-PR+ breast cancer, with OR 
estimates statistically significant for ER+PR+ cancer (OC use >5 yrs vs. none: OR=0.83, 95% 
CI=0.69-0.98). Inverse associations with hormone receptor positive subtypes were stronger when 
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OC use began in 1975 or later (OR=0.59, 95% CI 0.48-0.73, ER+PR+; OR=0.52, 95% CI, 0.36-
0.76, ER+PR-, OR=0.34, 95% CI, 0.21-0.56, ER-PR+). Findings for OC use pre or post-1975 
did not differ for cancer diagnosed pre- or post-menopausally (data not shown). 
In case-only analysis, there was a stronger association between OC use and ER-PR- cancer 
compared to ER+PR+ cancer (OR=1.35, 95% CI=1.07-1.70, OC use >5 years vs. none). Case-
case differences also existed for OC use pre- or post-1975, with statistically significant positive 
associations for ER-PR- cancer compared with ER+PR+ cancer. 
Role of Family History 
Breastfeeding remained significantly associated with ER-PR- cancer, compared with controls, in 
cases with a first-degree family history of breast cancer (OR=0.51, 95% CI 0.28-0.94), and the 
inverse association between breastfeeding and breast cancer, did not differ among those with and 
without a family history of breast cancer, for all ER/PR-defined subtypes. By contrast, parity was 
positively associated with ER-PR- cancer, compared with controls, only among ER-PR- cases 
without a first-degree family history of breast cancer (OR=1.64, 95% CI 1.16-2.33, ≥3 live births 
vs. nulliparous). There was no such association for ER-PR- cases with a family history 
(OR=1.11, 95% CI 0.54-2.27, ≥3 live births vs. nulliparous). Oral contraceptive use was also not 
associated with ER-PR- cancer in cases with a family history of breast cancer (OR=0.68, 95% CI 
0.40-1.15, >5 yrs of OC use, vs. none), but was associated in those without family history 
(OR=1.33, 95% CI 1.01-1.75, >5 yrs of OC use, vs. none). 
Differences by Race/Ethnicity 
African-American women (OR=1.71, 95% CI 1.22-2.40) and Hispanic women (OR=1.43, 95% 
CI 1.02-2.00) were more likely to be ER-PR- than ER+PR+, compared with non-Hispanic White 
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women. I found that the trend for the combined parity-breastfeeding measure held across 
race/ethnicities, with associations for ER-PR- cancer higher among parous women who did not 
breastfeed than among women who did, for non-Hispanic Whites, African Americans, Hispanics, 
and Asian Americans (Figure 2-1). 
In-depth Exploration of Selected Risk Factors by Birth Cohort 
Appendix Table A1-3 describes the frequency and prevalence of risk factors within cases and 
controls in four cohorts defined by birth year: birth year 1926-1939, birth year 1940-49, birth 
year 1950-59 and birth year 1960-81. Cases from the oldest cohort (birth year 1926-1939) had 
the lowest mean duration of OC use, and the highest proportion of OC users who commenced 
using OCs after their first live birth. The also had the lowest mean age at first live birth, and the 
highest parity, of all age cohorts. 
Figure 2-2 depicts the changing nature of oral contraceptive use over time, and shows in a forest 
plot the association of OC use with breast cancer risk, by hormone receptor status, within each 
birth-year-defined cohort. Because findings were not different based on categorical duration of 
OC use (≤5 year, > 5 years), these measures were combined into an oral contraceptive 
“Never/Ever” dichotomous variable. Additionally, ER+PR+, ER+PR-, and ER-PR+ cases were 
combined into a single “hormone positive” (HR+) subgroup, for comparison to the control group 
and the ER-PR- group. I found that among those in the oldest cohort (Cohort 1), who had the 
least experience with OCs, OC use was not associated with either HR+ or ER-PR- cancer, and 
ORs were similar between the case groups. In the 2nd oldest cohort (Cohort 2), for birth years 
1940-1949, OC use was associated with ER-PR- cancer, compared with controls (OR=1.53, 95% 
CI 1.04-2.24), but was not associated with HR+ cancer. In the cohort encompassing birth years 
1950-1959 (Cohort 3), OC use was not associated with ER-PR- cancer, but was inversely 
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associated with HR+ cancer (OR=0.66, 0.48-0.91). Cohort 2 mostly commenced use of OCs 
prior to 1975, whereas Cohort 3 commenced using OCs both before and after 1975. Among ER-
PR- patients in Cohort 2 who used OCs prior to 1975, the OR was 1.55 (95% CI, 1.04-2.29), 
while among those in Cohort 3 who used OCs prior to 1975 the OR was not statistically 
significantly elevated, but for those whose first used OCs in 1975 or later, both for HR+ and ER-
PR- cases there was an inverse association between OC use and risk, compared with controls 
(Appendix Table A1-4; Figure 2-2).  
Because the oldest cohort tended to use OCs after first live birth, while younger cohorts tended 
to begin use prior to first live birth, I examined whether OC use differed according to whether 
use had begun before or after first live birth (women who had used OCs but were nulliparous 
were excluded from analysis). Not accounting for age cohort, first use of OCs after first live birth 
was associated with ER-PR- cancer (OR=1.35, 95% 1.05-1.72), compared to never use, but was 
not associated with HR+ cancer. This estimate was stronger among women in age Cohort 2 (birth 
year 1940-49) and significant regardless of hormone receptor status (OR=2.12, 95% CI 1.35-3.33 
for ER-PR- cancer, OR=1.45, 1.06-1.99, HR+ cancer), but not significantly associated with other 
cohorts. I also examined whether first use after first live birth was associated with breast cancer 
risk, in women who began using OCs prior to 1975. Commencement of OCs after first live birth, 
rather than prior to first live birth, was associated with an increased risk of ER-PR- cancer 
(OR=1.71, 95% CI 1.28-2.28) in women who commenced use prior to 1975, which includes a 
large proportion of the women in the 1940-1949 birth cohort. In women who commenced use in 
1975 or later, the manner in which they used OCs (before or after first live birth) was not 
associated with breast cancer risk for either HR+ or ER-PR- women. 
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Parity and breastfeeding association with ER and PR status were also examined by age cohort. 
These findings are contained in Appendix Table A1-4. I found that parity is protective against 
ER+PR+ cancer among older women only, but this is primarily an age/menopausal status effect 
rather than an age cohort effect. In addition, there does not appear to be a cohort effect for 
breastfeeding. Rather, breastfeeding appears to be protective for all cohorts, and more strongly 
inversely associated with ER-PR- cancer in all women. 
Differences by Molecular Subtype 
Because only a small sample of cases had HER2 data available, findings by molecular subtype 
are shown in Appendix Table A1-5. In case-only analysis, high parity was associated with an 
increased risk of HER2+ and triple-negative breast cancer (OR=2.85, 95% CI 0.97-8.52, for 
HER2 vs. Luminal A cancer; OR=2.72, 95% CI 1.33-5.55, for triple-negative vs. Luminal A 
cancer), whereas breastfeeding was inversely associated with triple-negative cancer (OR=0.48, 
95% CI 0.28-0.81, < 12 months of breastfeeding vs. none; OR=0.56, 95% CI 0.31-1.01, ≥ 12 
months of breastfeeding vs. none). Parous women who did not breastfeed were more likely to 
have HER2+ (OR=3.37, 95% CI 1.21-9.40, HER2+ vs. Luminal A, for 1-2 live births, no 
breastfeeding; OR=3.01, 95% CI 0.92-9.86, ≥ 3 live births, no breastfeeding) or triple-negative 
cancer (OR=2.44, 95% CI 1.24-4.82, triple negative vs. Luminal A, for 1-2 live births, no 
breastfeeding; OR=2.10, 95% CI 0.93-4.76, for ≥ 3 live births, no breastfeeding) compared with 
nulliparous women. OC use of > 5 years, compared to never, was positively associated with 
triple-negative cancer (OR=1.73, 95% CI 1.03-2.90), as was OC use that began prior to 1975 




Pseudo-conditional likelihood findings 
Tables 2-4A and 2-4B present the multivariable ORs for ER+ vs. ER- tumors, PR+ vs. PR- 
tumors, and Grade 3 tumors vs. Grade 1,2 tumors, for the key risk factors of interest: oral 
contraceptive use, parity, and breastfeeding. For each tumor characteristic, the first (left-hand) 
column represents the multivariable OR unadjusted for correlation with the other tumor 
characteristics, and the 2nd (right-hand) column represents the multivariable OR, adjusted using 
the pseudo-conditional likelihood approach, to account for the correlation among tumor 
characteristics (i.e., ER status is adjusted for PR status and grade, PR status is adjusted for ER 
status and grade, and grade is adjusted for ER status and PR status.) 
Parity:  Parity was positively associated with ER- status, compared to ER+ status, in a 
multivariable model unadjusted for PR status and grade (OR=1.45, 95% CI 1.11-1.89, 1-2 live 
births vs. nulliparous; OR=1.61, 95% CI 1.19-2.17, ≥ 3 live births vs. nulliparous); and in a 
pseudo-conditional likelihood model adjusted for PR status and grade (OR=1.43, 95% CI 0.98-
2.09, 1-2 live births vs. nulliparous; OR=1.53, 95% CI 1.00-2.33, ≥ 3 live births vs. nulliparous). 
Parity was not associated with PR status or grade. 
Breastfeeding:  Breastfeeding for 12 months or longer was associated with a reduced risk of ER- 
cancer, compared to ER+ cancer, and PR- cancer compared to PR+ cancer (OR=0.65, 95% CI 
0.49-0.85, ER- vs. ER+, OR=0.72, 95% CI 0.55-0.92, PR- vs. PR+). However, in models 
adjusted for ER status and grade, breastfeeding history was no longer associated with PR status 
(OR=0.90, 95% CI 0.64-1.26, for ≥ 12 months of breast feeding vs. never), indicating apparent 
inverse associations between breastfeeding with PR-negativity are likely due to this factor’s 
correlation with ER-negativity. 
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Oral contraceptive use:  Those who used oral contraceptives for greater than 5 years were more 
likely to be ER- compared with never users (OR=1.26, 95% CI 1.00-1.59, Table 2-4B). Once the 
model was additionally adjusted for PR status and grade using the pseudo-conditional likelihood 
approach, ER status was no longer associated with OC use greater than 5 years (OR=1.07, 95% 
CI 0.77-1.50). OC use greater than 5 years was associated with high grade (OR=1.41, 95% CI 
1.15-1.86) and remained associated with high grade, compared to low grade, cancers after 
adjustment for ER and PR status (OR=1.37, 95% CI 1.08-1.73). OC use was also positively 
associated with grade, when OC use began in 1975 or later, in models both unadjusted and 
adjusted for ER and PR status. PR status alone was not associated with oral contraceptive use in 
any model. 
2.D. DISCUSSION 
Effects of Reproductive and Hormonal Risk Factors 
In this population-based study, which was enriched with women at higher than average 
population risk for breast cancer (due to oversampling of cases with early-onset breast cancer 
and/or a family history of breast cancer), I found that the factors of oral contraceptive use, parity, 
and breastfeeding differ for different subtypes of breast cancer defined by ER/PR status, that the 
effects of these risk factors can change over time, and that they can differ depending on whether 
cases have a family history of breast cancer  
I found that high parity was associated with an increased risk of ER-PR- cancer, compared with 
controls, and that breastfeeding for a total duration of ≥12 months reduced this risk. 
Breastfeeding for a total duration of 12+ months was protective against cancer regardless of 
hormone status, however findings differed when comparing the case groups to one another, such 
that breastfeeding was more strongly protective against ER-PR- cancer than ER+PR+ cancer. 
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Previous studies have found that duration of breastfeeding, coupled with parity level, is an 
important factor for risk of triple-negative (ER-PR-HER2-) breast cancer [81, 108, 151]. When I 
examined this combined variable for ER-PR- cancer, (the majority of which is likely to be triple-
negative) I also observed that multiparity, combined with no breastfeeding, was associated with 
an increased risk of ER-PR- cancer, and triple-negative cancer, but not with hormone receptor 
positive cancer. Thus the positive association I found between high parity and ER-PR- cancer, is 
mitigated by breastfeeding, such that women who are multiparous are no longer at increased risk 
of ER-PR- cancer if they breastfeed. I found that this association for ER-PR- cancer was similar 
across race/ethnicity, and that breastfeeding was inversely associated with ER-PR- cancer among 
those with and without first degree family history of breast cancer. 
Studies that examine joint ER/PR status have largely demonstrated an inverse association 
between parity and ER+/PR+ cancer risk, but not ER-PR- risk [40, 59, 70, 71, 90, 98]. A 
minority of studies has found no differential effect of parity on cancer risk by hormone status 
[41, 73, 89]. In studies examining higher risk women, a 2006 publication by Ma et al in women 
under age 50 found that the protective effect of parity was confined to ER+/PR+ cancers, and 
that the protective effect increased with each additional pregnancy [27], while another study, of 
premenopausal women in China and Vietnam, found that increasing parity (compared with 
nulliparity) was protective against ER+ cancer, but not significantly associated with ER- cancer 
[55]. In a study of very young women, 35 years and under, ER status was not associated with 
parity. Thus, the bulk of research in this area has suggested that any parity versus nulliparity, and 
multiparity compared with uniparity, offer protection against ER+ and PR+, but not ER-PR-, 
breast cancer. While my analysis did not find an association between parity and reduced cancer 
risk for hormone receptor positive breast cancer, I did find this to be true among postmenopausal 
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women with 1-2 births. I also found a positive association between parity and ER-PR- cancer, 
similar to the findings of Yang et al, in their case-only analysis [65], and reflecting similarities to 
findings among studies that examined triple-negative breast cancer [6, 74]. Research has shown 
that following pregnancy, women experience a transient increase in breast cancer risk that peaks 
approximately 5 to 6 years postpartum, and that over time, the increased risk following 
pregnancy diminishes, such that a crossover in risk occurs and women who have had their first 
birth below age 35, have a lower breast cancer risk than age-matched women who have never 
given birth [157, 158]. One potential mediator underlying the poor prognosis of breast cancer 
diagnoses following pregnancy is postpartum mammary gland involution [157]. Upon 
pregnancy, the epithelium extensively proliferates to meet the demand of lactation. Following 
lactation, or pregnancy if lactation does not occur, the mammary gland undergoes the process of 
postpartum involution to return to a state morphologically resembling the relatively simple ductal 
network of the pre-pregnant gland. Support for postpartum involution eliminating lactationally-
competent lobules in women is demonstrated by the observation that the epithelial content in the 
breast following pregnancy becomes indistinguishable from that of nulliparous women within 
18 months postpartum [157]. Evidence shows that the involuting mammary gland has similar 
characteristics to tumor-promotional microenvironments, indicating that the process can result in 
tumor proliferation [159]. This may be one of the processes by which multiparity in the absence 
of breastfeeding increases risk of some subtypes of breast cancer. 
This research confirms earlier findings that breastfeeding decreases risk of breast cancer, 
regardless of hormone receptor status. A recent review supported that ER or PR expression was 
not differentially associated with breastfeeding [19], and most other studies have confirmed this 
finding for both ER/PR-defined subtypes [27, 58, 62, 63, 90, 98], and subtypes defined by ER, 
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PR, and HER2 status [59, 83, 96]. Some studies have shown, as this one did, that the inverse 
association with breastfeeding is stronger for ER-, ER-PR-, or triple-negative breast cancer [6, 
54, 81, 96]. When examined in tandem, this research confirms earlier research demonstrating 
that high parity, coupled with lack of breastfeeding, is associated with increased risk of ER-PR- 
cancer, while high parity in the presence of breastfeeding is not associated with risk [6, 81]. 
Thus, among parous women, breastfeeding can reduce risk of ER-PR- cancer and represents a 
modifiable factor. One mechanism by which breastfeeding may mediate the effect of recent 
parity on breast cancer is to delay and slow the process of mammary gland involution. 
Proliferation of epithelial cells occurs during pregnancy; in the absence of breastfeeding, the 
involution of these mammary cells can occur rapidly. 
It has long been hypothesized that high- and low-risk breast tumors are distinct breast cancer 
subtypes with distinct risk factor profiles [6, 160, 161]. In this study, the increased risk found for 
ER-PR- cancer among women with high parity was primarily confined to women who did not 
breastfeed. Fifteen years ago, the Collaborative Group on Hormonal Risk Factors in Breast 
Cancer determined that breastfeeding is protective against breast cancer above and beyond the 
protection conferred by parity [162]. Hypothesized potential protective mechanisms include the 
removal of estrogens via breast fluid, excretion of carcinogenic agents through breast milk, delay 
in ovulation associated with breastfeeding, and induction of terminal differentiation of breast 
epithelial cells[163]. It has been shown that BRCA1 mutation carriers, who are typically 
diagnosed with ER-PR- cancer, were less likely to develop breast cancer if they breastfed for at 
least one year, compared with BRCA1 mutation carriers who did not breastfeed; there was no 
association with breastfeeding among BRCA2 mutation carriers, who usually have ER+ 
tumors[164]. It is hypothesized that full-term pregnancy followed by failure to breastfeed or 
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short duration of breastfeeding could result in retention of initiated progenitor cells (that would 
have died or differentiated during lactation) and these retained cells could presumably develop 
into “basal-like” breast tumors, which are often characterized, and usually defined, by ER- and 
PR- negativity. 
Oral contraceptive use  
Overall, oral contraceptive use greater than 5 years was associated with a reduced risk of 
hormone receptor positive breast cancer, and was not associated with ER-PR- cancer. Additional 
analysis revealed that, In particular, oral contraceptive use was associated with a decreased risk 
of ER+ cancer only if date of first use occurs in year 1975 or later, while OC use prior to 1975 is 
associated with increased risk of ER-PR- cancer. When year of birth was considered, I found that 
OC use was positively associated with ER-PR- cancer in women from the 1940-49 age cohort 
only, most of whom began using oral contraceptives prior to 1975, and that OC use was 
inversely associated with women born from 1950-1959, but this association was only maintained 
among women who began using oral contraceptives in 1975 or later. In addition to changes in 
OC formulation, timing of use associated with parity seemed to be important in the association 
between OC use and HR+ or ER-PR- cancer. Overall, first use of OCs after first childbirth was 
associated with an increased risk of ER-PR- cancer, and an increased risk of both HR+ and ER-
PR- cancer in the cohort born from 1940-1949. Earlier published studies reported positive 
associations between ER-PR- breast cancer and OC use (reviewed in [19], whereas most recent 
studies have demonstrated, like this study, no overall association between ER-PR- breast cancer 
and OC use [27, 98], (although some studies have reached different conclusions [99]). I found 
that OC use in 1975 or later was inversely associated with ER+PR+ breast cancer, and a positive 
association between OC use and ER-PR- breast cancer was limited to women who initiated use 
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prior to 1975. Analysis of year of initiation as an important variable in evaluating the association 
between OC use and breast cancer risk has become more common [12, 165, 166], but has not 
regularly been examined in previous research on OC use and breast cancer risk by hormone 
receptor status. Data on OC use and breast cancer risk in BRCA1 mutation carriers, including 
some from the BCFR study sample[153, 154, 167], have demonstrated no increased risk with OC 
use initiated after 1974 (and BRCA1 tumors are usually ER-PR-), and examination of OC use 
among women with family history of breast cancer found increased risk of breast cancer only 
among women who began OC use prior to 1975 [166]. Therefore, among these higher risk 
populations, findings were similar to those in my analysis, and may be an important factor in 
explaining why previous research regarding OC use and breast cancer risk has yielded 
conflicting results. In this study, findings were similar for any hormone-positive (ER+ and/or 
PR+) subtype, and only different for the ER-PR- type, indicating that any etiology related to OC 
use may be through both estrogen and progesterone-related mechanisms. It is unclear why OCs 
used prior to 1975 would be more strongly associated with ER-PR- cancer, and with high tumor 
grade. Studies of synthetic progestins used in oral contraceptives have generally found that the 
proliferative actions of progestins used in oral contraceptives are mediated through the estrogen 
receptor [168, 169] which does not explain why ER- cancer is more likely to be affected, unless 
the estrogen receptor is effectively “turned off” by such proliferation. Typical estrogen doses 
used in the 1960s were more than double the doses used in the 1980s, and progestin doses were 
also higher and included different types of progestins than current OCs[166]. Biologic and 
clinical evidence support a role for exogenous estrogen effects on carcinogenesis mediated 
through estrogen-receptor α (ERα) receptor, yet evidence supports that receptor-independent 
pathways may also exist [170]. This connection will require further investigation.  
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The inverse association between OC use and hormone positive breast cancers found in this study 
is inconsistent with most other published studies that have found either no association between 
OC use and hormone positive breast cancers or a positive association, although a recent study in 
a Chinese population found a protective effect in women who were hormone positive [98] as did 
a study using data from the Women’s Health Initiative [74]. Most previous studies of OC use and 
breast cancer risk have not examined findings by subjects’ birth years. A previous study of 
Icelandic women that examined OC use by birth year found an increased odds of breast cancer 
for longer duration of OC use among women with birth years after 1950, but did not separate the 
cancer by hormone status [171]. Women who were born between 1940-1949 and used OCs 
experienced increased risk of ER-PR- cancers, while women born earlier or later did not. The 
reason for the increased risk among this cohort appears to be explained by the fact that most of 
these women used OCs that were manufactured prior to 1975, which contained high doses of 
estrogen, and may also be due to the nature in which the women used OCs, with approximately 
half of this cohort initiating OC use after first full-term pregnancy, rather than before. Women 
born prior to 1940, in our study, would have used OCs in a similar manner, and been exposed to 
OCs that had the high estrogen content. However, these women did not experience an elevation 
in risk. This may be because OC use was less common and of shorter duration among these 
women, or could be due to the selection process of older women into the BCFR sample. Many 
older women were recruited into the study if they had family history of breast cancer, and it is 
possible that family history served as a competing risk in these women, rendering OC use less 
important as a causal factor. I also found that in the birth cohort of 1950-59, women who used 
OCs had reduced risk of breast cancer, and this was true in both HR+ and ER-PR- cancer. The 
reduced risk only occurred in women who initiated O
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change in estrogen and/or progesterone content of OCs at that time likely explains the protective 
effect. The protective effect does not carry into the youngest cohort of women, whose average 
age at cancer diagnosis was only 32. In these women, competing risks, primarily genetic in 
nature, likely drive breast cancer diagnosis, such that OC use may be unimportant in risk of early 
breast cancer. 
Pseudo-conditional likelihood findings 
I found, similar to other studies, that high parity was positively associated with ER-, compared 
with ER+ cancer [55, 62, 65, 89], and that breastfeeding was inversely associated with ER-, 
compared with ER+ cancer [91], associations that were maintained after adjustment for PR status 
and grade. I found that there was no association with PR status and parity, after adjustment for 
ER status and grade, in contrast with the few studies that have examined PR status individually 
in relation to parity, which found that nulliparity was inversely associated with PR negativity 
[65, 89]. Like most previous studies, I found no association with parity or breastfeeding, and 
tumor grade. Most studies examining ER status have found that parity is associated with a 
reduced risk of ER+ cancers [19, 58, 63, 65], with a greater reduction found in multiparous 
women. Parity is postulated to confer protection against breast cancer through four mechanisms: 
it increases differentiation in mammary gland tissue, induces changes in circulating hormone 
levels, parity decreases mammary stem cell activity, and decreases levels of estrogen receptor in 
the breast [172]. Decreasing levels of estrogen receptors, and inducing changes in hormone 
levels, in particular, would represent plausible mechanisms by which parity would decrease ER+, 
but not ER-, breast cancer. 
In comparisons of ER- vs. ER+ cases, PR- vs. PR+ cases, and low grade vs. high grade cases, 
after simultaneous adjustment for the other tumor characteristics, apparent associations between 
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ER- and PR-, and OC use, in fact seemed to be driven by these tumor characteristics’ correlation 
with high grade. It appeared that OC use was associated with high grade, rather than low grade 
tumors, although after adjustment for ER- and PR- status, this was only the case when OC use 
was initiated in 1975 or later. Only two previous studies have examined OC use and grade. One 
study (which studied extremely young women) found no association between OC use and grade. 
However a study in a small sample of cases (N=215), found that while “never users” of oral 
contraceptives had higher grade cancers, long duration of use was also positively associated with 
high grade [102]. Other data on OC use and tumor characteristics have been ambivalent. The 
Collaborative Group on Hormonal Factors in Breast Cancer found that “ever users” of OCs had 
tumors that were less clinically advanced [12]; however other studies have demonstrated that OC 
users have poorer prognosis tumors [173, 174]. Because of conflicting literature, the biological 
process by which OC use might result in high tumor grade are unclear.  
Methodologic Considerations  
Comparison group:  For this analysis, I used population-based controls as the common referent 
group. I did not observe some established associations between hormonal and reproductive 
factors and hormonal status. For example, while greater age at menarche is associated with a 
reduced risk of hormone positive breast cancer in most studies (See Review, Chapter 1). I did not 
find this to be true in this study. Similarly, I did not find high parity to be inversely associated 
with ER+PR+ cancer, except among postmenopausal women, while most studies have found 
parity to be protective against this subtype even among younger women (Review, Chapter 1). In 
the BCFR sample, differences have been observed between population controls and sister 
controls in some risk factors that are possibly associated with participation in research [175]. 
Specifically, BCFR population-based controls are more likely to have been highly educated, and 
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have fewer births and higher average age at first birth, than are sister controls. Because high 
education, low parity and older average age at first birth are established breast cancer risk 
factors, cases were not less likely to be nulliparous or have higher average age at first birth than 
population controls, however, they were more likely to be nulliparous and have higher average 
age at first birth than sister controls [175].  
For all the analyses reported in this chapter, I used both an unordered polytomous regression 
model, and a binary logistic model for the purposes of case/case comparisons. For the case/case 
analysis, my inferences would not be affected by any differential participation in the control 
group. For example, when comparing ER-PR- cases to ER+PR+ cases in terms of parity, I found 
that ER-PR- cases were significantly more likely to have three or more live births than ER+PR+ 
cases, with ORs that were similar to those found when comparing ER-PR- cases to population 
controls. 
Case Selection: The BCFR sample of cases is not representative of all women with breast 
cancer; they are younger, more often ethnic and racial minorities, and more often have a family 
history of breast cancer. As a result, the distribution of the different ER and PR-defined subtypes 
might not be representative of these subtypes in a sample of cases unselected for these 
characteristics. For example, among older cases (birth year before 1940), more than 40% had a 
first-degree family history of breast cancer, primarily because many women who were older 
when were diagnosed with breast cancer were required to have a family history of cancer in 
order to be included in the study. Regardless, the purpose of this analysis is to examine risk 
factor by tumor subtypes specifically in a high-risk population, therefore comparisons to 
“typical” populations are neither expected or of value versus comparisons to other high risk 
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populations. To this end, my findings do reflect findings that examine younger, more ethnically 
diverse populations. 
For the analysis of molecular subtypes, the population differed from the overall study sample in 
that it comprised mostly racial/ethnic minority cases from Northern California and Ontario, as 
few non-Hispanic whites were enrolled in the BCFR after year 2000, when HER2 data became 
available in the cancer registries. Due to these limitations, I conducted a case-only analysis and 
acknowledge that findings are preliminary, although they are in agreement with those of other 
studies.  
Selection Bias: For only a subgroup of cases was pathological data on hormonal status available 
for review. If these women were not representative of all eligible cases, one or more findings 
could be biased, with the direction of the bias differing depending on the differences between 
those who participated and had pathology for review and those who did not. Distributions of 
parity and other risk factors for my sample and the entire case sample were similar (data not 
shown), improving the likelihood that cases with ER and PR data available are representative of 
the distribution of these hormonal subtypes for the entire case sample.  
Case definitions: BCFR pathologists used common laboratory procedures and conducted a 
centralized pathology review to categorize cases as ER+PR+, ER+PR- ER-PR+, and ER-PR-. 
Unlike many previous studies, investigators did not rely on data from cancer registries for ER/PR 
classification. A recent study has demonstrated that registry-provided data may undercount the 
rarer ER/PR combinations (ER-PR+ and ER+PR-), and that centralized pathology review should 
be considered a gold-standard when classifying tumors by hormone receptor [176]. Thus, a 
centralized review is considered a strength of this study. The criteria for defining women as ER+, 
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PR+, or HER2+ were more stringent for this analysis, than criteria typically used today. This 
may limit the ability to compare this study’s findings, to similar analyses in patients who have 
been classified as HR+ or HER2+ under less stringent criteria for positivity. 
Information bias:  The possibility of recall bias exists because I relied on participants’ recalls of 
their exposures. However, the purpose of this analysis was to determine whether risk factor 
associations differed by subtype, using controls as a common comparison group. Because it is 
unlikely that cases report exposures differently based on their ER, PR, HER2 status, or grade, it 
is unlikely that OR estimates would be affected by recall bias of exposures that are differential 
by subtype.  
Multiple comparisons:  I conducted multiple comparisons with different exposures and 
outcomes, and used detailed constructs for exposures of interest (creating multiple categories for 
constructs) making it likely that one or more findings are due to chance. However, I did restrict 
my comparison to selected breast cancer risk factors and specifically examined whether key 
findings were robust. 
Summary 
Overall, I found that multiparity is associated with an increased risk of ER-PR- cancer, but this 
risk is reduced by breastfeeding, such that multiparous women who breastfeed are no longer at 
increased risk, regardless of race. Breastfeeding had a protective effect on both hormone-positive 
and ER-PR- cancer, but was more strongly protective against ER-PR- cancer. Although 
childbearing practices and breastfeeding incidence and duration have changed over time, neither 
of these factors appears to be associated with a cohort effect. I also found that oral contraceptive 
use was positively associated with ER-PR- cancer only among women who had begun use prior 
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to 1975, and risk differed according to age cohort and timing of use (before or after first live 
birth). In this study, which examined a high risk population using centralized pathology review, I 
confirmed previous findings regarding the role of pregnancy and breastfeeding in ER-PR- 
cancer, found that these findings are maintained across different race/ethnicity, and shed new 
light on the role that oral contraceptive use may have played in both HR+ and hormone-negative 
cancer in both older and younger women. I also determined that parity and breastfeeding appear 
more specifically related to ER status, rather than PR status an grade, however OC associations 
with ER and PR negativity, may in fact reflect an association with high tumor grade. These 
findings add to increasing evidence that risk factors differ depending on hormone receptor, 
confirm that such cancers need to be considered as separate entities, and provide preventive 
opportunities, in the form of breastfeeding promotion, against ER-PR- breast cancer. In the 
United States, initiation of breastfeeding has increased steadily since the 1970’s and the average 
duration of breastfeeding is also increasing (Source: Surgeon General’s Call to Action to Support 
Breastfeeding, Dept. of Health and Human Services, 2011). Recent trends examining SEER 
incidence data suggest that rates of ER-PR- breast cancer are decreasing and will likely continue 
to decrease in the coming years[2]. African-American women have lower rates of breastfeeding 
than other racial/ethnic groups (McDowell, M.M., NCHS report, 2008), and also have higher 
rates of ER-PR- breast cancer, suggesting that improving breastfeeding rates across all 




Table 2-1: Demographic and Tumor Characteristics by ER/PR status, Breast Cancer Family 
Registry Population-Based Sample 
















Age (µ± s.d.) 47.6±10.3 47.1±9.3 48.6±9.8 43.8±8.0 44.5±9.8 
Race  
     
  White 2487 (86) 1542 (62) 222 (56) 158 (76) 506 (55) 
  Black 96 (3) 221 (9) 45 (11) 16 (8) 131 (14) 
  Hispanic 72 (2) 229 (9) 46 (11) 7 (3) 113 (12) 
  Asian 165 (6) 445 (18) 79 (20) 23 (11) 149 (16) 
 Other 82 (3) 35 (1) 5 (1) 4 (2) 14 (2) 
Site      
  Ontario 1706 (57) 705 (28) 95 (24) 50 (24) 238 (26) 
  Australia 668 (22) 562 (23) 75 (19) 93 (45) 199 (22) 
  California 623 (21) 1219 (49) 227 (57) 65 (31) 483 (53) 
First degree 
family history 
     
  No  2732 (91) 1761 (71) 291 (73) 161 (78) 673 (73) 
  Yes 263 (9) 714 (29) 106 (27) 45 (22) 244 (27) 
Menopausal 
Status 
     
  Pre 1566 (55) 1431 (60) 172 (46) 149 (76) 574 (65) 
  Post 1262 (45) 951 (40) 205 (54) 47 (24) 310 (35) 
Education      
 < High school 908 (30) 710 (29) 114 (29) 56 (27) 289 (32) 
 ≥  High school 2082 (70) 1740 (71) 275 (71) 150 (73) 602 (68) 
OC Use      
  Never 646 (22) 648 (27) 124 (32) 49 (24) 198 (23) 
  ≤  5 years 1117 (37) 948 (39) 129 (34) 71 (34) 328 (37) 
  > 5 years 1216 (41) 847 (35) 131 (34) 86 (42) 353 (40) 
Date of first OC 
use 
     
Never 646 (22) 648 (27) 124 (32) 49 (24) 198 (23) 
Before 1975 1435(48) 1165 (48) 167 (43) 97 (47) 370 (42) 
1975 or later 898 (30) 630 (26) 93 (24) 60 (29) 310 (35) 
Time of last OC 
use 
     
Never user 646 (24) 648 (30) 124 (36) 49 (27) 198 (26) 
≤10 years 457 (18) 340 (15) 42 (12) 42 (23) 151 (20) 
>10, <20 years 704 (26) 613 (28) 80 (23) 52 (29) 199 (27) 
≥ 20 years 926 (34) 604 (27) 98 (28) 39 (21) 202 (27) 
HRT Use      
  Never 2081 (70) 1756 (74) 264 (70) 175 (88) 699 (80) 
  Former 246 (8) 199 (8) 37 (10) 9 (5) 59 (7) 





     
 ≤ 11 406 (14) 528 (22) 64 (16) 43 (20) 183 (21) 
  12 711 (28) 590 (24) 100 (26) 44 (21) 215 (24) 
  ≥  13 1760 (68) 1317 (54) 225 (58) 125 (59) 482 (55) 
Parity      
  Nulliparous 531 (18) 565 (23) 95 (24) 51 (25) 191 (21) 
  1-2 1334 (45) 1015 (41) 166 (42) 71 (34) 391 (42) 
≥ 3 1132 (38) 906 (36) 136 (34) 86 (41) 338 (37) 
Age at first 
birth 
24.8 25.1 25.0 24.7 24.6 
Breastfeeding 
duration 
     
  Never 1203 (40) 1105 (45) 194 (49) 95 (46) 448 (50) 
  <12 mos. 991 (33) 764 (31) 113 (29) 51 (25) 267 (30) 
  ≥  12 mos. 803 (27) 595 (24) 86 (22) 60 (29) 187 (21) 
Smoking      
  Never Smoker 1542 (52) 1474 (60) 230 (59) 120 (58) 555 (61) 
  Former Smoker 919 (31) 611 (25) 99 (25) 47 (23) 200 (22) 
 Current Smoker 533 (18) 387 (15) 63 (16) 39 (19) 156 (17) 
BMI  25.9 26.0 26.0 24.7 26.6 
Tumor Grade      
  1, 2 NA 1546 (74) 220 (67) 60 (39) 154 (20) 
  3 NA 554 (26) 109 (33) 93 (61) 628 (80) 
BRCA1 status      
Status missing NA 801 (32) 117 (29) 72 (35) 274 (30) 
BRCA1 positive NA 16 (1) 4 (1) 6 (3) 69 (8) 






Table 2-2: Association Between Parity and Breastfeeding, and Breast Cancer Classified by 












OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) 
Parity (number of live 
births) 
     
  Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  1-2 0.80 (0.65-0.99) 0.93 (0.64-1.35) 1.20 (0.71-2.02) 1.33 (1.00-1.76) 1.62 (1.24-2.13) 
  ≥ 3 0.93 (0.73-1.17) 0.97  (0.64-1.49) 1.50 (0.85-2.65) 1.59 (1.15-2.18) 1.66 (1.23-2.25) 
Breastfeeding 
duration (months) 
     
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  < 12 1.04 (0.87-1.23) 0.84 (0.61-1.16) 0.66 (0.41-1.05) 0.72 (0.57-0.91) 0.70 (0.56-0.88) 
  ≥ 12 0.80 (0.66-0.98) 0.69 (0.48-0.99) 0.57 (0.35-0.94) 0.52 (0.40-0.68) 0.64 (0.50-0.84) 
Parity and 
breastfeeding (BF) 
    
 
Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
1-2 live births, never BF 0.80(0.63-1.00) 0.92 (0.62-1.38) 1.49 (0.86-2.60) 1.30 (0.96-1.75) 1.59 (1.19-2.13) 
≥ 3 live births, never BF 0.90 (0.68-1.19) 0.95 (0.58-1.54) 1.01(0.49-2.06) 1.57 (1.10-2.24) 1.69 (1.20-2.38) 
1-2 live births, ever BF 0.78 (0.64-0.93) 0.73 (0.52-1.05) 0.63 (0.38-1.05) 0.88 (0.68-1.14) 1.12 (0.87-1.45) 
≥ 3 live births, ever BF 0.82 (0.67-0.99) 0.72 (0.50-1.04) 1.00 (0.64-1.56) 0.93 (0.71-1.22) 1.09 (0.84-1.42) 
PREMENOPAUSAL WOMEN 
Parity (number of live 
births) 
 
    
  Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  1-2 0.86 (0.65-1.15) 1.14 (0.78-2.54) 1.27 (0.66-2.42) 1.50 (1.04-2.17) 1.73 (1.21-2.48) 




    
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  < 12 1.05 (0.81-1.35) 0.86 (0.51-1.46) 0.75 (0.42-1.35) 0.74 (0.54-1.02) 0.70 (0.51-0.96) 
  ≥ 12 0.76 (0.58-1.01) 0.88(0.50-1.54) 0.68 (0.36-1.19) 0.61 (0.43-0.87) 0.80 (0.56-1.13) 
Parity and 
breastfeeding (BF)  
 
    
Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
1-2 live births, never BF 0.80 (0.59-1.09) 1.43 (0.76-2.67) 1.62 (0.83-3.18) 1.56 (1.06-2.32) 1.94 (1.32-2.85) 
≥ 3 live births, never BF 1.05 (0.70-1.58) 1.08 (0.45-2.62) 1.04 (0.41-2.62) 1.49 (0.87-2.55) 1.35 (0.89-2.29) 
1-2 live births, ever BF 0.84 (0.67-1.06) 1.23 (0.75-2.01) 0.79 (0.44-1.41) 1.03 (0.75-1.40) 1.21 (0.89-1.64) 
≥ 3 live births, ever BF 0.80 (0.63-1.01) 0.99 (0.58-1.68) 1.20 (0.72-2.00) 1.13 (0.81-1.56) 1.37 (0.99-1.89) 
POSTMENOPAUSAL WOMEN 
Parity (number of live 
births) 
 
    
Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
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  1-2 0.66 (0.47-0.93) 0.54 (0.33-0.91) 0.62 (0.25-1.54) 0.84 (0.52-1.33) 1.26 (0.81-1.97) 
  ≥ 3  0.84 (0.58-1.21) 0.77 (0.44-1.34) 0.82 (0.30-2.28) 1.11 (0.68-1.85) 1.30 (0.80-2.11) 
Breastfeeding 
duration (months) 
     
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  < 12 1.08 (0.83-1.39) 0.83 (0.54-1.26) 0.56 (0.24-1.30) 0.75 (0.53-1.07) 0.70 (0.49-0.99) 
  ≥ 12 0.91 (0.67-1.27) 0.49 (0.29-0.83) 0.37 (0.13-1.03) 0.34 (0.21-0.54) 0.37 (0.23-0.58) 
Parity and 
breastfeeding (BF)  
     
Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
1-2 live births, never BF 0.70 (0.48-1.00) 0.58 (0.34-0.98) 0.73 (0.29-1.85) 0.80 (0.39-1.30) 1.13 (0.72-1.81) 
≥ 3 live births, never BF 0.75 (0.50-1.14) 0.70 (0.38-1.28) 0.61 (0.19-1.67) 1.12 (0.66-1.92) 1.46 (0.88-2.44) 
1-2 live births, ever BF 0.65 (0.46-0.91) 0.38 (0.22-0.65) 0.24 (0.08-0.72) 0.57 (0.35-0.93) 0.88 (0.55-1.41) 
≥ 3 live births, ever BF 0.86 (0.62-1.20) 0.51 (0.31-0.85) 0.44 (0.17-1.10) 0.54 (0.83-0.88) 0.60 (0.38-0.97) 
Note: Odds ratios (OR) and 95% confidence interval (CI),  adjusted for age, race/ethnicity, study site, OC use, HT 
use, BMI, menopausal status, age at menarche, and education. ORs in bold are statistically significant. 





Table 2-3: Association Between Oral Contraceptive Use and Breast Cancer Classified by 












OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) 
OC use      
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  ≤ 5 years 0.97 (0.82-1.15) 0.73 (0.54-0.99) 0.67 (0.44-1.04) 1.16 (0.92-1.47) 1.18 (0.94-1.49) 
  > 5 years 0.83 (0.69-0.98) 0.74 (0.55-1.01) 0.79 (0.52-1.20) 1.13 (0.89-1.44) 1.35 (1.07-1.70) 
Year of first OC 
use 
     
Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Before 1975 1.06(0.91-1.25) 0.80 (0.59-1.07) 1.12(0.73-1.73) 1.32 (1.04-1.67) 1.28 (1.03-1.60) 






  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  ≤ 5 years 0.97 (0.76-1.22) 0.65 (0.41-1.05) 0.62 (0.37-1.04) 1.00 (0.73-1.38) 1.05 (0.78-1.41) 






  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  ≤ 5 years 0.89 (0.69-1.14) 0.77 (0.51-1.15) 0.58 (0.25-1.32) 1.38 (0.95-1.99) 1.50 (1.05-2.15) 
  > 5 years 0.89 (0.68-1.16) 0.63 (0.41-0.98) 0.76 (0.35-1.67) 1.23 (0.83-1.81) 1.36 (0.96-1.98) 
Note: Odds ratios (OR) and 95% confidence interval (CI) adjusted for age, race/ethnicity, study site, parity, 
breastfeeding, HT use, BMI, menopausal status, age at menarche, and education. ORs in bold are statistically 
significant. 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2-4A: Associations between parity, breastfeeding and select tumor characteristics: case-
case analysis and pseudo-conditional likelihood findings, Population-Based sites of the BCFR 
 ER- (vs. ER+) PR+ (vs. PR-) Grade (3 vs. 1,2) 
OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) 
 Logistic PCL Logistic PCL Logistic PCL 
       
Parity       
  Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  1-2 live births 1.45 (1.11-1.89) 1.43 (0.98-2.09) 1.26 (0.98-1.61) 1.00 (0.72-1.40) 1.09 (0.85-1.40) 0.93 (0.70-1.22) 
  ≥ 3 live births 1.61 (1.19-2.17) 1.53 (1.00-2.33) 1.32 (0.99-1.75) 0.97 (0.73-1.30) 1.22 (0.92-1.62) 1.01 (0.74-1.39) 
Breastfeeding 
duration 
      
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  < 12 mos. 0.68 (0.54-0.85) 0.67 (0.48-0.92) 0.78 (0.63-0.97) 0.97 (0.73-1.29) 0.95(0.77-1.17) 1.14 (0.90-1.45) 
  ≥ 12 mos. 0.65 (0.49-0.85) 0.70 (0.48-1.03) 0.72 (0.55-0.92) 0.90 (0.64-1.26) 0.81 (0.63-1.04) 0.97 (0.73-1.28) 
Parity and 
Breastfeeding 
   
 
  
Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
1, 2 live births, no 
BF 
1.42 (1.07-1.89) 1.47 (0.98-2.20) 1.19 (0.91-1.55) 0.93 (0.65-1.33) 1.07 (0.82-1.40) 0.91 (0.68-1.23) 
≥ 3 live births, no 
BF 
1.62 (1.15-2.27) 1.54 (0.95-2.48) 1.39 (1.01-1.92) 1.08 (0.70-1.66) 1.20 (0.87-1.66) 0.98 0.69-1.41) 
1, 2 live births, 
some BF 
0.96 (0.74-1.25) 0.94 (0.65-1..36) 0.97 (0.76-1.24) 0.99 (0.72-1.36) 0.99 (0.78-1.25) 1.00 (0.77-1.30) 
≥ 3 live births, 
some BF 
1.03 (0.79-1.35) 1.08 (0.74, 1.56) 0.95 (0.74-1.22) 0.87(0.62-1.21) 1.06 (0.83-1.36) 1.07 (0.82-1.40) 
Note: All ORs adjusted for age, race, study site, education, oral contraceptive use, bmi, age at first birth, age at 




Table 2-4B: Associations between oral contraceptive use and select tumor characteristics: 
case-case analysis and pseudo-conditional likelihood findings, Population-Based sites of the 
BCFR 
 ER- (vs. ER+) PR+ (vs. PR-) Grade (3 vs. 1,2) 
OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) 
 Logistic PCL Logistic PCL Logistic PCL 
       
OC Use       
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  ≤ 5 years 1.12 (0.90-1.41) 1.12 (0.81-1.54) 0.99 (0.81-1.23) 0.86 (0.65-1.13) 1.21 (0.99-1.49) 1.20 (0.96-1.51) 
  > 5 years 1.26 (1.00-1.59) 1.07 (0.77-1.50) 1.13 (0.91-1.40) 0.96 (0.72-1.28) 1.41 (1.14-1.74) 1.37 (1.08-1.73) 
OC Use 1975       
Never Used OCs 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Used OC before 
1975 
1.21 (0.96-1.52) 1.23 (0.89-1.70) 1.02 (0.82-1.25) 0.84 (0.64-1.11) 1.21 (0.98-1.49) 1.16 (0.92-1.46) 
Used OC 1975 or 
later 
1.12 (0.86-1.45) 0.89 (0.61-1.30) 1.13 (0.88-1.44) 1.05 (0.75-1.45) 1.46 (1.15-1.86) 1.49 (1.15-1.94) 
Note: All ORs adjusted for age, race, study site, education, parity, breastfeeding, bmi, age at first birth, and menopausal status; 






Chapter 3: Select Reproductive Risk Factors for Breast Cancer defined by Estrogen and 




The past two decades have transformed what we know about tumor biology and tumor markers 
for breast cancer, and the current paradigm for examining risk factor associations with breast 
cancer prevalence is to examine risk factors on disease outcome subdivided by relevant tumor 
characteristics or biomarkers. In breast cancer, most studies have focused on defining breast 
cancer by the tumor characteristics of estrogen-receptor (ER), and/or progesterone receptor (PR) 
expression, and more recently by human epidermal growth factor receptor 2 (HER2) expression. 
Tumor grade is a characteristic that is less commonly examined according to risk factor, however 
it is an important prognostic characteristic that has been demonstrated, in some studies, to differ 
according to risk factor [5, 14]. 
The bulk of published studies have analyzed average-risk populations, and associated most 
reproductive and hormonal risk factors, such as parity, age at first birth, and exogenous hormone 
use, with hormone-positive (ER+ and PR+) cancers [19, 27, 40, 55, 58, 63, 65, 70, 71, 90, 98]. 
By contrast, ER and PR negative breast cancer (ER-PR-) which is positively associated with 
younger age, high tumor grade, and poor prognosis compared with ER+PR+ cancer, does not 
demonstrate the same associations with reproductive and hormonal risk factors [6, 27, 40, 41, 65, 
70, 71, 73, 81, 98], although breastfeeding is one of the few reproductive risk factors consistently 
associated with a reduction in both hormone receptor positive and negative breast cancer in a 
majority of studies [19, 27, 58, 70, 90, 98]. Evaluations of risk factor associations with ER- and 
PR-defined breast cancer are less common in high-risk populations, therefore findings have been 
less consistent across studies (see Table 1-4). Whether breastfeeding is protective against ER-
PR- cancer in populations at high risk of breast cancer is critical for prevention, as there are few 
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prevention options available for these women apart from risk-reducing surgeries and 
chemoprevention. 
Previous studies have also supported that another modifiable factor, oral contraceptive (OC) use 
is either positively associated, or not associated, with breast cancer, however, most studies have 
failed to examine year of commencing use of OCs in regards to effect on risk, even though 
previous studies have supported that year of OC use is an important variable in assessing breast 
cancer risk [152, 153], as estrogen and progestin concentrations were higher in older 
formulations of OCs (prior to 1975). Similar to breastfeeding, few studies have examined the 
role of oral contraceptive use in higher risk populations, by ER- and PR- status [67, 100, 101]. 
Additionally, few studies have examined risk factor associations with breast cancer tumor grade. 
Tumor grade classifies cancer cells according to their appearance under a microscope (how 
abnormal they look compared to normal breast tissue) and how quickly the tumor is likely to 
grow and spread. Poorly differentiated tumors are more aggressive, less amenable to treatment 
and have poorer prognosis compared with well differentiated tumors. While few studies have 
examined whether risk factors differ according to tumor grade, because prognosis differs for high 
and low grade, increased understanding of the role of different risk factors into the etiology of 
high or low grade tumors could be of value in determining cancer prevention measures. 
In Chapter 2 of this dissertation, I focused on examination of breast cancer risk factors defined 
by joint ER and PR status, as well as molecular subtypes, using data from the population-based 
sites of the Breast Cancer Family Registry, and focusing on the risk factors of parity, 
breastfeeding, a combined parity-breastfeeding measure, and oral contraceptive use, with a 
control group serving as the primary reference group. In the analysis from Chapter 2, I found 
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that, within the population-based cohorts of the BCFR, high parity (3+ live births) without 
breastfeeding was positively associated with ER-PR- tumors (odds ratio [OR] =1.57, 95% 
confidence interval [CI], 1.10-2.24), but not with ER+PR+ tumors. Breastfeeding was associated 
with a reduced risk of all breast cancer subtypes, but most strongly with ER-PR- cancer 
(OR=0.52, 95% CI 0.40-0.68, ≥12 months of breastfeeding vs. never). High parity, when 
coupled with breastfeeding, was no longer associated with ER-PR- cancer (OR=0.93, 95% CI 
0.71-1.22). Compared with controls, oral contraceptive (OC) use prior to 1975 was associated 
with an increased risk of ER-PR- cancer (OR=1.32, 95% CI 1.04-1.67), but not HR+ cancer. For 
women who began OC use in 1975 or later there was no increased risk conferred by OC use. 
Findings differed according to whether cases did or did not have a first-degree relative with 
breast cancer, as well as by pre- or postmenopausal status. Cases-only analyses of individual 
tumor characteristics indicated that high parity and breastfeeding were specifically associated 
with ER status, while OC use was associated with tumor grade, no risk factor correlated 
specifically with PR status after accounting for ER status and grade. 
In this chapter, I will repeat the analyses from Chapter 2 using cases and controls from the clinic-
based sites of the Breast Cancer Family Registry (sites in New York, NY, Philadelphia, PA, and 
Salt Lake City, UT). The clinic-ascertained cases differ from the population-based cases in that 
they were recruited through breast cancer clinics rather than identified through cancer registries. 
The clinic-based sites also recruited family members, rather than unrelated individuals, to serve 
as the control population. Because the controls are related to the cases, analysis will be 
performed using both traditional polytomous logistic regression, as well as using the method of 
generalized estimating equations (GEE) which accounts for the correlation occurring due to 
family relationships among the members of the dataset. I will then use the clinic-based datasets 
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to examine parity, breastfeeding and oral contraceptive use according to independent ER status, 
PR status, and tumor grade, and then adjust for the correlation between ER and PR status, and 
grade, to determine how correlation among these tumor characteristics may affect the 
interpretations of the differential role of etiologies on tumor characteristics. The two aims of this 
Chapter are therefore to 1) Determine whether the findings regarding breastfeeding, parity, and 
oral contraceptive use found in Chapter 2 are also observed in a clinic-based population and 2) to 
use a novel statistical approach, the pseudo-statistical likelihood method, to ascertain what effect 
correlation of various tumor characteristics with one another has on interpretation of findings, in 
a clinic-ascertained population. As in the previous chapter, the primary risk factors of interest 
will be parity, breastfeeding, the combination of parity and breastfeeding, and oral contraceptive 
use. 
3.B. MATERIALS AND METHODS 
Study Population 
In 1995, the National Cancer Institute funded six international sites establishing the Breast 
Cancer Family Registry (BCFR), a resource for genetic studies of breast cancer. Six participating 
sites from the USA, Canada, and Australia ascertained families either from population-based 
cancer registries (San Francisco Bay, CA, Ontario, Canada, and Melbourne and Sydney, 
Australia) or from clinical and community settings (producing clinic-based families in New 
York, NY, Philadelphia, PA, and Salt Lake City, UT)[155]. The sample for this analysis is taken 
from clinic-based sites. 
The three clinic-based sites enrolled families with multiple or early-onset cases of breast or 
ovarian cancer identified through community contacts and clinical settings including screening 
centers, family cancer clinics, surgical and medical oncology offices. Probands were defined as 
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the first family member enrolled in the Breast Cancer Family Registry and may or may not have 
had a personal history of breast or ovarian cancer. Eligibility for women was based on one or 
more of the following criteria: two or more relatives with a personal history of breast or ovarian 
cancer, a woman diagnosed with breast or ovarian cancer at a young age, a woman with a history 
of both breast and ovarian cancer, or known BRCA1 or BRCA2 mutation carriers. 
Case and Control Ascertainment  
At each of the three study sites, incident breast cancer cases were identified through clinical and 
community-based settings. There were 1647 clinic-based families with an affected proband, 
including 1379 females with a primary invasive breast cancer (the remaining families had 
females with a 2nd breast cancer or males with breast cancer) and there were 1187 clinic-based 
families without an affected proband, including 1163 females, for a total of 2834 probands. Of 
the total probands, 2666 completed the epidemiology questionnaire, and 2641 provided a blood 
or mouthwash sample. Of 8264 relatives, 4604 completed the epidemiology questionnaire, and 
3973 provided a blood or mouthwash sample.  
All sites used common questionnaires on family history and epidemiologic risk factors. The 
family history questionnaire was completed by the proband (initial person contacted in the 
family; this person was not required to have breast cancer in the clinic-based sites) and obtained 
information on vital status, dates of birth, dates of death, and dates of cancer diagnosis for all 
first-degree relatives, and more distant relatives with a personal history of cancer. The risk factor 
questionnaire was completed by participating probands and relatives and sought information on 
demographics, personal history of cancer, breast and ovarian surgeries, radiation exposure, 
smoking and alcohol consumption, menstrual and pregnancy history, breast feeding history, 
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hormone use, weight, height, and physical activity. Details of the recruitment criteria can be 
found in Appendix Table A1-1. 
A total of 2627 women with a primary invasive breast cancer (1458 from New York, 725 from 
Philadelphia, and 444 from Salt Lake City) have been enrolled in the clinic-based sites and 
completed the epidemiology questionnaire. In addition, 3794 familial controls (2124 in New 
York, 882 in Philadelphia, and 788 in Utah), have been enrolled and completed the epidemiology 
questionnaire. The overall clinic-based study sample size is 2627 female cases, and 3794 related 
female controls.  
Of the cases, 32% of women have both ER and PR information available and were therefore 
eligible for analysis, including 522 cases from New York, 150 from Philadelphia, and 178 from 
Salt Lake City. Because this is a familial study that includes previous generations, many of the 
cases were diagnosed with breast cancer prior to 1995, and ER and PR data for these cases was 
not commonly ascertained (N=1,719 66% of sample). In addition, several cases (N=30, 2% of 
sample) were described to have “mixed” ER+/- or PR+/- tumor structure, and were excluded. I 
used data from all 3794 related controls that completed the epidemiology questionnaire. 
Appendix Figure A1-2 describes the ER and PR missingness data in further detail. 
Risk Factor Data Collection 
Cases and controls completed structured questionnaires assessing breast cancer risk factors and 
family history of cancer. In addition to detailed family history, information was collected on 
established and suspected breast cancer risk factors, including oral contraceptive use, hormone 
replacement therapy use, age at menarche, parity, age at first live birth, breastfeeding history, 
smoking history, alcohol use, education, body mass index, and menopausal status.  
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Tumor Marker Data Collection 
BCFR study pathologists ascertained estrogen and progesterone status and tumor grade from 
patient tissue and/or pathology reports examined using a standardized protocol and pathology 
reporting forms, or through data available from the pertinent tumor registry. 
Eligible cases had data available on ER status and PR status through either pathology samples 
(tumor samples) or pathology reports/medical records available for central review. The 
distribution of risk factors was no different between cases that did and did not have pathology 
data available for review. However, clinic-based cases who were diagnosed prior to 1995 were 
much less likely to have ER/PR information available than cases who were diagnosed in 1995 or 
later (86% of the 1521 cases diagnosed prior to 1995 did not have ER/PR information available, 
compared with 49% of the 982 cases diagnosed in 1995 or later). HER2 data were not available 
for the clinic-based sample. Details of missingness are available in Appendix Figure A1-2.  
For cases for whom tissue samples were obtained, BCFR pathologists examined sections from 
histologic slides and/or paraffin tumor blocks and categorized tumors as ER or PR positive if 
≥10% of tumor cells stained positive. Where tissue samples were not obtained, pathologists 
reviewed pathology reports and medical records and recorded the ER and PR status listed on the 
report, or, if information existed on the percent of cells staining positive, employed the same 
requirements that ≥10% of cells stained positive resulted in a definition of ER or PR positive. 
This cutoff for positivity was typical for samples collected and examined at the time of data 
collection, although current practice classifies tumors as ER or PR positive when greater than 1% 
of tumor cells stain positive. Of the 843 cases with ER/PR clearly coded as positive or negative 




For tumor grade, BCFR pathologists reviewed pathology reports and medical records to 
determine the tumor grade. Tumor grade was missing in 40% of the population with known 
ER/PR status, including all Philadelphia-based samples. Therefore for analyses including ER, 
PR, and Grade, only 524 subjects were available for analysis, all from the New York and Utah 
sites. 
Statistical Analysis 
 I conducted both case-control and case-case analysis using several statistical techniques. To 
examine the association of risk factors with ER/PR status, I used unordered polytomous 
regression, resulting in 4 ER- and PR- defined subgroups, which were compared to a common 
control group. In the case-control analysis, ER+PR+ and ER-PR- patients were compared with 
familial controls. Because of the low incidence of ER+PR- and ER-PR+ subtypes, the findings 
for these subtypes are not reported in the Results section. In the case-only analysis, I additionally 
compared ER-PR- tumors to ER+PR+ tumors as the referent to assess case/case differences. 
Case-control analyses and were conducted using both polytomous logistic regression and GEE. 
Case-only analysis was conducted using binomial logistic regression and GEE. 
To examine these tumor characteristics after accounting for their correlation with one another, I 
examined ER, PR, and the additional tumor characteristic of grade in case-only analyses using 
binary logistic regression, comparing ER- tumors to ER+ tumors, PR- tumors to PR+ tumors, 
and high-grade tumors to low-grade tumors (where high grade was considered grade 3, and low-
grade was considered grade 1,2). I then accounted for the correlation between these factors by 
simultaneously adjusting for the correlation of ER status to PR status, for example, to see how 
findings changed, using the pseudo-conditional likelihood regression approach [125]. 
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For the analysis, I concentrated on examining the following known or suspected breast cancer 
risk factors, adjusted for age, race, study site, first-degree family history (Yes/No), and 
menopausal status: oral contraceptive use (≥ 5 years, < 5 years, never), timing of oral 
contraceptive use (any use prior to 1975, all use after 1975, never); Parity (nulliparous, 1-2 live 
births, 3 or more live births), and a combined breastfeeding/parity measure. Findings were 
additionally stratified by first-degree family history status, and examined among cases that were 
positive for BRCA1/BRCA2 mutation. 
The multivariable models were adjusted for the variables of interest as well as for age, site, race, 
family history of breast cancer, and menopausal status. Other variables, including age at 
menarche (≤11, 12, ≥ 13), age at first birth (continuous), smoking (Never Smoker, Former 
Smoker, Current Smoker), BMI (continuous), education (< high school, ≥ high school), alcohol 
use (<7 drinks per week, ≥7 drinks per week, non-drinker) were evaluated to see if they were 
strongly associated with a risk factor of interest, such that they confounded the association 
between that factor and the outcome when added to a regression. I considered a risk factor to be 
a confounder if the suspected confounder changed the effect measure [β] of the risk factor of 
interest on the outcome by 10% or greater, or if a preponderance of previous literature supported 
an association. A risk factor was considered significantly related to the outcome if the 95% 
confidence interval did not include the value of “1”. 
Menopausal status was missing in for 138 cases and 264 controls. In order to estimate 
menopausal status for these subjects, cases and controls were coded as menopausal if they had 
experienced bilateral oophorectomy, or if they were age 51 or older, at the time of diagnosis for 
the cases, and at the time of interview for the controls. Subjects who were younger than 51 and 
had not had a bilateral oophorectomy were coded as premenopausal. Analyses including this 
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estimation of menopause did not significantly alter the study findings, compared to analyses 
excluding these subjects, but allowed for inclusion of these cases in analysis to improve study 
power. 
All statistical analyses used SAS Version 9.4 Software (SAS Institute, Cary, NC), and 
MATLAB. 
3.C. RESULTS 
Table 3-1 summarizes demographic, risk factor and (for the cases) tumor characteristic 
frequencies by joint ER and PR status. The control population was young, with a mean age of 44, 
similar to the ages of ER-PR+ and ER-PR- cases, but younger than ER+PR+ and ER+PR- cases. 
Controls and cases that were ER- were more often premenopausal compared with ER+ cases, 
likely due to a lower mean age. ER+PR+ and ER+PR- cases were more likely to be never users 
of oral contraceptives. Nearly 30% of controls were nulliparous, compared to 17% of ER+PR+ 
and 12% of ER+PR- cases. The low relative age of the controls may indicate that some were 
nulliparous primarily due to young age. As parity among controls was low, a full 50% had never 
breastfed. Because controls were all familially related to a case, BRCA1 positivity among 
controls was high, at 7%, higher than that for ER+PR+ and ER+PR- cases. ER-PR+ and ER-PR- 
had the highest rates of BRCA1 positivity, at 11 and 22%, respectively. ER-PR+ and ER-PR- 
cases were also characterized by high tumor grade (72%, ER-PR+, and 82%, ER-PR-). 
Appendix Table A1-6 summarizes demographic, risk factor and tumor characteristic frequencies, 
for cases categorized separately according to independent ER status, PR status, and grade. ER-, 
PR-, and high grade cases were more likely to be younger and more likely to be BRCA1 positive, 
and were more likely to have ever used oral contraceptives and less likely to have ever used 
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HRT. Cases who were ER- were more often premenopausal. Cases who were ER- and had high 
grade tumors more often had a first-degree family history of breast cancer. 
Parity and Breastfeeding 
Table 3-2 presents adjusted ORs for parity, breastfeeding, and a combined parity/breastfeeding 
variable, comparing ER+PR+ cases to controls, ER-PR-cases to controls, and ER+PR+ cases to 
ER-PR- cases (Data are not shown for ER+PR- cases, or ER-PR+ cases, due to low sample size 
for these subtypes). Data are analyzed using both logistic regression, and the method of 
generalized estimating equations (GEE), which accounts for correlation of the data points 
resulting from using familial controls.  
Both ER+PR+ and ER-PR- cases were significantly more likely to be parous than were controls, 
however for ER+PR+ cases, these findings were significant only for 1-2 live births, not for 3 or 
more live births, while ER-PR- cases were significantly more likely to be parous than controls, 
regardless of number of live births (OR=2.10, 95% CI 1.27-3.48, ER-PR- vs. control, 1-2 live 
births vs. none; OR=2.10, 95% CI 1.16-3.81, ER-PR- vs. controls, ≥3 live births vs. none). GEE 
findings were similar to those using logistic regression. Although point estimates were higher in 
ER-PR-, compared with ER+PR+ cases, the association between parity and increased likelihood 
of ER-PR-, rather than ER+PR+ breast cancer, was not  significant (OR=1.37, 95% CI 0.72-2.59, 
≥ 3 live births vs. nulliparous, ER-PR- cases vs. ER+PR+ cases).  
A non-significant inverse association was found between ER-PR- cancer and breastfeeding, 
compared with controls, in logistic regression (OR=0.70, 95% CI 0.45-1.11 ≥12 months of 
breastfeeding vs. never), and GEE (OR=0.69, 95% CI 0.43-1.10, ≥12 months of breastfeeding 
vs. never). No association with breastfeeding was found for ER+PR+ cases. The association 
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estimate remained, when comparing ER-PR- patients to ER+PR+ patients (OR=0.60, 95% CI 
0.35-1.02, ER-PR- compared to ER+PR+, ≥12 months of breastfeeding vs. never). When 
breastfeeding analysis was limited to parous women only, the association persisted and was 
statistically significant (OR=0.56, 95% CI 0.35-0.90, ER-PR- vs. controls, parous women only, 
≥12 months of breastfeeding vs. never). Using a combined parity/breastfeeding variable, parity 
coupled with lack of breastfeeding, was significantly associated with ER-PR- breast cancer 
(OR=1.75, 95% CI 1.00-3.04 1-2 live births, no breastfeeding vs nulliparity, OR=2.07, 95% CI 
1.09-3.33, ≥ 3 live births, no breastfeeding vs. nulliparity) and elevated, though not statistically 
significantly, among women with ER+PR+ cancer. Among parous women who breastfed, there 
was no longer a positive association between parity and ER-PR- cancer, however an association 
emerged for ER+PR+ cancer, only among women with 1-2 live births (OR=2.11, 95% CI 1.34-
3.33, for 1-2 live births + any breastfeeding, vs. nulliparous).  
Because the finding that parity was positively associated with ER+PR+ cancer was unexpected, 
given that most literature supports an inverse association, or no association, between ER+PR+ 
cancer and parity, I examined the association between ER and PR status and parity, in relation to 
the timing between diagnosis and interview, to understand whether the positive association could 
be associated with cancer survival, rather than incidence. Additionally, findings excluding 
BRCA1 and BRCA2 positive cases were examined, to determine whether the positive association 
between parity and cancer was related to the presence of BRCA1 and 2+ cases in the case dataset, 
and time since last birth was examined, to determine if recent parity was elevating risk, as risk of 
breast cancer is typically elevated within the first several years after childbirth [172]. Details of 
these findings are available in Appendix Table A1-7. I found that when including only those 
cases interviewed within 2 years of diagnosis, that there was no association between parity and 
 94 
 
ER+PR+ cancer (OR=1.04, 95% CI0.65-1.67, 1-2 live births vs. nulliparity). The association 
between parity and ER-PR- cancer was maintained regardless of time between diagnosis and 
interview. Omitting BRCA1 and 2 cases from analysis, did not change point estimates or 
interpretation, and time since last birth analysis also did not materially affect point estimates 
(data not shown). 
In further analysis, to determine whether risk-factor associations differed depending on whether 
cases had a first-degree family history of breast cancer, cases were stratified by whether they had 
at least one first-degree relative with breast cancer, vs. none. Among cases with a first degree 
family history, the positive association between ER-PR- and ER+PR+ breast cancer and parity, 
diminished and became non-significant. Among cases with no first-degree family history, parity 
was more strongly associated with both ER+PR+ and ER-PR- breast cancer (OR for 3+ live 
births: 3.06, 95% CI 1.46-6.42, for ER-PR- with no first-degree family history vs. control). 
Among cases with a first-degree family history, the inverse association between ER-PR- breast 
cancer, and at least 12 months of breastfeeding, became more negative (OR=0.51, 95% CI 0.24-
1.07), while breastfeeding was not inversely associated with ER-PR- cancer among those with no 
first-degree family history of breast cancer (OR=0.90, 95% CI 0.50-1.63) (Figure 3-1).  
Additional analysis of ER+PR+ and ER-PR- cases who were BRCA1 positive or BRCA2 positive 
indicated that among cases that were BRCA1 or 2 positive (compared with BRCA1 or BRCA2 
positive controls), parity was more positively associated with ER+PR+ tumors, than it was with 
ER-PR- tumors, although findings were non-significant. Most BRCA1 positive women are ER-
PR-, whereas most BRCA2 women are ER+. Breastfeeding appeared to be more protective 
among BRCA1/2+ cases, then among all ER-PR- cases (OR=0.35, 95% CI 0.14-0.93, BRCA1/2+ 
cases vs. BRCA 1/2+ controls, at least 12 months total breastfeeding vs. none) (Table 3-4). 
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Oral Contraceptive Use 
Table 3-3 presents adjusted ORs for length and starting year of oral contraceptive use, comparing 
ER+PR+ cases to controls, ER-PR-cases to controls, and ER+PR+ cases to ER-PR- cases. Data 
are analyzed using both logistic regression and GEE. Oral contraceptive use was associated with 
ER-PR-, but not ER+PR+, breast cancer (Logistic regression, OR, 1.49, 95% CI 1.00-2.21; GEE, 
OR 1.50, 95% CI 1.01-2.23 OC Use > 5 years vs. Never). This association was also significant 
when comparing ER-PR- cases, to ER+PR+ cases (OR=1.90, 95% CI 1.17-3.06, OC use >5 
years vs. never). In analysis of starting year of use, OC use was positively associated with ER-
PR- cancer (but not ER+PR+ cancer), among cases who used oral contraceptives prior to 1975 
(OR=1.60, 95% CI 1.08-2.37). Among cases who used OCs after 1975, there was no association 
with OC use and ER-PR- cancer, and there was a reduced odds of ER+PR+ cancer (OR=0.56, 
95% CI 0.41-0.78). Findings did not differ significantly according to logistic regression or GEE. 
As with the parity and breastfeeding variable, I examined whether the relation between OC use 
and ER-PR- or ER+PR+ breast cancer differed by family history of breast cancer (Figure 3-1). 
In cases with at least one first-degree relative with breast cancer, the association between OC use 
prior to 1975, and ER-PR- breast cancer, became non-significant, while it became more positive 
in those without a first-degree relative with breast cancer (OR=1.88, 95% CI 1.06-3.33, for ER-
PR- cases vs. controls, OC use prior to 1975, vs. never use).  
As with parity and breastfeeding, the association between OC use and ER- and PR- defined 
breast cancer was also examined among BRCA1/BRCA2+ cases, versus BRCA1/2+ controls. 
Among BRCA1/2+ cases, >5 years of OC use, was positively associated with ER-PR- cancer , 
but not with ER+PR+ cancer (OR=3.53, 95% CI 1.59-7.86); similarly, use prior to 1975 was 
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associated with ER-PR- cancer among BRCA1/2+ cases, compared with controls (OR=3.43, 
95% CI 1.52-7.75) (Table 3-4). 
Pseudo-Conditional Likelihood findings 
Tables 3-5A and 3-5B present the multivariable ORs for ER+ vs. ER- tumors, PR+ vs. PR- 
tumors, and Grade 3 tumors vs. Grade 1,2 tumors, for the key risk factors of interest: parity and 
breastfeeding (Table 3-5A), and oral contraceptive use (Table 3-5B). For each tumor 
characteristic, the first (left-hand) column represents the multivariable OR unadjusted for 
correlation with the other tumor characteristics, and the 2nd (right-hand) column represents the 
multivariable OR, adjusted using the pseudo-conditional likelihood approach, to account for the 
correlation among tumor characteristics (i.e., ER status is adjusted for PR status and grade, PR 
status is adjusted for ER status and grade, and grade is adjusted for ER status and PR status.). 
Because grade was not available for the Philadelphia-based cases, the sample for this case-only 
analysis includes cases from New York and Utah. 
Parity: Parity was not associated with an increased risk for ER- status, compared to ER+ status, 
in a multivariable model unadjusted for PR status and grade, or in a pseudo-conditional 
likelihood model adjusted for PR status and grade, nor was it associated with PR status in either 
the adjusted or unadjusted models. However, parity was associated with high grade (grade 3) vs. 
low grade (grade 1,2) tumors, in a model unadjusted for ER and PR status (OR=1.90, 95% CI 
1.00-3.59, 1-2 live births vs. none and OR=1.96, 95% CI, 0.95-4.01, 3+ live births vs none), and 
in a model adjusted for both ER and PR status (OR=2.17, 95% CI 1.08-4.38, 1-2 live births vs. 
none and OR=2.23, 95% CI 1.02-4.86, ≥ 3 live births vs. none). 
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Breastfeeding: Breastfeeding for 12 months or longer was associated with reduced odds of ER- 
cancer, compared to ER+ cancer, and PR- cancer compared to PR+ cancer, in multivariable 
models unadjusted for PR status and grade (OR=0.49, 95% CI 0.28-0.84, ER- vs. ER+, 
OR=0.58, 95% CI 0.35-0.97, PR- vs. PR+). However, in multivariable models simultaneously 
adjusted for PR status and grade, breastfeeding was no longer associated with ER status. In 
models adjusted for ER status and grade, breastfeeding was no longer associated with PR status, 
although the point estimate remained similar to the logistic regression model. Breastfeeding of 
any duration was associated with reduced odds of high grade, vs. low grade cancer (OR=0.54, 
95% CI 0.32-0.91, breastfeeding <12 months vs. never and OR=0.40, 95% CI 0.21-0.73, 
breastfeeding ≥12 months vs. never), and this association remained after adjustment for ER and 
PR status. 
Oral contraceptive use: In the multivariable models in Table 3-5B, cases who used oral 
contraceptives were more likely to be ER-, rather than ER+ compared with never users 
(OR=1.56, 95% CI 1.02-2.40, ≤5 years use vs. never, OR=1.74, 95% CI 1.09-2.77 > 5 years use 
vs. never), however once the model was additionally adjusted for PR status and grade using the 
pseudo-conditional likelihood approach, ER status was no longer significantly associated with 
OC use, although point estimates changed only minimally. OC use prior to 1975 was associated 
with ER- vs. ER+ cancer, compared with never use (OR=1.75, 95% CI 1.15-2.67); upon 
adjustment for PR status and grade, this association became non-significant, although the point 
estimate remained similar (OR=1.90, 95% CI 0.95-3.80). By contrast, OC use in 1975 or later 
was positively associated with PR-, vs. PR+ status, compared with never use (OR=1.78, 95% CI 
1.11-2.84), this association also became non-significant, but the point estimate remained similar, 
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after adjustment for ER status and grade (OR=1.88, 95% CI 0.92-3.83, for PR- vs. PR+ cancer). 
OC use was not associated with cancer grade in the clinic-based population. 
3.D. DISCUSSION 
Parity and Breastfeeding 
In the clinic-based population of the BCFR, comprised of breast cancer cases and familial 
controls, I found that high parity was positively associated with both ER+PR+, and ER-PR- 
tumors, and breastfeeding was only associated with reduced odds of ER-PR- cancer. Having 
children and not breastfeeding them was associated with an increased risk of ER-PR- tumors. 
This risk was mitigated by breastfeeding in the ER-PR- tumors, but not in the ER+PR+ tumors. I 
found that the effect of these risk factors can differ depending on whether cases have a first-
degree family history of breast cancer. 
Analysis of the nature of the association between ER+PR+ cancer and parity indicated that 
among cases who were interviewed between 0-2 years after diagnosis, there was no association 
between parity and ER+PR+ cancer, with odds ratios close to 1. When time between diagnosis 
and interview was between 0-5 years, the association between ER+PR+ cancer and parity 
became positive, but was still non-significant. Only when all cases, even those interviewed more 
than 10 years after diagnosis, were included in the case group, was the significantly positive 
association between parity and ER+PR+ breast cancer maintained, indicating that among the 
ER+PR+ cases, parity is likely associated with breast cancer survival, rather than breast cancer 
incidence. By contrast, parity was positively associated with ER-PR- cancer, regardless of the 
timing between diagnosis and interview, indicating this association between parity and ER-PR- 
status is more likely to reflect risk of incidence (i.e., may have an etiological basis).  
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Most studies support that parity is inversely associated with ER+ breast cancer risk, whereas, 
after accounting for time between diagnosis and interview, I found no association between ER 
positivity and parity. Studies reporting an inverse association between parity and ER+PR+ 
cancer often contain a preponderance of postmenopausal women [19, 58], whereas the BCFR 
clinic-based sample has a high proportion of premenopausal women, particularly among 
controls. Studies of younger, primarily premenopausal women have found conflicting results 
regarding ER+ and parity, including several studies that have found no association [54, 69, 91]. 
Many studies have reported a positive association between parity and ER- breast cancer, 
particularly when parity is combined with a lack of breastfeeding [5, 56, 65, 67, 71, 75, 82, 177]. 
Most studies have found breastfeeding to be protective regardless of subtype, while this study 
does not show an inverse effect of breastfeeding on ER+PR+ cancers. However, some studies 
have indicated that breastfeeding confers greater protection against ER-PR-, or triple-negative 
cancer, and can mitigate the positive risk conferred by parity [81, 95, 108, 151]. The 
Collaborative Group on Hormonal Risk Factors in Breast Cancer has determined that 
breastfeeding is protective against breast cancer above and beyond the protection conferred by 
parity [162]. Hypothesized potential protective mechanisms include the removal of estrogens via 
breast fluid, excretion of carcinogenic agents through breast milk, delay in ovulation associated 
with breastfeeding, and induction of terminal differentiation of breast epithelial cells [163]. In 
addition, as mentioned in Chapter 2, involution of mammary tissue occurs after breastfeeding, 
but in the absence of breastfeeding, may occur sooner postpartum; this process has been 




Oral Contraceptive Use 
Overall, oral contraceptive use was associated with an increased risk of ER-PR- breast cancer, 
however, by further defining OC use by starting year of use, I found that this increased risk was 
only present in women who began their oral contraceptive use prior to 1975. After 1975, OC use 
was not significantly associated with ER-PR- breast cancer, and was shown to be protective 
against ER+PR+ breast cancer. Earlier published studies reported positive associations between 
ER-PR- breast cancer and OC use (reviewed in[19]), whereas most recent studies have found no 
overall association between ER-PR- breast cancer and OC use [19, 27, 67, 73, 96, 98, 177]. A 
few studies have found, as this one did, an inverse association between OC use and ER+PR+ 
cancers [74, 81]. Analysis of year of initiation as an important variable in evaluating the 
association between OC use and breast cancer risk has become more common [12, 165, 166], but 
has not regularly been examined in previous research on OC use and breast cancer risk by 
hormone receptor status. OC use both before and after the year 1975 was associated with an 
increased risk of ER-PR- cancer, among cases who were interviewed soon after diagnosis. This 
could indicate that, among cases for whom use occurred after 1975, recency or total duration of 
use may be positively associated with ER-PR- cancer, as has been found in an additional study of 
young, triple-negative breast cancer cases [101]. Additionally, analysis in Chapter 2 indicated an 
age-cohort effect regarding OC use and ER-PR- cancer. The same age-cohort effect could be 
operating in this sample, although smaller sample size in this population did not allow for an age 
cohort analysis. 
It is unclear why OCs used prior to 1975 would be more strongly associated with ER-PR- cancer. 
Studies of synthetic progestins used in OCs have generally found that the proliferative actions of 
progestins used in OCs are mediated through the ER [168, 178], which does not explain why ER- 
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breast cancer is more likely to be affected, unless the ER is effectively “turned off” by such 
proliferation. Typical estrogen doses used in the 1960s were more than double the doses used in 
the 1980s, and progestin doses were also higher and included different types of progestins than 
current OCs [166]. Biologic and clinical evidence support a role for exogenous estrogen effects 
on carcinogenesis mediated through estrogen-receptor α (ERα) receptor, yet evidence supports 
that receptor-independent pathways may also exist [170]. 
Role of family history 
In this population with a high proportion of both cases and controls with a first-degree relative 
with breast cancer, it was feasible to examine findings stratified by family history. It should be 
noted that those cases and controls without a first degree relative with breast cancer, often have 
one or more 2nd degree relative with breast cancer, so cannot be considered to have non-familial 
breast cancer. Parity was more strongly associated with positive risk of breast cancer, among 
cases without a first-degree family history of breast cancer, particularly among ER-PR- cases. 
Breastfeeding was inversely associated with breast cancer, only among ER-PR- cases with a 
first-degree family history of breast cancer. And OC use (prior to 1975) was associated with 
increased risk of ER-PR- breast cancer, among both women with and without a first degree 
relative with breast cancer, but the association was more negative among those without first-
degree family history. After 1975, OC use was protective against ER+PR+ cancer, only among 
women without a first degree relative with breast cancer. 
Some studies have indicated that for women with a familial risk of breast cancer, the role of 
environmental risks (such as childbirth) in contributing to breast cancer etiology may be 
minimized [44, 47]. In cases without a predisposed genetic risk of breast cancer, environmental 
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factors may play a heightened role. My analysis comprised a relatively young sample of women, 
some of whom were of childbearing age, and experienced a cancer diagnosis within 5 years of 
childbirth. For cases with no genetic predisposition, recent childbirth might be considered 
causative (along with other factors) to breast cancer etiology [179]. However, for cases with an 
existing predisposition, breast cancer diagnosis at a young age may coincide with recent 
childbirth, but childbirth may have less of a causative role. This assumption is supported by the 
findings, that breast cancer molecular subtype distribution is not different in those with 
pregnancy-associated breast cancer, when family history is considered [180], and that those with 
family history have not been found at increased risk of breast cancer, within10 years of 
pregnancy [181]. This may be why, among cases with first degree family history, parity was less 
associated with increased odds of breast cancer, than among cases without. 
Stratification by first-degree family history in this analysis demonstrated the value of 
breastfeeding for women with a first degree affected relative (and thus a likely genetic 
predisposition to breast cancer) in possibly modifying this risk. It has been shown in a recent 
meta-analysis that BRCA1 mutation carriers, who are typically diagnosed with ER-PR- cancer, 
were significantly less likely to develop breast cancer if they breastfed for at least one year, 
compared with BRCA1 mutation carriers who did not breastfeed; there was no association with 
breastfeeding among BRCA2 mutation carriers, who usually have ER+ tumors [182]. The 
conclusion of the meta-analysis was that breastfeeding is inversely associated with BRCA1 (but 
not BRCA2) carrier status, however, it could in fact be that breastfeeding is inversely associated 
with ER-PR- status, regardless of carrier status. Women who were BRCA1 positive made up 13% 
of all clinic-based cases in this analysis, but 22% of ER-PR-cases, and breastfeeding was found 
to be protective against ER-PR- breast cancer cases that were BRCA1/2 positive, indicating even 
 103 
 
among BRCA1/2 positive women, there is some differential pathway, potentially involving 
breastfeeding, by which cases become estrogen receptor or progesterone receptor negative, rather 
than positive. 
In other analyses of parity and BRCA1/2 carriers, including the meta-analysis, parity has been 
unassociated with BRCA1 status [182, 183]; this study also found that parity was unassociated 
with ER-PR- status, which would be largely made up of BRCA1 cases. Parity has been positively 
associated in a few studies with BRCA2 status or BRCA/2 status [184, 185]. These analyses did 
not classify cases by ER or PR subtype, potentially resulting in a finding confounded by 
heterogeneity of tumor characteristics. Age incidence curves for breast cancer tend to be younger 
for carriers of BRCA1 or 2, such that factors that occur close to the timing of diagnosis, may 
appear to be strongly related to risk. In this analysis, parity was positively (though non-
significantly) associated with ER+PR+ BRCA1/2 carriers, however, the average age of breast 
cancer diagnosis in BRCA2 carriers (the bulk of whom are ER+), is less than 45, indicating that 
recent pregnancy and case status may be co-occurring, but not causally related. 
Regarding oral contraceptive use, findings among cases with/without family history and among 
BRCA1/2 carriers, were similar for ER-PR- cases. Thus findings may reflect that, prior to 1975, 
OCs conferred an increased risk of ER-PR- cancer, regardless of pre-existing genetic 
predisposition. Studies that have examined OC use among women with family history of breast 
cancer found increased risk of breast cancer only among women who began OC use prior to 
1975 [166], as did my findings. Data on OC use and breast cancer risk in BRCA1/2 mutation 
carriers, including some from the breast cancer family registry, have demonstrated no increased 
risk with OC use initiated after 1974, for use of ≥1 year [153, 154, 167, 186]. Additional studies 
have supported long duration of use, greater than 5 years, is positively associated with BRCA1 
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positivity in carriers, as was found in this study for ER-PR- cases with BRCA1/2 positivity [187, 
188]. These studies did not report findings by ER/PR subtype. 
Case-Case Analysis of Tumor Characteristics  
The challenges of understanding the possibly differential effects of estrogens and progestins on 
hormone positive and negative breast cancer risk can perhaps be better parsed out using the 
additional analyses in this chapter. There are few previous analyses of this type in breast cancer, 
and none that specifically consider ER status, PR status, and grade using the risk factors of 
parity, breastfeeding, and oral contraceptive use.  
In this sample, OC use was positively associated with ER- (compared with ER+) cancer, but only 
in use prior to 1975. OC use was positively associated with PR- (compared with PR+) cancer, 
but only among users who initiated use after 1975. OC use was not associated with grade. OC 
use before 1975, when OCs contained high doses of estrogen and progestin, was positively 
associated with ER- tumors, while OC use after 1975 (when newer types of progestins were 
introduced into OCs) was positively associated with PR- tumors. Thus the specific formulation 
of the oral contraceptive over time, may have affected what subtype of cancer cases incurred, 
even if overall cancer risk was not affected. 
Parity was positively associated with both ER+ and ER- cases, in case-control analysis, and thus 
not differentially associated with ER-, vs. ER+, in case-only analysis. However, parity was 
positively associated with high grade, even after accounting for ER and PR status (ER negativity 
and PR negativity are closely correlated to high grade). The association with high grade among 
parous women, regardless of ER/PR status, may be related to the high rate of BRCA1 and BRCA2 
positive women in the sample, since presence of this mutation is associated with high grade 
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tumors regardless of ER/PR status. Publications have also noted that familial breast cancers are 
often of high grade, even when not associated with BRCA1 or BRCA2 positivity [189], indicating 
that the associations found in this analysis may be related to the high prevalence of familial 
breast cancer in the sample. Most interesting, breastfeeding was negatively associated with high 
grade vs. low grade tumors, and also with ER and PR negativity, even after these factors were 
adjusted for one another, giving further evidence that breastfeeding may truly reduce risk of 
acquiring poorer prognosis tumors, such as those that are ER-, PR- and high grade, even in cases 
where a familial predisposition to such cancers exists. 
Methodologic Considerations  
Selection Bias: Pathological data on hormonal status was available for review for only a 
subgroup of the clinic-based sample. If these women were not representative of all eligible cases, 
one or more findings could be biased, with the direction of the bias differing depending on the 
differences between those who participated and had pathology for review and those who did not. 
Distributions of parity and other risk factors for my sample and the entire case sample were 
similar (data not shown), improving the likelihood that cases with ER and PR data available are 
representative of the distribution of these hormonal subtypes for the entire case sample, however 
the requirement that ER and PR status be known resulted in a case sample with more recent 
diagnosis, and more recent history of relevant risk factors, such as parity, breastfeeding, and oral 
contraceptive use, resulting in small sample size for evaluating risk factors occurring further in 
the past (such as OC use prior to 1975). Additional follow-up and information gathering for the 
clinic-based sample, where case information is missing, would make findings more robust to 
selection bias. In addition, detection bias may have played a role in diagnosis of the cases. 
Although detection bias is more often considered an issue of prospective studies, in this instance, 
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cases may have screened more often and diagnosed early, because of a known family history of 
breast cancer; some cases may also have diagnosed prospectively, if controls with family history 
or BRCA1/2 carriers, converted to cases status during the study. Detection bias, if present, would 
have tended to find cancers of smaller tumor size and earlier stage, and also resulted in younger 
age at diagnosis, resulting in poorer generalizability of the case sample to breast cancer cases 
found through more typical surveillance levels. 
Comparison group:  For this analysis, I used family-based controls as the common referent 
group. I did not observe some established associations between hormonal and reproductive 
factors and hormonal status. For example, I did not find high parity to be inversely associated 
with ER+PR+ cancer, while most studies have found parity to be protective against this subtype 
even among younger women (Table 1-3, Table 1-4). However, given the high familial 
component of cancer risk in this population, it is not surprising that risk factors associated with 
average-risk breast cancer populations, would not have the same association in a population with 
high familial risk and a sizable contingent of BRCA mutation carriers. Generalized estimating 
equations were performed, to minimize the correlation effect of related controls on case findings. 
Case definitions: BCFR pathologists used common laboratory procedures and conducted a 
centralized pathology review to categorize the majority of cases. A recent study has 
demonstrated that cancer registry-provided data may undercount the rarer ER/PR combinations, 
such as ER-PR+ and ER+PR- tumors, and that centralized pathology review should be 
considered a gold-standard when classifying tumors by hormone receptor status [176]. The 
criteria for defining women as ER+ or PR+ were more stringent for this analysis than criteria 
typically used today. This may limit the ability to compare this study’s findings to similar 
analyses in patients who have been classified as HR+ under less stringent criteria for positivity. 
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Information Bias: The possibility of recall bias exists, because I relied on participants’ recalls of 
their exposures, and in some instances, interviews occurred several years after breast cancer 
diagnosis, which may not only affect accuracy of recall, but also introduced survivor bias. 
However, the purpose of this analysis was to determine whether risk factor associations differed 
by subtype, using controls as a common comparison group. Because it is unlikely that cases 
report exposures differently based on their ER status, PR status, or grade, it is unlikely that OR 
estimates would be affected by recall bias of exposures that are differential by subtype. Survivor 
bias can be minimized by limiting the analysis to cases that completed their interview within 2 
years of initial breast cancer diagnosis. 
Generalizability: My sample of cases is not representative of all women with breast cancer; they 
are younger, and are likely to have a strong family history of breast cancer and to be BRCA1 or 
BRCA2+. Controls are also non-representative of a population-based control sample; the controls 
are young, and have higher than average risk of breast cancer due to family history of disease, or 
BRCA1 or 2 positivity. As a result my distribution of the different ER and PR-defined subtypes is 
not representative of these subtypes in a sample of cases unselected for these characteristics. 
Regardless, the purpose of this analysis is to examine risk factor by tumor subtypes specifically 
in a high-risk, familial, population, therefore comparisons to “typical” populations are neither 
expected or of value versus comparisons to other high-risk populations. To this end, my findings 
do reflect previous reports that examine younger women with high familial risk, including 
BRCA1 carriers. 
A familial (related) sample is expected to have limited generalizability to a more typical 
population. Familial breast cancers have been found to differ in their prevalence of various 
clinical and immunohistochemical features [48]. For example, women  with familial breast 
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cancers are more often younger, have microcalcifications on mammography [48], have tumors  
of smaller size on detection (likely a result of increased surveillance), and are less likely to be ER 
and PR+, than sporadic breast cancers [48]. Hispanics with a family history of breast cancer are 
more likely to have ER-, but not ER+ breast cancers, while whites with a family history of breast 
cancer are more likely to have ER+, but not ER- breast cancers [190]. In particular, 
generalizability to older patients may be inappropriate. 
Summary 
Overall, I found that multiparity is associated with an increased risk of ER-PR- and ER+PR+ 
cancer, in a high-risk population, compared to familial controls. Among cases interviewed within 
2 years of breast cancer diagnosis, this finding was not maintained for ER+PR+ cases. I found 
that the risk for ER-PR- cancer can be mitigated by breastfeeding, such that multiparous women 
with a history of breastfeeding are no longer at increased risk of ER-PR- cancer. I found that oral 
contraceptive use is associated with increased risk of ER-PR- cancer, but only in populations 
who began use prior to 1975. In populations using newer formulations of oral contraceptive, a 
protective effect against ER+PR+ cancer was demonstrated. As 1975 is now more than 40 years 
in the past, more recent contraceptive use may not be a risk factor for breast cancer, according to 
this study, and may even be associated with a preventive effect against ER+PR+ cancer.  
I found that in cases with a high genetic predisposition to breast cancer, the causal association of 
environmental factors may be minimized, resulting in different risk factor associations for high-
risk populations, than may exist for average risk populations. Finally, I found that several risk 
factors were associated with high grade tumors (parity, oral contraceptive use) and that breast 
feeding was protective against ER-, PR-, and high grade tumors, in a population with a high 
genetic predisposition for cancer. The breastfeeding findings indicate that the acquisition of 
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certain poor-prognosis tumor characteristics in breast cancer, such as ER and PR negativity, and 
high grade, may be ameliorated through environmental actions, such as breastfeeding, even in 
women who have a high genetic predisposition to cancer, including BRCA carriers. These 
findings have significance for reducing the rate of poor-prognosis tumor characteristics, in 




Table 3-1: Demographic and Tumor Characteristics by ER/PR status, BCFR Clinic-Based 
Sample 
















Age (µ± s.d.) 44.4±15.0 50.2±12.3 51.6±15.0 43.2±10.3 44.2±11.1 
Race       
  White 3031 (80) 284 (74) 59 (71) 34 (72) 145 (66) 
  Black 66 (2) 17 (5) 6 (7) 1 (2) 20 (9) 
  Hispanic 474 (13) 61 (15) 14 (17) 7 (14) 39 (17) 
  Asian 85 (2) 9 (2) 2 (2) 7 (4) 149 (3) 
 Other 125 (3) 15 (4) 2 (2) 4 (8) 12 (5) 
Site      
  Philadelphia 882 (23) 69 (16) 26 (25) 3 (5) 51 (20) 
  New York 2124 (56) 287 (66) 58 (58) 39 (73) 137 (54) 
  Utah 788 (21) 80 (18) 16 (17) 11 (22) 66 (26) 
Menopausal 
Status 
     
  Pre 2530 (67) 159 (37) 36 (36) 22 (42) 127 (50) 
  Post  1264 (33) 277 (63) 64 (64) 31 (58) 127 (50) 
Education      
 < High school 756 (20) 103 (24) 20 (24) 9 (18) 64 (28) 
 ≥ High school 3028 (80) 285 (76) 63 (76) 39 (82) 160 (72) 
OC Use      
  Never 1245 (36) 164 (46) 35 (46) 13 (32) 59 (30) 
  ≤ 5 years 1319 (38) 112 (33) 25 (30) 14 (32) 80 (40) 
  > 5 years 867 (25) 76 (22) 19 (24) 16 (36) 59 (30) 
Date of first OC 
use 
     
Never 1245 (34) 164 (42) 35 (44) 13 (28) 59 (26) 
Before 1975 959 (26) 134 (35) 23 (28) 23 (48) 73 (34) 
1975 or later 1479 (40) 85 (23) 25 (29) 12 (24) 90 (40) 
HRT Use      
  Never 2778 (77) 300 (74) 66 (76) 41 (82) 189 (80) 
  Former 335 (9) 7 (2) 1 (1) 3 (6) 37 (5) 
  Current 496 (14) 97 (24) 19 (22) 6 (12) 11 (16) 
Age at 
menarche 
     
 ≤ 11 734 (20) 94 (23) 14 (16) 11 (22) 37  (15) 
  12 1020 (27) 118 (29) 25 (29) 11 (22) 89 (37) 
  ≥ 13 1983 (53) 193 (48) 48 (55) 28 (56) 113 (48) 
Parity      
  Nulliparous 1114 (29) 66 (17)     10 (12) 14 (29) 49 (22) 
 1-2 live births 1517 (40) 179 (46)     44 (53)      30 (61) 99 (44) 
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 ≥3 live births 1157 (31) 143(37)     29 (35) 5 (10) 76 (34) 
Age at first 
birth 
25.1±5.1 25.3±5.3 25.1±4.9 26.2±6.5 24.3±5.2 
Breastfeeding 
duration 
     
  Never 1847 (50) 164 (42) 35 (43) 28 (55) 108 (47) 
  < 12 mos. 1072 (29) 137 (36) 33 (39) 18 (37) 74 (35) 
  ≥ 12 mos. 757 (21) 82 (22) 15 (18) 3 (8) 39 (18) 
BMI  25.2 26.1 25.6 24.5 26.5 
Tumor Grade      
  1, 2 NA 179 (63) 39 (66) 11 (28) 30 (18) 
  3 NA 106 (37) 20 (34) 28 (72) 135 (82) 
BRCA1 status      
Status missing 1006 (25) 106 (22) 32 (32) 8 (15) 61 (24) 
BRCA1 positive 262 (7) 14 (4) 5 (5) 6 (11) 56 (22) 
BRCA1 negative 2526 (67) 324 (74) 63 (63) 39 (74) 137 (54) 
BRCA2 status      
Status missing 1071 (28) 97 (23) 33 (33) 9 (17) 73 (29) 
BRCA2 positive 173 (5) 32 (7) 6 (6) 6 (11) 18 (7) 




Table 3-2: Association between parity and breastfeeding, and breast cancer classified by 
hormone status in the BCFR Clinic, adjusted models* 








OR (95%CI) OR (95%CI) OR (95%CI) 
Parity, LOGISTIC    
Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  1-2 live births 1.63 (1.13-2.36) 1.90 (1.20-3.00) 1.16 (0.66-2.04) 
  ≥ 3 live births 1.35 (0.89-2.06) 1.85 (1.09-3.13) 1.37 (0.72-2.59) 
Parity, GEE    
Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  1-2 live births 1.62 (1.10-2.38) 2.10 (1.27-3.48) 1.01 (0.58-1.77) 
  ≥ 3 live births 1.40 (0.90-2.19) 2.10 (1.16-3.81) 1.14 (0.59-2.18) 
Breastfeeding 
duration, LOGISTIC 
   
 Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  < 12 mos. 1.23 (0.91-1.64) 0.88 (0.61-1.29) 0.72 (0.46-1.13) 
  ≥ 12 mos. 1.17  (0.84-1.65) 0.70 (0.45-1.11) 0.60 (0.35-1.02) 
Breastfeeding 
duration, GEE 
   
  Never    
  <12 mos. 1.19 (0.89-1.59) 0.83 (0.57-1.19) 0.73 (0.47-1.13) 





Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 
1-2 live births, never BF 1.41 (0.94-2.13) 1.65 (1.00-2.73) 1.17 (0.63-2.16) 
≥ 3 live births, never BF 1.47 (0.92-2.36) 1.72 (0.95-3.13) 1.17 (0.57-2.40) 
1-2 live births, ever BF 2.25 (1.45-3.49) 1.44 (0.80-2.61) 0.64 (0.32-1.29) 
≥ 3 live births, ever BF 1.39 (0.95-2.05) 1.22 (0.76-1.98) 0.88 (0.49-1.59) 
Breastfeeding and 
parity, GEE 
   
Nulliparous    
1-2 live births, never BF 1.45 (0.95-2.21) 1.75 (1.00-3.04) 1.01 (0.56-1.80) 
≥ 3 live births, never BF 1.63 (0.91-2.48) 2.07 (1.09-3.91) 1.03 (0.50-2.11) 
1-2 live births, ever BF 2.11 (1.34-3.33) 1.56 (0.84-2.88) 0.60 (0.28-1.30) 
≥ 3 live births, ever BF 1.47 (0.98-2.20) 1.31 (0.77-2.24) 0.76 (0.43-1.36) 
*Adjusted for age, center, parity, oral contraceptive use, race, breastfeeding, menopausal status, family history 




Table 3-3: Association between oral contraceptive use and breast cancer classified by hormone 







OR (95%CI) OR (95%CI) OR (95%CI) 
OC Use , LOGISTIC    
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  ≤ 5 years 0.77 (0.58-1.02) 1.40 (0.97-2.03) 1.83 (1.17-2.84) 
  > 5 years 0.79 (0.58-1.07) 1.49 (1.00-2.21) 1.90 (1.17-3.06) 
OC Use, GEE    
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  ≤ 5 years 0.76 (0.57-1.01) 1.45 (0.99-2.11) 1.60(1.04-2.44) 
  > 5 years 0.81 (059-1.11) 1.50 (1.01-2.23) 1.56 (0.97-2.53) 
Date of first OC use, 
LOGISTIC 
   
Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Before 1975 0.94 (0.73-1.22) 1.62 (1.11-2.36) 1.71 (1.11-2.64) 
1975 or later 0.56 (0.41-0.78) 1.18 (0.80-1.75) 2.10 (1.29-3.42) 
Date of first OC use, 
GEE 
   
Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Before 1975 0.95 (0.72-1.23) 1.60 (1.08-2.37) 1.46 (0.95-2.25) 
1975 or later 0.56 (0.41-0.78) 1.22 (0.83-1.80) 1.80 (1.07-3.03) 
*Adjusted for age, center, parity, oral contraceptive use, race, breastfeeding, menopausal status, family history 




Table 3-4: Association between parity, breastfeeding, and oral contraceptive use and breast 






OR (95%CI) OR (95%CI) 
Parity, LOGISTIC   
  Nulliparity 1.0 (ref) 1.0 (ref) 
  1-2 live births 3.21 (0.90-11.47) 1.42 (0.56-3.61) 
  3+  live births 2.78 (0.70-11.23) 1.99 (0.70-5.66) 
Parity, GEE   
  Nulliparity 1.0 (ref) 1.0 (ref) 
  1-2 live births 3.39 (0.80-14.36) 1.39 (0.53-3.68) 




  Never 1.0 (ref) 1.0 (ref) 
  <12 mos. 1.65 (0.67-4.02) 1.28 (0.59-2.80) 
  ≥ 12 mos. 0.62  (0.21-1.84) 0.35 (0.14-0.93) 




  Never 1.0 (ref) 1.0 (ref) 
  <12 mos. 1.49 (0.60-3.67) 1.29 (0.61-2.71) 
  ≥ 12 mos. 0.60 (0.19-1.92) 0.41 (0.16-1.06) 
OC Use, LOGISTIC   
  Never 1.0 (ref) 1.0 (ref) 
  ≤ 5 years 1.61 (0.64-4.05) 1.65 (0.71-3.87) 
  > 5 years 1.17 (0.38-3.66) 4.37 (1.85-10.36) 
OC Use, GEE   
  Never 1.0 (ref) 1.0 (ref) 
  ≤ 5 years 1.15 (0.52-2.55) 1.74 (0.78-3.87) 
  > 5 years 1.67 (0.73-3.80) 3.53 (1.59-7.86) 
Date of first OC use, 
LOGISTIC 
  
Never 1.0 (ref) 1.0 (ref) 
Before 1975 1.17 (0.52-2.63) 4.10 (1.98-8.51) 
1975 or later 1.20 (0.52-2.80) 1.60 (0.77-3.35) 
Date of first OC use, GEE    
Never 1.0 (ref) 1.0 (ref) 
Before 1975 0.97 (0.41-2.32) 3.43 (1.52-7.75) 
1975 or later 1.39 (0.60-3.21) 1.73 (0.81-3.71) 
*Adjusted for age, center, menopausal status, family history and factors in the table 

































































































































































































































































































































































































































































Table 3-5A: Associations between parity, breastfeeding and select tumor characteristics; case-
case analysis and pseudo-conditional likelihood findings, Clinic-Based sites of the BCFR  
 ER- (vs. ER+) PR- (vs. PR+) Grade (3 vs. 1,2) 
OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) 
 Polytomous PCL Polytomous PCL Polytomous PCL 
 
      
Parity       
  Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  1-2 live births 0.98 (0.58-1.66) 0.52 (0.22-1.27) 1.17 (0.70-1.95) 1.77 (0.80-3.90) 1.90 (1.00-3.59) 2.17 (1.08-4.38) 
  ≥ 3 live births 1.00 (0.56-1.80) 0.46 (0.17-1.29) 1.24 (0.70-2.18) 1.50 (0.62-3.62) 1.96 (0.95-4.01) 2.23 (1.02-4.86) 
Breastfeeding 
duration 
      
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
 <12 mos. 0.68 (0.44-1.05) 1.34 (0.65-2.74) 0.80 (0.53-1.21) 0.95 (0.51-1.90) 0.54 (0.32-0.91) 0.48 (0.27-0.86) 
  ≥ 12 mos. 0.49 (0.28-0.84) 0.79 (0.33-1.89) 0.58 (0.35-0.97) 0.72 (0.34-1.56) 0.40 (0.21-0.73) 0.47 (0.25-0.91) 
Parity and 
Breastfeeding 
   
 
  
Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
1, 2 live births, 
no BF 
1.09 (0.62-1.93) 0.65 (0.24-1.80) 1.23 (0.70-2.15) 2.06 (0.84-5.08) 1.78 (0.89-3.57) 1.84 (0.85-3.96) 
≥ 3 live births, 
no BF 
0.82 (0.41-1.63) 0.29 (0.08-1.05) 1.23 (0.63-2.37) 1.96 (0.66-5.81) 1.53 (0.67-3.53) 1.96 (0.80-4.81) 
1, 2 live births, 
some BF 
0.41 (0.20-0.85) 0.42 (0.13-1.33) 0.58 (0.29-1.16) 1.24 (0.41-3.78) 0.62 (0.28-1.35) 0.84 (0.36-1.98) 
≥ 3 live births, 
some BF 
0.64 (0.36-1.13) 0.51 (0.18-1.41) 0.92 (0.53-1.61) 1.54 (0.63-3.76) 0.84 (0.44-1.62) 0.91 (0.44-1.88) 
Note: All ORs adjusted for age, race, study site, parity, breastfeeding, oral contraceptive use, family history, and menopausal 






Table 3-5B: Associations between oral contraceptive use and select tumor characteristics; 
case-case analysis and pseudo-conditional likelihood findings, Clinic-Based sites of the BCFR  
 ER- (vs. ER+) PR- (vs. PR+) Grade (3 vs. 1,2) 
OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) 
 Polytomous PCL Polytomous PCL Polytomous PCL 
       
OC Use       
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  ≤ 5 years 1.56 (1.02-2.40) 1.49 (0.75-2.97) 1.57 (1.04-2.37) 1.51 (0.81-2.83) 1.42 (0.86-2.33) 1.16 (0.67-2.01) 
  > 5 years 1.74 (1.09-2.77) 1.53 (0.70-3.34) 1.41 (0.90-2.20) 1.42 (0.71-2.82) 1.48 (0.84-2.63) 1.24 (0.66-2.33) 
OC Use 1975       
Never Used OCs 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Used OC before 1975 1.75 (1.15-2.67) 1.90 (0.95-3.80) 1.29 (0.87-1.92) 1.10 (0.60-2.02) 1.27 (0.79-2.06) 1.01 (0.60-1.71) 
Used OC 1975 or later 1.33 (0.82-2.15) 1.16 (0.53-2.55) 1.78 (1.11-2.84) 1.88 (0.92-3.83) 1.09 (0.61-1.94) 0.96 (0.51-1.80) 
Note: All ORs adjusted for age, race, study site, parity, breastfeeding, oral contraceptive use, family history, and menopausal 




Chapter 4: Comparison of Population-Based and Clinic-Based Findings, and Conclusion 
In the previous two chapters, I examined select risk factors, primarily breastfeeding (and its 
relationship with parity) and oral contraceptive use, in high risk and familial populations. The 
changing nature of these risk factors was accounted for in the analysis of the population-based 
cases, as was the effect of these factors when paired with family history and the presence of 
genetic mutations that predispose to breast cancer (BRCA1 and 2). 
Table 4-1 compares the demographic, risk factor and tumor characteristic frequencies for cases 
and controls at the population-based sites, with cases and controls at the clinic-based sites. 
Differences largely reflect that the clinic-based patients consist of a population with familial 
breast cancer, while population-based cases may or may not be familial. The clinic-based cases 
are more likely to be ER-PR- (30% of clinic-based cases vs. 23% of population-based cases), to 
have a high-tumor grade (53% of clinic-based cases grade 3, 41% of population-based cases 
grade 3), to be BRCA1 positive (13% of clinic-based cases, vs 7% of population-based cases), 
and BRCA2 positive (10% of clinic-based cases, vs. 5% of population-based cases). The 
population-based cases, for whom racial minorities were purposefully over-sampled, are more 
ethnically diverse (61% Non-Hispanic White, vs. 71% Non-Hispanic White among the clinic-
based cases), however a higher percentage of clinic-based cases are Hispanic (16%, vs. 10% of 
population-based cases), likely due to the sites of recruitment for clinic-based populations. 
Clinic-based cases and controls were more likely to be never-users of oral contraceptives (40% 
and 36% of clinic-based cases and controls were never users, vs. 26% and 22% of population-
based cases and controls). Twenty-nine percent of clinic-based controls were nulliparous, 
compared with 18% of population-based controls. Population-based cases were more likely to 
have been current users of HRT (16% compared to 3% of clinic-based) while clinic-based cases 
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were more likely to be former users (20% of clinic-based cases compared to 8% of population-
based cases). Population-based controls were more likely to be age 13 or greater at menarche, 
than were clinic-based controls (68%, vs. 53%). Clinic-based controls were more likely to have 
never breast-fed (50%), compared with population-based controls (40%), which is unsurprising 
given the lower rate of parity among the clinic-based controls. Given differences between cases 
and controls in the two populations studied, it is perhaps unsurprising to find differences in risk 
factor associations with ER-PR- defined breast cancer subtypes. 
Differences in Analytic Findings: Population-Based and Clinic-Based Data 
Parity and Breastfeeding: In the analysis from Chapter 2, I found that, within the population-
based cohorts of the BCFR, high parity (3+ live births) without breastfeeding was positively 
associated with ER-PR- tumors, but not with ER+PR+ tumors. Breastfeeding was associated 
with a reduced risk of all breast cancer subtypes, but most strongly with ER-PR- tumors. High 
parity, when coupled with breastfeeding, was no longer associated with ER-PR- cancer.  
In Chapter 3, where the same analysis was completed with a clinic-based population of breast 
cancer cases and familial controls, high parity was associated with both ER+PR+, and ER-PR- 
tumors, and breastfeeding was only associated with reduced odds of ER-PR- cancer. However, 
after limiting the clinic-based analysis to cases who were interviewed within 2 years of diagnosis 
(to minimize potential survivorship bias), parity was no longer associated with ER+PR+ tumors. 
Childbirth associated with lack of breastfeeding was associated with an increased risk of ER-PR- 




Thus, the polytomous logistic findings for the ER-PR- patients are generally consistent across the 
clinic-based and population-based samples in regards to parity and breastfeeding, despite the 
differences in the sample (Table 4-2). 
Risk factors are less consistent in their associations with ER+PR+ cancers (Table 4-2). Parity and 
breastfeeding findings have different interpretations, across the population-based and clinic-
based samples. The parity association in the clinic-based sample may have limited 
interpretability due to possible survivorship bias, but even among clinic-based cases interviewed 
close to diagnosis, when this bias is not present, there is no association (rather than an inverse 
association) between parity and ER+PR+ type, different from what was found in the population-
based cases. Parity has been found to have a different association with ER/PR status among post-
menopausal and premenopausal women, in other studies as well as in Chapter 2 of this 
dissertation, which found parity to be protective only among postmenopausal women.  
Additionally, there is no protective association of breastfeeding on ER+PR+ cancer in the clinic-
based sample, in contrast to the findings in the population-based sample, which found long-term 
breastfeeding to be protective against all subtypes. However, analysis stratified by menopause 
also indicated that there was no association between breastfeeding and postmenopausal ER+PR+ 
status. Additional analysis in premenopausal, vs. postmenopausal, cased in the clinic-based 
sample, should be undertaken to determine if findings by menopause are similar to those in the 
population-based sample. 
Findings remain inconsistent when comparing findings from the pseudo-conditional likelihood 
approach, in the population-based and clinic-based samples. Parity is positively associated with 
ER negativity, but not PR negativity or grade, in the population-based cases. Parity is positively 
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associated with Grade, but not ER negativity or PR negativity, in the clinic-based cases. The 
association with breastfeeding is more consistently maintained:  breastfeeding is inversely 
associated with ER negativity, in both population-based and clinic-based samples, and 
breastfeeding is unassociated with PR status, in both analyses. 
In the population-based sample, associations between parity and ER- cancer, appear to be driven 
through estrogen receptor negativity, whereas in the clinic-based sample, apparent associations 
between parity and ER- cancer appear to in fact be an association between parity and high grade. 
(One or both associations could also be linked to another tumor characteristic not studied in-
depth in this dissertation, that correlates to both ER status and grade, such as HER2 status). 
Hypotheses about why parity would be associated with negative ER status, and high grade, are 
provided in the discussions in Chapters 2 and 3. The reasons behind the difference by sample 
type could be due to the “level” of familial risk in each sample. The differences related to parity, 
and its association with different tumor characteristics (ER-status in the population-based 
sample, and grade in the clinic-based sample) may result from structural differences of the 
sample constructs. Although both samples represent high-risk populations, the population-based 
cases had fewer first-degree (and total) relatives with breast cancer, than did clinic-based cases. 
They also were about half as likely to be BRCA1 or BRCA2 positive. BRCA1 and BRCA2 
positive cases typically have high grade tumors, regardless of ER/PR status, and some studies 
have demonstrated that familial cancer (whether BRCA+ or not) tends to be of higher grade than 
non-familial cancer [38, 87]. It could be that in the familial sample, an apparent association 
between parity and grade, is simply the effect  being a familial or BRCA positive case, and grade 
obfuscates (or minimizes) any individual risk factors. 
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In the population-based sample, because younger women (but not always women with family 
history) were purposefully recruited, the population-based cases may represent those who had a 
higher “environment-driven” predilection for breast cancer, while the clinic-based cases had a 
higher genetic component to their breast cancer, thus limiting the role of environmental factors in 
contributing to breast cancer etiology. In such a case, a factor (such as parity) may have an 
apparent link to tumor characteristic such as grade, but may in fact not be causative. Among 
cases with a first-degree family history, across both population-based and clinic-based samples, 
findings were more similar: parity remained positively associated with ER-PR- cancer, only in 
those cases without a first degree family history, in both samples. The similarity of findings 
when stratifying by family history lends further support to the idea that considering family 
history is of value when comparing risk factor associations with tumor characteristics, across 
different samples of cases, and also demonstrates that in the presence of family history, 
environmental risk factor effects on disease incidence may be diminished. 
The findings regarding breastfeeding are more consistent across samples, and in line with 
findings of previous studies, demonstrating that breastfeeding appears to provide the strongest 
protection against ER- cancer, with pseudo-conditional findings indicating that the estrogen 
receptor status is the tumor characteristic (among ER, PR, or grade) most influenced by 
breastfeeding. This protective effect may be due to breastfeeding’s effect on alterations in 
hormones such as androgens, which may suppress cell proliferation in ER+ tumors, but can 
promote tumorigenesis in ER-tumors [191]. 
Oral contraceptive use: In the population-based sample in cases compared with controls, oral 
contraceptive (OC) use prior to 1975 was associated with an increased risk of ER-PR- cancer but 
not ER+PR+ cancer. For women who began use in 1975 or later there was no increased risk 
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conferred by OC use, in the ER-PR- cases, and an inverse association between OC use and 
ER+PR+ cancer. In the clinic-based sample, compared with controls, oral contraceptive use was 
associated only with a risk of ER-PR- tumors, and in case-only analysis, was associated with ER-
PR- tumors compared with ER+PR+ tumors. Similar to women in the population-based findings, 
for women who used oral contraceptives prior to 1975, there was an increased risk of ER-PR- 
cancer, compared with controls, and no such association with ER+PR+ cancer. For women who 
began using contraceptives in 1975 or later, there was no significant association with ER-PR- 
cancer, when compared with controls, and there was an inverse association between OC use and 
ER+PR+ cancer, among women who began using OCs after 1975. Thus, the findings regarding 
OC use are generally consistent across the population and clinic-based samples, when comparing 
ER+PR+ cases from each sample set, and ER-PR- cases from each sample set. The consistency 
of findings indicates that the finding is robust to study design and sample composition, and that 
OCs can have null, protective, and negative effects, depending on start date and duration of use, 
in populations regardless of their existing levels of genetic predisposition to breast cancer. 
As was the case with parity and breastfeeding, the findings between cases in the population-
based sample, and in the clinic-based sample, are less consistent when examining the association 
for ER- vs. ER+, PR- vs. PR+, and low grade vs. high grade tumors, after accounting for 
correlation of these factors. Oral contraceptive use of greater than 5 years was associated with 
ER negativity, PR negativity, and high grade, in the clinic-based sample, but with only high 
grade, in the population-based sample. Oral contraceptive use prior to 1975 was associated with 
ER- in the clinic-based sample, but only slightly elevated in the population-based sample. Oral 
contraceptive use after 1975 was associated with high grade in the population-based, but not the 
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clinic-based sample, but OC use after 1975 was associated with PR negativity in the clinic-based 
sample, but not the population-based sample.  
Because some of these estimates are non-significant, particularly in the clinic-based sample 
where there are fewer cases for analysis, interpretability of these differences is challenging. 
However it is feasible that oral contraceptives operate differently, in women with high genetic 
predisposition to cancer [167, 187, 192]. Thus although both populations are affected by oral 
contraceptive use, the high rate of BRCA1 and BRCA2 carriers and individuals with multiple 
family members with breast cancer, in the clinic-based cases, may affect both the mechanism by 
which oral contraceptives affect breast cancer risk, as well as familial control (and case ) 
decisions to use oral contraceptives. It is notable that in cases with at least one first-degree 
relative with breast cancer, the association between oral contraceptive use and breast cancer was 
minimized or non-significant, and this was true for both clinic-based and population-based cases. 
Therefore oral contraceptive use may be a bigger driver of breast cancer risk (or protection) 
among women who do not already have an elevated genetic predisposition to breast cancer. 
Conclusion 
In this dissertation, I summarized existing literature on reproductive and hormonal risk factors 
for breast cancer defined by estrogen receptor and progesterone receptor status and molecular 
subtype, among average-risk and high-risk populations. I also independently examined the role 
of parity, breastfeeding, and oral contraceptive use, in development of different cancer subtypes 
and tumor characteristics, in two populations at high risk for breast cancer. Findings regarding 
breastfeeding and oral contraceptive use were generally consistent across studies, as were 
findings related to parity for the ER-PR- subtype. Parity findings regarding the ER+PR+ subtype 
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were inconsistent, for reasons that may be related to case ascertainment in the clinic-based 
sample. Additional analyses using a two-stage regression approach, the pseudo-conditional 
likelihood method, revealed that apparent associations with parity and ER negativity or oral 
contraceptive use, may actually represent associations with the correlated tumor characteristic of 
grade, a finding that allows for hypothesis generation around mechanism of action in terms of 
how the risk factor leads to specific tumor subtype. Specific analyses in the population-based 
sample further demonstrated the changing nature of oral contraceptive use and breast cancer risk, 
according to age cohort, demonstrated that the protective nature of breastfeeding against ER-PR- 
cancer exists regardless of race, and also confirmed findings in previous literature, regarding the 
associations between breastfeeding, parity, and triple-negative subtypes. Analyses in both the 
population-based and clinic-based sample described the way in which risk factor associations 
may differ in regard to outcome, for those with and without first-degree relatives with cancer, 
and analysis of BRCA1/2 cases demonstrated the importance of modifiable risk factors in 
reducing risk of poor prognosis disease. They also contribute to a relatively small body of 
literature evaluating risk factor associations with tumor characteristics in higher risk populations. 
Inclusion of these populations in such analyses is of value for understanding the relative 
importance of risk factors in all populations, as well as understanding biological mechanisms by 
which such factors may operate. 
Due to the high missingness of ER and PR status in the clinic-based sample and unavailability of 
HER2 status, I was unable to confirm all of the findings of the population-based sample, nor was 
I able to conduct age-cohort analyses, stratify by race, or conduct molecular subtype analyses. 
Grade was also missing for a large portion of the sample, limiting the power of the case-only 
analyses to determine significant findings. An update of both tumor and epidemiological data 
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from the clinic-based sites of the Breast Cancer Family Registry, should be undertaken to 
improve the power of the sample to detect associations or confirm null findings. 
Despite these limitations, these studies confirm a previous body of literature indicating that 
breastfeeding confers protection against ER-PR- and cancers, even in populations with existing 
genetic predisposition for breast cancer, and across all races and ethnicities. They also indicate 
that breastfeeding may protect against development of higher grade tumors. The studies also 
demonstrate that oral contraceptive use may be associated with risk primarily in cases with low 
to no genetic predisposition to breast cancer, but also that in general, oral contraceptive use is not 
associated with breast cancer risk in women whose OC use primarily occurred after 1975, thus 
recent formulations of contraceptives may confer little or no increased risk for breast cancer. 
Additional studies should continue to examine risk factor associations with tumor characteristics 
associated with prognosis, such as grade, to add to this limited body of literature, and provide 
hypothesis generation to understand possible mechanisms by which OC use may contribute to 
high grade.  
Many studies have examined the relation between breast cancer risk factors and breast cancer 
tumor markers. Despite the wealth of information on this topic, few studies have examined risk 
factors in high-risk or familial populations. If we can understand how environmental breast 
cancer risk factors differentially affect risk in high risk populations, women at high risk of breast 
cancer may be better able to make decisions that allow for reduction in overall risk. If, in 
addition, we can understand the role that these risk factors play in the etiology of subtypes with 
prognostic ramifications, we could tailor behavioral modifications to reduce the risk of those 
types of breast cancer associated with fewer treatment options and poorer survival, such as ER-
PR- or triple-negative breast cancers. For example, the World Cancer Research Fund/American 
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Institute for Cancer Research has estimated that over 40% of post-menopausal breast cancer 
could be prevented by reductions in alcohol, excess body weight, and inactivity [193]. However, 
most women at higher than average risk are more likely to be diagnosed prior to menopause, and 
alcohol and BMI have not been as strongly linked to premenopausal cancers [109, 111, 122, 194, 
195], thus the presence of these factors in higher risk women may not adequately aid in risk 
assessment, and risk may not be ameliorated by reducing such factors. Popular risk assessment 
models, such as the Gail model, include as part of risk assessment factors such as age at first live 
birth and age at menarche. Older age at first birth and younger age at menarche are known risk 
factors in average-risk women, but have not been consistently associated with increased risk in 
higher risk women, or consistently associated with development of poorer prognosis, ER-PR- 
tumors [19, 40, 54, 70, 98] . It is therefore unclear that incorporating such factors in risk 
assessment models is helpful in assessing risk for women at higher than average risk for not only 
breast cancer overall, but for poorer prognosis breast cancers. Thus, examining risk factor 
heterogeneity in the presence or absence of known risks such as family history, is not only 
important for improving understanding of disease etiology, but may also allow for more tailored 
evaluation of risk, as well as improve the ability to prevent cancers associated with poorer 
prognosis, among those for whom breast cancer may be less avoidable. 
The findings of this dissertation therefore have important implications, not only for generating 
hypotheses in regard to the etiology of different breast cancer subtypes, but also when 
considering which factors to evaluate in risk assessments of higher-risk women, and when 
counseling women at high risk for breast cancer on environmental factors that may reduce their 
risk for poorer prognosis tumors. The findings also add to the increasing body of literature that 
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demonstrates the value of breastfeeding on reduction of poorer prognosis tumors, across the risk 




Table 4-1: Comparison Risk Factor Frequencies in Population-Based and Clinic-Based 
BCFR Populations  
 Cases Controls 
 Population-Based 
Sites 
 Clinic-Based Sites Population-Based 
Sites 
Clinic-Based Sites 
 # % # % # % # % 
Sample Size 4011 100 843 100 2997 100 3794 100 
ERPR Status         
  ER+PR+ 2486 62 436 52 NA  NA  
  ER+PR- 397 10 100 12 NA  NA  
  ER-PR+ 208 5 53 6 NA  NA  
  ER-PR- 920 23 254 30 NA  NA  
Age at dx* (µ± s.d.) 47.5±9.5  48.1±12.6  47.6±10.3  44.4±15.0  
Tumor Grade         
  1, 2 1980 59 245 47 NA  NA  
  3 1384 41 273 53 NA  NA  
First Degree FH         
No 2886 72 344 46 2732 91 1252 33 
Yes 1109 28 403 54 263 9 2357 67 
BRCA1 positivity         
Negative 1264 93 571 87 NA  2526  91 
Positive 95 7 83 13 NA  262  9 
BRCA2 positivity         
Negative 1606 95 575 90 NA  2550 94 
Positive 78 5 65 10 NA  173 6 
Race         
  White 2428 61 522 71 2487 86 3031 80 
  Black 413 10 44 6 96  3 66 2 
  Hispanic 395 10 121 16 72 2 474 13 
  Asian 696 17 21 3 165  6 85  2 
  Other 58 1 32 4 82 3 125 3 
Menopausal Status         
  Pre 2326 61 344 41 1566 55 2530 67 
  Post 1513 39 499 59 1262  45 1264 33 
Education         
 ≤ High school 1169 30 196 26 908 30 756 20 
 > High school 2767 70 547 74 2082  70 3028  80 
OC Use         
  Never 1019 26 287 40 646 22 1245 36 
  ≤ 5 years 1476 38 241 34 1117 37 1319 38 
  > 5 years 1417 36 180 26 1216 41 867  25 
Date of first OC use         
Never 1019 26 287 37 646 22 1245 34 
Before 1975 1799 46 254 34 1435 48 959 26 
1975 or later 1093 28 218 29 898 30 1479 40 
HRT Use         





  Former 304 8 148 20 246 8 335 9 
  Current 625 16 21 3 663 22 496 14 
Age at menarche         
 ≤ 11 818 21 146 20 406 14 734 20 
  12 949 24 232 31 711 28 1020 27 
  ≥ 13 2149 55 365 49 1760 68 1983 53 
Parity         
  Nulliparous 902 22 141 19 531 18 1114 29 
  1-2 Live Births 1643 41 355 47 1334 45 1517 40 
  ≥ 3 Live Births 1466 37 259 34 1348 46 1157 31 
Age at first birth 25.0  25.0  24.8  25.1  
Breastfeeding duration         
  Never 1842 46 340 46 1203 40 1847 50 
  <12 mos. 1195 30 267 36 991 33 1072 29 
  ≥ 12 mos. 928 23 140 19 803  27 757 21 
Parity+Breastfeeding         
Nulliparous 902 23 141 20 531 19 1114 32 
1-2 live births, never BF 589 15 116 16 448 16 460 13 
3+ live births, never BF 351 9 83 11 224 8 272 8 
1-2 live births, ever BF 1029 26 208 29 768 27 891 25 
3+ live births, ever BF 1094 28 167 23 836 30 795 23 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































1. Jemal, A., E. Ward, and M.J. Thun, Recent trends in breast cancer incidence rates by age 
and tumor characteristics among U.S. women. Breast Cancer Res, 2007. 9(3): p. R28. 
2. Anderson, W.F., H.A. Katki, and P.S. Rosenberg, Incidence of breast cancer in the 
United States: current and future trends. J Natl Cancer Inst, 2011. 103(18): p. 1397-402. 
3. Brinton, L.A., et al., Recent trends in breast cancer among younger women in the United 
States. J Natl Cancer Inst, 2008. 100(22): p. 1643-8. 
4. Albain, K.S., et al., Racial disparities in cancer survival among randomized clinical 
trials patients of the Southwest Oncology Group. J Natl Cancer Inst, 2009. 101(14): p. 
984-92. 
5. Carey, L.A., et al., Race, breast cancer subtypes, and survival in the Carolina Breast 
Cancer Study. Jama, 2006. 295(21): p. 2492-502. 
6. Millikan, R.C., et al., Epidemiology of basal-like breast cancer. Breast Cancer Res Treat, 
2007. 
7. DeSantis, C.E., et al., Breast cancer statistics, 2015: Convergence of incidence rates 
between black and white women. CA Cancer J Clin, 2016. 66(1): p. 31-42. 
8. Kohler, B.A., et al., Annual Report to the Nation on the Status of Cancer, 1975-2011, 
Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J 
Natl Cancer Inst, 2015. 107(6): p. djv048. 
9. Blows, F.M., et al., Subtyping of breast cancer by immunohistochemistry to investigate a 
relationship between subtype and short and long term survival: a collaborative analysis 
of data for 10,159 cases from 12 studies. PLoS Med. 7(5): p. e1000279. 
10. Cancello, G., et al., Prognosis and adjuvant treatment effects in selected breast cancer 
subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol. 
11. Garcia-Closas, M., et al., Heterogeneity of breast cancer associations with five 
susceptibility loci by clinical and pathological characteristics. PLoS Genet, 2008. 4(4): 
p. e1000054. 
12. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data 
on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 
epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. 
Lancet, 1996. 347(9017): p. 1713-27. 
13. Anderson, D.E. and M.D. Badzioch, Combined effect of family history and reproductive 
factors on breast cancer risk. Cancer, 1989. 63(2): p. 349-53. 
14. Garcia-Closas, M., et al., Established breast cancer risk factors by clinically important 
tumour characteristics. Br J Cancer, 2006. 95(1): p. 123-9. 
15. Ricks, L.J., et al., Family history of cancer associated with breast tumor 
clinicopathological features. J Community Genet, 2014. 5(3): p. 233-40. 
16. Foulkes, W.D., et al., Estrogen receptor status in BRCA1- and BRCA2-related breast 
cancer: the influence of age, grade, and histological type. Clin Cancer Res, 2004. 10(6): 
p. 2029-34. 
17. Piccart-Gebhart, M.J., et al., Trastuzumab after adjuvant chemotherapy in HER2-positive 
breast cancer. N Engl J Med, 2005. 353(16): p. 1659-72. 
18. Romond, E.H., et al., Trastuzumab plus adjuvant chemotherapy for operable HER2-
positive breast cancer. N Engl J Med, 2005. 353(16): p. 1673-84. 
 133 
 
19. Althuis, M.D., et al., Etiology of hormone receptor-defined breast cancer: a systematic 
review of the literature. Cancer Epidemiol Biomarkers Prev, 2004. 13(10): p. 1558-68. 
20. Bardou, V.J., et al., Progesterone receptor status significantly improves outcome 
prediction over estrogen receptor status alone for adjuvant endocrine therapy in two 
large breast cancer databases. J Clin Oncol, 2003. 21(10): p. 1973-9. 
21. Yu, K.D., et al., Breast cancer patients with estrogen receptor-negative/progesterone 
receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen 
treatment. J Cancer Res Clin Oncol, 2008. 134(12): p. 1347-54. 
22. Yang, X.R., et al., Differences in risk factors for breast cancer molecular subtypes in a 
population-based study. Cancer Epidemiol Biomarkers Prev, 2007. 16(3): p. 439-43. 
23. Foulkes, W.D., I.E. Smith, and J.S. Reis-Filho, Triple-negative breast cancer. N Engl J 
Med, 2010. 363(20): p. 1938-48. 
24. Prat, A., et al., Clinical implications of the intrinsic molecular subtypes of breast cancer. 
Breast, 2015. 24 Suppl 2: p. S26-35. 
25. Ishitha, G., et al., Clinicopathological Study of Triple Negative Breast Cancers. J Clin 
Diagn Res, 2016. 10(9): p. EC05-EC09. 
26. Gammon, M.D., et al., Oral contraceptive use and other risk factors in relation to HER-
2/neu overexpression in breast cancer among young women. Cancer Epidemiol 
Biomarkers Prev, 1999. 8(5): p. 413-9. 
27. Ma, H., et al., Hormone-related risk factors for breast cancer in women under age 50 
years by estrogen and progesterone receptor status: results from a case-control and a 
case-case comparison. Breast Cancer Res, 2006. 8(4): p. R39. 
28. Ellingjord-Dale, M., et al., Parity, hormones and breast cancer subtypes - results from a 
large nested case-control study in a national screening program. Breast Cancer Res, 
2017. 19(1): p. 10. 
29. Islam, T., et al., Reproductive and hormonal risk factors for luminal, HER2-
overexpressing, and triple-negative breast cancer in Japanese women. Ann Oncol, 2012. 
30. Lambertini, M., et al., Reproductive behaviors and risk of developing breast cancer 
according to tumor subtype: A systematic review and meta-analysis of epidemiological 
studies. Cancer Treat Rev, 2016. 49: p. 65-76. 
31. Reeves, G.K., et al., Hormonal therapy for menopause and breast-cancer risk by 
histological type: a cohort study and meta-analysis. Lancet Oncol, 2006. 7(11): p. 910-8. 
32. Reeves, G.K., et al., Reproductive factors and specific histological types of breast 
cancer: prospective study and meta-analysis. Br J Cancer, 2009. 100(3): p. 538-44. 
33. Li, C.I., et al., Relationship between established breast cancer risk factors and risk of 
seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers 
Prev, 2006. 15(5): p. 946-54. 
34. Work, M.E., et al., Risk factors for uncommon histologic subtypes of breast cancer using 
centralized pathology review in the Breast Cancer Family Registry. Breast Cancer Res 
Treat, 2012. 
35. Yiangou, C., S. Shousha, and H.D. Sinnett, Primary tumour characteristics and axillary 
lymph node status in breast cancer. Br J Cancer, 1999. 80(12): p. 1974-8. 
36. Terry, M.B., et al., Oral contraceptive use and cyclin D1 overexpression in breast cancer 
among young women. Cancer Epidemiol Biomarkers Prev, 2002. 11(10 Pt 1): p. 1100-3. 
37. Schwartz, A.M., et al., Histologic grade remains a prognostic factor for breast cancer 
regardless of the number of positive lymph nodes and tumor size: a study of 161 708 
 134 
 
cases of breast cancer from the SEER Program. Arch Pathol Lab Med, 2014. 138(8): p. 
1048-52. 
38. Familial breast cancer: collaborative reanalysis of individual data from 52 
epidemiological studies including 58,209 women with breast cancer and 101,986 women 
without the disease. Lancet, 2001. 358(9291): p. 1389-99. 
39. Pharoah, P.D., et al., Family history and the risk of breast cancer: a systematic review 
and meta-analysis. Int J Cancer, 1997. 71(5): p. 800-9. 
40. Setiawan, V.W., et al., Breast cancer risk factors defined by estrogen and progesterone 
receptor status: the multiethnic cohort study. Am J Epidemiol, 2009. 169(10): p. 1251-9. 
41. Rosenberg, L.U., et al., Risk factors for hormone receptor-defined breast cancer in 
postmenopausal women. Cancer Epidemiol Biomarkers Prev, 2006. 15(12): p. 2482-8. 
42. Colditz, G.A., et al., Risk factors for breast cancer according to estrogen and 
progesterone receptor status. J Natl Cancer Inst, 2004. 96(3): p. 218-28. 
43. McCredie, M.R., et al., Risk factors for breast cancer in young women by oestrogen 
receptor and progesterone receptor status. Br J Cancer, 2003. 89(9): p. 1661-3. 
44. Jiang, X., et al., Family history and breast cancer hormone receptor status in a Spanish 
cohort. PLoS One, 2012. 7(1): p. e29459. 
45. Melchor, L., et al., Distinct genomic aberration patterns are found in familial breast 
cancer associated with different immunohistochemical subtypes. Oncogene, 2008. 
27(22): p. 3165-75. 
46. Phipps, A.I., et al., Family history of breast cancer in first-degree relatives and triple-
negative breast cancer risk. Breast Cancer Res Treat, 2011. 126(3): p. 671-8. 
47. Welsh, M.L., et al., Population-based estimates of the relation between breast cancer 
risk, tumor subtype, and family history. Breast Cancer Res Treat, 2009. 114(3): p. 549-58. 
48. D'Eredita, G., et al., Familial and Sporadic Breast Cancers: Differences in Clinical, 
Histopathological and Immunohistochemical Features. Int J Surg Pathol. 
49. Colditz, G.A., B.A. Rosner, and F.E. Speizer, Risk factors for breast cancer according to 
family history of breast cancer. For the Nurses' Health Study Research Group. J Natl 
Cancer Inst, 1996. 88(6): p. 365-71. 
50. Anderson, K.N., R.B. Schwab, and M.E. Martinez, Reproductive risk factors and breast 
cancer subtypes: a review of the literature. Breast Cancer Res Treat, 2014. 144(1): p. 1-
10. 
51. Carey, L., et al., Triple-negative breast cancer: disease entity or title of convenience? Nat 
Rev Clin Oncol, 2010. 7(12): p. 683-92. 
52. Gierach, G.L., A. Burke, and W.F. Anderson, Epidemiology of triple negative breast 
cancers. Breast Dis, 2010. 32(1-2): p. 5-24. 
53. Li, L., et al., Association between oral contraceptive use as a risk factor and triple-
negative breast cancer: A systematic review and meta-analysis. Mol Clin Oncol, 2017. 
7(1): p. 76-80. 
54. Largent, J.A., A. Ziogas, and H. Anton-Culver, Effect of reproductive factors on stage, 
grade and hormone receptor status in early-onset breast cancer. Breast Cancer Res, 
2005. 7(4): p. R541-54. 
55. Nichols, H.B., et al., Differences in breast cancer risk factors by tumor marker subtypes 
among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers 
Prev, 2005. 14(1): p. 41-7. 
 135 
 
56. Ambrosone, C.B., et al., Parity and breastfeeding among African-American women: 
differential effects on breast cancer risk by estrogen receptor status in the Women's 
Circle of Health Study. Cancer Causes Control, 2014. 25(2): p. 259-65. 
57. Cui, Y., et al., Associations of hormone-related factors with breast cancer risk according 
to hormone receptor status among white and African American women. Clin Breast 
Cancer, 2014. 14(6): p. 417-25. 
58. Ma, H., et al., Pregnancy-related factors and the risk of breast carcinoma in situ and 
invasive breast cancer among postmenopausal women in the California Teachers Study 
cohort. Breast Cancer Res, 2010. 12(3): p. R35. 
59. Ma, H., et al., Use of four biomarkers to evaluate the risk of breast cancer subtypes in the 
women's contraceptive and reproductive experiences study. Cancer Res, 2010. 70(2): p. 
575-87. 
60. Palmer, J.R., et al., Parity, lactation, and breast cancer subtypes in African American 
women: results from the AMBER Consortium. J Natl Cancer Inst, 2014. 106(10). 
61. Ritte, R., et al., Reproductive factors and risk of hormone receptor positive and negative 
breast cancer: a cohort study. BMC Cancer, 2013. 13: p. 584. 
62. Sweeney, C., et al., Reproductive history in relation to breast cancer risk among 
Hispanic and non-Hispanic white women. Cancer Causes Control, 2008. 19(4): p. 391-
401. 
63. Ursin, G., et al., Reproductive factors and subtypes of breast cancer defined by hormone 
receptor and histology. Br J Cancer, 2005. 93(3): p. 364-71. 
64. Warner, E.T., et al., Estrogen receptor positive tumors: do reproductive factors explain 
differences in incidence between black and white women? Cancer Causes Control, 2013. 
24(4): p. 731-9. 
65. Yang, X.R., et al., Associations of breast cancer risk factors with tumor subtypes: a 
pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer 
Inst, 2011. 103(3): p. 250-63. 
66. Iwasaki, M., et al., Body size and risk for breast cancer in relation to estrogen and 
progesterone receptor status in Japan. Ann Epidemiol, 2007. 17(4): p. 304-12. 
67. Bertrand, K.A., et al., Differential Patterns of Risk Factors for Early-Onset Breast 
Cancer by ER Status in African American Women. Cancer Epidemiol Biomarkers Prev, 
2017. 26(2): p. 270-277. 
68. Dolle, J.M., et al., Risk factors for triple-negative breast cancer in women under the age 
of 45 years. Cancer Epidemiol Biomarkers Prev, 2009. 18(4): p. 1157-66. 
69. Jia, X., et al., Reproductive factors and hormone receptor status among very young (<35 
years) breast cancer patients. Oncotarget, 2015. 6(27): p. 24571-80. 
70. Ma, H., et al., Reproductive factors and breast cancer risk according to joint estrogen 
and progesterone receptor status: a meta-analysis of epidemiological studies. Breast 
Cancer Res, 2006. 8(4): p. R43. 
71. Palmer, J.R., et al., Parity and lactation in relation to estrogen receptor negative breast 
cancer in African American women. Cancer Epidemiol Biomarkers Prev, 2011. 20(9): p. 
1883-91. 
72. Song, Q., et al., The diverse distribution of risk factors between breast cancer subtypes of 
ER, PR and HER2: a 10-year retrospective multi-center study in China. PLoS One, 2013. 
8(8): p. e72175. 
 136 
 
73. Rusiecki, J.A., et al., Breast cancer risk factors according to joint estrogen receptor and 
progesterone receptor status. Cancer Detect Prev, 2005. 29(5): p. 419-26. 
74. Phipps, A.I., et al., Reproductive history and oral contraceptive use in relation to risk of 
triple-negative breast cancer. J Natl Cancer Inst, 2011. 103(6): p. 470-7. 
75. Phipps, A.I., et al., Reproductive history and risk of three breast cancer subtypes defined 
by three biomarkers. Cancer Causes Control, 2011. 22(3): p. 399-405. 
76. Lara-Medina F, P.-S.V., Saavedra-Perez D, Blake-Cerda M, Arce C, Motola-Kuba D, 
Villarreal-Garza C, Gonzalez-Angulo AM, Bargallo E, Aquilar JL, Mohar A, Arrieta O, 
Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and 
association with menopausal status, body mass index, and parity. Cancer, 2011. 117(16): 
p. 3658-3669. 
77. Bartow, S.A., et al., Breast mammographic pattern: a concatenation of confounding and 
breast cancer risk factors. Am J Epidemiol, 1995. 142(8): p. 813-9. 
78. von Au, A., et al., Impact of reproductive factors on breast cancer subtypes in 
postmenopausal women: a retrospective single-center study. Arch Gynecol Obstet, 2017. 
295(4): p. 971-978. 
79. Ma, H., et al., Reproductive factors and the risk of triple-negative breast cancer in white 
women and African-American women: a pooled analysis. Breast Cancer Res, 2017. 
19(1): p. 6. 
80. Li, H., et al., BMI, reproductive factors, and breast cancer molecular subtypes: A case-
control study and meta-analysis. J Epidemiol, 2017. 27(4): p. 143-151. 
81. Kwan, M.L., et al., Epidemiology of breast cancer subtypes in two prospective cohort 
studies of breast cancer survivors. Breast Cancer Res, 2009. 11(3): p. R31. 
82. Phipps, A.I., et al., Reproductive and hormonal risk factors for postmenopausal luminal, 
HER-2-overexpressing, and triple-negative breast cancer. Cancer, 2008. 113(7): p. 1521-
6. 
83. Xing, P., J. Li, and F. Jin, A case-control study of reproductive factors associated with 
subtypes of breast cancer in Northeast China. Med Oncol, 2010. 27(3): p. 926-31. 
84. Lee, J.S., et al., Reproductive factors and subtypes of breast cancer defined by estrogen 
receptor, progesterone receptor, and human epidermal growth factor receptor 2: a 
register-based study from Korea. Clin Breast Cancer, 2014. 14(6): p. 426-34. 
85. Chen, L., et al., Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and 
Triple-Negative Breast Cancer Among Multiethnic Women. Cancer Epidemiol 
Biomarkers Prev, 2016. 25(9): p. 1297-304. 
86. Butt, S., et al., Parity and age at first childbirth in relation to the risk of different breast 
cancer subgroups. Int J Cancer, 2009. 125(8): p. 1926-34. 
87. Albrektsen, G., I. Heuch, and S.O. Thoresen, Histological type and grade of breast 
cancer tumors by parity, age at birth, and time since birth: a register-based study in 
Norway. BMC Cancer, 2010. 10: p. 226. 
88. Somasegar, S., L. Li, and C.L. Thompson, No association of reproductive risk factors 
with breast cancer tumor grade. Eur J Cancer Prev, 2016. 
89. Iwasaki, M., et al., Role and impact of menstrual and reproductive factors on breast 
cancer risk in Japan. Eur J Cancer Prev, 2007. 16(2): p. 116-23. 
90. Lord, S.J., et al., Breast cancer risk and hormone receptor status in older women by 
parity, age of first birth, and breastfeeding: a case-control study. Cancer Epidemiol 
Biomarkers Prev, 2008. 17(7): p. 1723-30. 
 137 
 
91. Li, C.I., et al., Reproductive factors and risk of estrogen receptor positive, triple-
negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. 
Breast Cancer Res Treat, 2013. 137(2): p. 579-87. 
92. Ambrosone, C.B., et al., Important Role of Menarche in Development of Estrogen 
Receptor-Negative Breast Cancer in African American Women. J Natl Cancer Inst, 2015. 
107(9). 
93. Ritte, R., et al., Height, age at menarche and risk of hormone receptor-positive and -
negative breast cancer: a cohort study. Int J Cancer, 2013. 132(11): p. 2619-29. 
94. Orgeas, C.C., et al., The influence of menstrual risk factors on tumor characteristics and 
survival in postmenopausal breast cancer. Breast Cancer Res, 2008. 10(6): p. R107. 
95. Islami, F., et al., Breastfeeding and breast cancer risk by receptor status--a systematic 
review and meta-analysis. Ann Oncol, 2015. 26(12): p. 2398-407. 
96. Gaudet, M.M., et al., Risk factors by molecular subtypes of breast cancer across a 
population-based study of women 56 years or younger. Breast Cancer Res Treat, 2011. 
130(2): p. 587-97. 
97. Butt, S., et al., Breastfeeding in relation to risk of different breast cancer characteristics. 
BMC Res Notes, 2014. 7: p. 216. 
98. Bao, P.P., et al., Association of hormone-related characteristics and breast cancer risk by 
estrogen receptor/progesterone receptor status in the shanghai breast cancer study. Am J 
Epidemiol, 2011. 174(6): p. 661-71. 
99. Rosenberg, L., et al., Oral contraceptive use and estrogen/progesterone receptor-
negative breast cancer among African American women. Cancer Epidemiol Biomarkers 
Prev, 2010. 19(8): p. 2073-9. 
100. Beaber, E.F., et al., Recent oral contraceptive use by formulation and breast cancer risk 
among women 20 to 49 years of age. Cancer Res, 2014. 74(15): p. 4078-89. 
101. Beaber, E.F., et al., Oral contraceptives and breast cancer risk overall and by molecular 
subtype among young women. Cancer Epidemiol Biomarkers Prev, 2014. 23(5): p. 755-
64. 
102. Veneroso, C., R. Siegel, and P.H. Levine, Early age at first childbirth associated with 
advanced tumor grade in breast cancer. Cancer Detect Prev, 2008. 32(3): p. 215-23. 
103. Li, C.I., et al., Trends in incidence rates of invasive lobular and ductal breast carcinoma. 
Jama, 2003. 289(11): p. 1421-4. 
104. Slanger, T.E., et al., Menopausal hormone therapy and risk of clinical breast cancer 
subtypes. Cancer Epidemiol Biomarkers Prev, 2009. 18(4): p. 1188-96. 
105. Rosenberg, L.U., et al., Menopausal hormone therapy in relation to breast cancer 
characteristics and prognosis: a cohort study. Breast Cancer Res, 2008. 10(5): p. R78. 
106. Cui, Y., et al., Interactions of hormone replacement therapy, body weight, and bilateral 
oophorectomy in breast cancer risk. Clin Cancer Res, 2014. 20(5): p. 1169-78. 
107. Collins, L.C., et al., Pathologic features and molecular phenotype by patient age in a 
large cohort of young women with breast cancer. Breast Cancer Res Treat, 2012. 131(3): 
p. 1061-6. 
108. Bauer, K.R., et al., Descriptive analysis of estrogen receptor (ER)-negative, progesterone 
receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-
negative phenotype: a population-based study from the California cancer Registry. 
Cancer, 2007. 109(9): p. 1721-8. 
 138 
 
109. Stead, L.A., et al., Triple-negative breast cancers are increased in black women 
regardless of age or body mass index. Breast Cancer Res, 2009. 11(2): p. R18. 
110. Ambrosone, C.B., et al., Associations between estrogen receptor-negative breast cancer 
and timing of reproductive events differ between African American and European 
American women. Cancer Epidemiol Biomarkers Prev, 2014. 23(6): p. 1115-20. 
111. Chen, L., et al., Body mass index and risk of luminal, HER2-overexpressing, and triple 
negative breast cancer. Breast Cancer Res Treat, 2016. 157(3): p. 545-54. 
112. Borgquist, S., et al., Anthropometric factors in relation to different tumor biological 
subgroups of postmenopausal breast cancer. Int J Cancer, 2009. 124(2): p. 402-11. 
113. Canchola, A.J., et al., Body size and the risk of postmenopausal breast cancer subtypes in 
the California Teachers Study cohort. Cancer Causes Control, 2012. 
114. Vona-Davis, L., et al., Triple-negative breast cancer and obesity in a rural Appalachian 
population. Cancer Epidemiol Biomarkers Prev, 2008. 17(12): p. 3319-24. 
115. Maiti, B., et al., The association of metabolic syndrome with triple-negative breast 
cancer. Breast Cancer Res Treat, 2009. 
116. Rosenberg, L.U., et al., Menopausal hormone therapy and other breast cancer risk 
factors in relation to the risk of different histological subtypes of breast cancer: a case-
control study. Breast Cancer Res, 2006. 8(1): p. R11. 
117. Daling, J.R., et al., Relation of body mass index to tumor markers and survival among 
young women with invasive ductal breast carcinoma. Cancer, 2001. 92(4): p. 720-9. 
118. Brinton, L.A., et al., Anthropometric and hormonal risk factors for male breast cancer: 
male breast cancer pooling project results. J Natl Cancer Inst, 2014. 106(3): p. djt465. 
119. Kabat, G.C., et al., Smoking and alcohol consumption in relation to risk of triple-negative 
breast cancer in a cohort of postmenopausal women. Cancer Causes Control, 2011. 
22(5): p. 775-83. 
120. Manjer, J., et al., Smoking associated with hormone receptor negative breast cancer. Int J 
Cancer, 2001. 91(4): p. 580-4. 
121. Suzuki, R., et al., Alcohol and postmenopausal breast cancer risk defined by estrogen 
and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst, 2005. 
97(21): p. 1601-8. 
122. Suzuki, R., et al., Alcohol intake and risk of breast cancer defined by estrogen and 
progesterone receptor status--a meta-analysis of epidemiological studies. Int J Cancer, 
2008. 122(8): p. 1832-41. 
123. Lew, J.Q., et al., Alcohol and risk of breast cancer by histologic type and hormone 
receptor status in postmenopausal women: the NIH-AARP Diet and Health Study. Am J 
Epidemiol, 2009. 170(3): p. 308-17. 
124. Li, C.I., et al., The relationship between alcohol use and risk of breast cancer by 
histology and hormone receptor status among women 65-79 years of age. Cancer 
Epidemiol Biomarkers Prev, 2003. 12(10): p. 1061-6. 
125. Chatterjee, N., A two-stage regression model for epidemiologic studies with multivariate 
disease classification data. J American Statistical Association, 2004. 99(465): p. 127-
138. 
126. Miao, J., et al., Analysis of Multivariate Disease Classification Data in the Presence of 
Partially Missing Disease Traits. J Biom Biostat, 2014. 5. 
127. Sherman, M.E., et al., Variation in breast cancer hormone receptor and HER2 levels by 
etiologic factors: a population-based analysis. Int J Cancer, 2007. 121(5): p. 1079-85. 
 139 
 
128. Berndt, S.I., et al., Transforming growth factor beta 1 (TGFB1) gene polymorphisms and 
risk of advanced colorectal adenoma. Carcinogenesis, 2007. 28(9): p. 1965-70. 
129. Moore, L.E., et al., GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced 
colorectal adenoma. Cancer Epidemiol Biomarkers Prev, 2005. 14(7): p. 1823-7. 
130. Hou, L., et al., CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use, and 
risk for colorectal adenoma. Carcinogenesis, 2005. 26(6): p. 1122-8. 
131. Show classification by ER/PR, and molecular, and grade? 
132. Allen-Brady, K., et al., Lobular breast cancer: excess familiality observed in the Utah 
Population Database. Int J Cancer, 2005. 117(4): p. 655-61. 
133. Mavaddat, N., et al., Familial relative risks for breast cancer by pathological subtype: a 
population-based cohort study. Breast Cancer Res, 2010. 12(1): p. R10. 
134. Li, C.I., A.J. Littman, and E. White, Relationship between age maximum height is 
attained, age at menarche, and age at first full-term birth and breast cancer risk. Cancer 
Epidemiol Biomarkers Prev, 2007. 16(10): p. 2144-9. 
135. Nagatsuma, A.K., et al., Impact of recent parity on histopathological tumor features and 
breast cancer outcome in premenopausal Japanese women. Breast Cancer Res Treat, 
2013. 138(3): p. 941-50. 
136. McTiernan, A., et al., Risk factors for estrogen receptor-rich and estrogen receptor-poor 
breast cancers. J Natl Cancer Inst, 1986. 77(4): p. 849-54. 
137. Stanford, J.L., et al., A case-control study of breast cancer stratified by estrogen receptor 
status. Am J Epidemiol, 1987. 125(2): p. 184-94. 
138. Cooper, J.A., et al., Risk factors for breast cancer by oestrogen receptor status: a 
population-based case-control study. Br J Cancer, 1989. 59(1): p. 119-25. 
139. Nasca, P.C., et al., Alcohol consumption and breast cancer: estrogen receptor status and 
histology. Am J Epidemiol, 1994. 140(11): p. 980-8. 
140. Potter, J.D., et al., Progesterone and estrogen receptors and mammary neoplasia in the 
Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer 
Epidemiol Biomarkers Prev, 1995. 4(4): p. 319-26. 
141. Yoo, K.Y., et al., Breast cancer risk factors according to combined estrogen and 
progesterone receptor status: a case-control analysis. Am J Epidemiol, 1997. 146(4): p. 
307-14. 
142. Morabia, A., et al., Relation of smoking to breast cancer by estrogen receptor status. Int J 
Cancer, 1998. 75(3): p. 339-42. 
143. Wohlfahrt, J., et al., Reproductive risk factors for breast cancer by receptor status, 
histology, laterality and location. Int J Cancer, 1999. 81(1): p. 49-55. 
144. Enger, S.M., et al., Body size, physical activity, and breast cancer hormone receptor 
status: results from two case-control studies. Cancer Epidemiol Biomarkers Prev, 2000. 
9(7): p. 681-7. 
145. Huang, W.Y., et al., Hormone-related factors and risk of breast cancer in relation to 
estrogen receptor and progesterone receptor status. Am J Epidemiol, 2000. 151(7): p. 
703-14. 
146. Britton, J.A., et al., Risk of breast cancer classified by joint estrogen receptor and 
progesterone receptor status among women 20-44 years of age. Am J Epidemiol, 2002. 
156(6): p. 507-16. 
 140 
 
147. Li, C.I., K.E. Malone, and J.R. Daling, Differences in breast cancer hormone receptor 
status and histology by race and ethnicity among women 50 years of age and older. 
Cancer Epidemiol Biomarkers Prev, 2002. 11(7): p. 601-7. 
148. Chen, W.Y., et al., Association of hormone replacement therapy to estrogen and 
progesterone receptor status in invasive breast carcinoma. Cancer, 2004. 101(7): p. 
1490-500. 
149. Chu, K.C., et al., Frequency distributions of breast cancer characteristics classified by 
estrogen receptor and progesterone receptor status for eight racial/ethnic groups. 
Cancer, 2001. 92(1): p. 37-45. 
150. Clarke, C.A., et al., Age-specific incidence of breast cancer subtypes: understanding the 
black-white crossover. J Natl Cancer Inst, 2012. 104(14): p. 1094-101. 
151. Redondo, C.M., et al., Breast feeding, parity and breast cancer subtypes in a spanish 
cohort. PLoS One, 2012. 7(7): p. e40543. 
152. Iodice, S., et al., ABO blood group and cancer. Eur J Cancer, 2010. 46(18): p. 3345-50. 
153. Milne, R.L., et al., Oral contraceptive use and risk of early-onset breast cancer in 
carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol 
Biomarkers Prev, 2005. 14(2): p. 350-6. 
154. Iodice, S., et al., Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 
carriers: a meta-analysis. Eur J Cancer, 2010. 46(12): p. 2275-84. 
155. John, E.M., et al., The Breast Cancer Family Registry: an infrastructure for cooperative 
multinational, interdisciplinary and translational studies of the genetic epidemiology of 
breast cancer. Breast Cancer Res, 2004. 6(4): p. R375-89. 
156. John, E.M., et al., Medical radiation exposure and breast cancer risk: findings from the 
Breast Cancer Family Registry. Int J Cancer, 2007. 121(2): p. 386-94. 
157. Fornetti, J., et al., Mammary gland involution as an immunotherapeutic target for 
postpartum breast cancer. J Mammary Gland Biol Neoplasia, 2014. 19(2): p. 213-28. 
158. Callihan, E.B., et al., Postpartum diagnosis demonstrates a high risk for metastasis and 
merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res 
Treat, 2013. 138(2): p. 549-59. 
159. Lyons, T.R., et al., Postpartum mammary gland involution drives progression of ductal 
carcinoma in situ through collagen and COX-2. Nat Med, 2011. 17(9): p. 1109-15. 
160. Anderson, W.F., I. Jatoi, and S.S. Devesa, Distinct breast cancer incidence and 
prognostic patterns in the NCI's SEER program: suggesting a possible link between 
etiology and outcome. Breast Cancer Res Treat, 2005. 90(2): p. 127-37. 
161. Bernards, R. and R.A. Weinberg, A progression puzzle. Nature, 2002. 418(6900): p. 823. 
162. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 
epidemiological studies in 30 countries, including 50302 women with breast cancer and 
96973 women without the disease. Lancet, 2002. 360(9328): p. 187-95. 
163. Lipworth, L., L.R. Bailey, and D. Trichopoulos, History of breast-feeding in relation to 
breast cancer risk: a review of the epidemiologic literature. J Natl Cancer Inst, 2000. 
92(4): p. 302-12. 
164. Jernstrom, H., et al., Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 
mutation carriers. J Natl Cancer Inst, 2004. 96(14): p. 1094-8. 
165. Kahlenborn, C., et al., Oral contraceptive use as a risk factor for premenopausal breast 
cancer: a meta-analysis. Mayo Clin Proc, 2006. 81(10): p. 1290-302. 
 141 
 
166. Grabrick, D.M., et al., Risk of breast cancer with oral contraceptive use in women with a 
family history of breast cancer. Jama, 2000. 284(14): p. 1791-8. 
167. Haile, R.W., et al., BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and 
breast cancer before age 50. Cancer Epidemiol Biomarkers Prev, 2006. 15(10): p. 1863-
70. 
168. Jeng, M.H., C.J. Parker, and V.C. Jordan, Estrogenic potential of progestins in oral 
contraceptives to stimulate human breast cancer cell proliferation. Cancer Res, 1992. 
52(23): p. 6539-46. 
169. Jordan, V.C., et al., The estrogenic activity of synthetic progestins used in oral 
contraceptives. Cancer, 1993. 71(4 Suppl): p. 1501-5. 
170. Yue, W., et al., Effects of estrogen on breast cancer development: Role of estrogen 
receptor independent mechanisms. Int J Cancer, 2010. 127(8): p. 1748-57. 
171. Tryggvadottir, L., H. Tulinius, and G.B. Gudmundsdottir, Oral contraceptive use at a 
young age and the risk of breast cancer: an Icelandic, population-based cohort study of 
the effect of birth year. Br J Cancer, 1997. 75(1): p. 139-43. 
172. Dall, G., G. Risbridger, and K. Britt, Mammary stem cells and parity-induced breast 
cancer protection- new insights. J Steroid Biochem Mol Biol, 2017. 170: p. 54-60. 
173. Brinton, L.A., et al., Oral contraceptives and breast cancer risk among younger women. J 
Natl Cancer Inst, 1995. 87(11): p. 827-35. 
174. Olsson, H., et al., Early oral contraceptive use and premenopausal breast cancer--a 
review of studies performed in southern Sweden. Cancer Detect Prev, 1991. 15(4): p. 
265-71. 
175. Milne, R.L., et al., The potential value of sibling controls compared with population 
controls for association studies of lifestyle-related risk factors: an example from the 
Breast Cancer Family Registry. Int J Epidemiol, 2011. 
176. Ma, H., et al., Breast cancer receptor status: do results from a centralized pathology 
laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev, 2009. 
18(8): p. 2214-20. 
177. Work, M.E., et al., Reproductive risk factors and oestrogen/progesterone receptor-
negative breast cancer in the Breast Cancer Family Registry. Br J Cancer, 2014. 110(5): 
p. 1367-77. 
178. Jordan, V.C., Growth factor regulation by tamoxifen is demonstrated in patients with 
breast cancer. Cancer, 1993. 72(1): p. 1-2. 
179. Ruiz, R., et al., Epidemiology and pathophysiology of pregnancy-associated breast 
cancer: A review. Breast, 2017. 35: p. 136-141. 
180. Collins, L.C., et al., Molecular Phenotype of Breast Cancer According to Time Since Last 
Pregnancy in a Large Cohort of Young Women. Oncologist, 2015. 20(7): p. 713-8. 
181. Johansson, A.L., et al., Family history and risk of pregnancy-associated breast cancer 
(PABC). Breast Cancer Res Treat, 2015. 151(1): p. 209-17. 
182. Pan, H., et al., Reproductive factors and breast cancer risk among BRCA1 or BRCA2 
mutation carriers: results from ten studies. Cancer Epidemiol, 2014. 38(1): p. 1-8. 
183. Andrieu, N., et al., Pregnancies, breast-feeding, and breast cancer risk in the 
International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst, 2006. 98(8): p. 
535-44. 
184. Cullinane, C.A., et al., Effect of pregnancy as a risk factor for breast cancer in 
BRCA1/BRCA2 mutation carriers. Int J Cancer, 2005. 117(6): p. 988-91. 
 142 
 
185. Jernstrom, H., et al., Pregnancy and risk of early breast cancer in carriers of BRCA1 and 
BRCA2. Lancet, 1999. 354(9193): p. 1846-50. 
186. Lee, E., et al., Effect of reproductive factors and oral contraceptives on breast cancer 
risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based 
study. Cancer Epidemiol Biomarkers Prev, 2008. 17(11): p. 3170-8. 
187. Brohet, R.M., et al., Oral contraceptives and breast cancer risk in the international 
BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, 
and the IBCCS Collaborating Group. J Clin Oncol, 2007. 25(25): p. 3831-6. 
188. Narod, S.A., et al., Oral contraceptives and the risk of breast cancer in BRCA1 and 
BRCA2 mutation carriers. J Natl Cancer Inst, 2002. 94(23): p. 1773-9. 
189. Arpino, G., et al., Tumor characteristics and prognosis in familial breast cancer. BMC 
Cancer, 2016. 16(1): p. 924. 
190. Hines, L.M., et al., Differences in estrogen receptor subtype according to family history 
of breast cancer among Hispanic, but not non-Hispanic White women. Cancer Epidemiol 
Biomarkers Prev, 2008. 17(10): p. 2700-6. 
191. McNamara, K.M., et al., Androgen receptor in triple negative breast cancer. J Steroid 
Biochem Mol Biol, 2013. 133: p. 66-76. 
192. Silvera, S.A., A.B. Miller, and T.E. Rohan, Oral contraceptive use and risk of breast 
cancer among women with a family history of breast cancer: a prospective cohort study. 
Cancer Causes Control, 2005. 16(9): p. 1059-63. 
193. Howell, A., et al., Risk determination and prevention of breast cancer. Breast Cancer 
Res, 2014. 16(5): p. 446. 
194. Ellingjord-Dale, M., et al., Alcohol, Physical Activity, Smoking, and Breast Cancer 
Subtypes in a Large, Nested Case-Control Study from the Norwegian Breast Cancer 
Screening Program. Cancer Epidemiol Biomarkers Prev, 2017. 26(12): p. 1736-1744. 
195. McGuire, V., et al., No increased risk of breast cancer associated with alcohol 
consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years. Cancer 





APPENDIX 1: Supplementary Tables and Additional Details of Methodology 
 
 
A. Description of Pseudo-Conditional Likelihood Approach: 
 
Most previous research regarding risk factor and breast cancer tumor characteristics has been via 
case-control design, and the examination of the association between the risk factor(s) of interest 
and the outcome of breast cancer performed using polytomous logistic regression, where the 
outcome of breast cancer is divided into several sub-outcomes defined, for example, by joint ER 
and PR status. Etiologic heterogeneity is measured as the difference in the regression parameters 
across subtype.  The number of regression parameters will be large due to several disease 
characteristics, each with multiple levels [126]. However, with each additional tumor 
characteristic of interest (such as HER2 status and grade), conducting analysis for each subtype 
defined by each characteristic results in loss of statistical power and may be clinically irrelevant. 
For example, an analysis of ER status, PR status, grade, and nodal score using polytomous 
logistic regression yields 14 categorical subtypes (See figure A1-1). As a result, one might 
choose to focus on one or two tumor characteristics; however this method ignores the fact that 
these characteristics are correlated, and that a risk factor’s association with a tumor characteristic 
may in fact be due to that characteristic’s correlation with a different tumor characteristic. 
An alternative analytic technique exists that allows for examination of the association of multiple 
tumor characteristics by specific risk factors. This technique is known as the pseudo-conditional 
likelihood method, and it is an offshoot of polytomous logistic regression [125]. This type of 
regression allows for the adjustment of correlated tumor characteristics, when examining a risk 
factor’s association with a cancer outcome more specifically defined by the presence or absence 
of a tumor marker. Using this method, allows for adjustment of the “dependent” variable side of 
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the equation for correlated tumor characteristics, such that multiple tumor characteristics 




The method allows for the determination of which risk factor associated with several correlated 
tumor characteristics is “most important”. A limitation of the method is that it can only be 
conducted as a case/case analysis, there is no intercept in the model, and therefore no estimate of 
baseline risk.  Additionally, the tumor characteristics must be defined in a binary fashion (e.g. 
high grade vs. low grade, rather than as grade 1, 2, 3). 
Recently, an additional publication has describe a means for performing the pseudo-conditional 






 = β1x1 + β2x2 + έ 
Set of tumor characteristics 
(T): 




Figure A1-1: Example of subtype sample in a categorization of ER Status, PR status, 



































Table A1-1a: Ascertainment criteria for women in the 3 population-based BCFR sites 
identified from 1996-2005 
Geographic Area Greater San Francisco, 
CA, USA 




• Age 18-34: all 
• Age 35-64: at least one 
marker of high or 
familial cancer risk, 
including: 
o Bilateral breast cancer 
dx’d before age 50 
o Previous dx of ovarian 
or childhood cancer 
o 1+ first degree relative 
with breast, ovarian or 
childhood cancer 
• Age 35-64: 2.5% of 
Whites, 15% of 
minorities not meeting 
high risk criteria 
• Age 18-35: all 
• Age 36-54: at least one 
marker of high or familial 
cancer risk, including: 
o Previous diagnosis of 
breast or ovarian cancer 
o 1+ first or 2+ 2nd –
degree relatives with 
breast or ovarian cancer 
o Multiple primary breast 
cancers 
o Breast and ovarian 
cancer 
• Age 55-69: 35% of those 
meeting high risk criteria; 
8.75% of those not 
meeting high risk criteria 
• Age 18-39: all 
• Age 40-49: 50% 
random sample 





Random digit dialing, no 
personal history of breast or 
ovarian cancer; in same 
catchment area as cases 
Random digit dialing, no 
personal history of breast or 
ovarian cancer, in same 
catchment area as cases 
Electoral rolls, no personal 
history of breast or ovarian 
cancer, in same catchment 
area as cases 
 
Table A1-1b: Ascertainment criteria for women in clinic-based BCFR families identified at 3 
sites from 1996-2000  




• Breast or ovarian 
cancer diagnosed at 
age <45 
• Breast and ovarian 
cancer (diagnosed at 
any age) 
• Multiple first or 2nd 
degree relatives with 
breast or ovarian 
cancer 
• BRCA1 or BRCA2 
mutation carrier 
 
• Breast or ovarian 
cancer diagnosed at age 
<35 
• Breast and ovarian 
cancer (diagnosed at 
any age) 
• Bilateral breast cancer 
and 1st diagnosis at age 
<50 
• 2 individuals in 2 
generations with breast 
or ovarian cancer 
• BRCA1 or BRCA2 
mutation carrier 
 
• Breast or ovarian 
cancer diagnosed at 
age <45 
• Breast and ovarian 
cancer (diagnosed at 
any age) 
• Multiple 1st or 2nd 
degree relatives with 
breast or ovarian 
cancer 
• BRCA1 or BRCA2 
mutation carrier 
Relationship to Proband First- second- and third-
degree relative 
First- and –second degree 
relative 
Any relative 
Both Figures Adapted from John, E. et al [155]. “The Breast Cancer Family Registry: an infrastructure for 
cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer” 





Table A1-2: Demographic and Tumor Characteristics by ER status, PR status, and grade, 























47.9±9.5 44.9±9.6 <0.0001 47.5±9.4 46.3±10.1 =0.0006 48.8±9.2 44.5±9.7 <0.0001 
Race           
  White 1415 (58) 525 (56) =0.0003 1352 (60) 588 (53) <0.0001 1160 (59) 780 (57) =0.0004 
  Black 241 (10) 139  (15)  220 (10) 160 (14)  184 (9) 196 (14)  
  Hispanic 254 (10) 104 (11)  215 (10) 143 (13)  220 (11) 138 (10)  
  Asian 478 (20) 148 (16)   426 (19) 200 (18)  383 (19) 243 (18)  
 Other 33 (1) 14  (2)  32 (1) 15 (1)  27 (1) 20 (1)  
Site          
  Ontario 733 (30) 251 (27) =0.002 688 (31) 296 (27) =0.022 604 (31) 380 (27) <0.0001 
  Australia 362 (15) 184 (20)  373 (17) 173 (16)  271 (14) 275 (20)  
  California 1334 (55) 500 (53)  1192 (53) 642 (58)  1105 (56) 729 (53)  
Menopaus
al Status 
         
  Pre 1347 (58) 593 (66) <0.0001 1313 (62) 627 (60) =0.23 1105 (55) 917 (69) <0.0001 
  Post 979 (42) 305 (34)  843 (38) 441 (40)  868 (45) 416 (31)  
Education          
 < High 
school 
685 (29) 273 (29) =0.41 628 (29) 330 (30) =0.17 557 (29) 401 (29) =0.40 
 ≥ High 
school 





         
  No  1693 (70) 679 (73) =0.09 1563 (70) 809 (73) =0.052 1355 (69) 1017 (74) =0.0011 
  Yes 725 (30) 251 (27)  677 (30) 299 (27)  617 (31) 359 (26)  
OC Use          
  Never 673 (28) 205 (23) =0.0011 604 (27) 274 (26) =0.069 577 (28) 301 (21) <0.0001 
  ≤ 5 years 903 (38) 335 (37)  855 (39) 383 (36)  744 (39) 494 (38)  
  > 5 years 804 (34) 356 (40)  754 (34) 406 (38)  632 (33) 528 (41)  
OC Use 
1975 
         
Never Used 
OCs 
673 (28)  205 (23) <0.0001 604 (27) 274 (26) =0.002 577 (30) 301 (23) <0.0001 
Used OC 
before 1975 




609 (26) 310 (35)  578 (26) 341 (32)  421 (22) 498 (38)  
HRT Use          
  Never 1708 (74) 721 (81) <0.0001 1617 (75) 812 (78) =0.24 1351 (72) 1078 (82) <0.0001 
  Former 199 (9) 56 (6)  181 (8) 74 (6)  172 (9) 83 (6)  
  Current 414 (18) 108 (12)  360 (16) 162 (16)  366 (19) 156 (12)  
Age at 
menarche 
         
 ≤ 11 505 (21) 184 (21) =0.55 483 (22) 206 (19) =0.10 400 (21)  289 (22) =0.91 
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  12 582 (24) 215 (24)  533 (24) 264 (25)  483 (25) 314 (24)  
  ≥ 13 1291 (55) 494 (55)  1188 (54) 597 (56)  1063 (55) 722 (54)  
Parity          
  3+ Live 
Births 
805 (33) 326 (35) =0.49 757 (34) 374  (34) =0.66 668 (34) 463 (33) =0.24 
1,2 Live 
Births 
1064 (44) 399 (43)  979 (43) 484 (44)  876 (44) 587 (42)  
  
Nulliparous 
560 (23) 210 (22)  517 (23) 253 (23)  436 (22) 334 (24)  
Age at first 
birth 




         
  Never 1123 (47) 470 (51) =0.058 1035 (46) 558 (51) =0.022 928 (47) 665 (49) =0.53 
  <12 mos. 758 (32) 262 (29)  696 (31) 324 (30)  607 (31) 413 (30)  
  ≥ 12 
mos. 




         
  
Nulliparous 




















         
 
Nulliparous 
428 (18) 154 (16) <0.0001 396 (18) 186 (17) =0.056 324 (16) 258 (19) <0.0001 
≤10 years 557 (23) 286 (31)  540 (24) 303 (27)  412 (21) 431 (31)  
>10 yrs, ≤
20 yrs 
571(25) 201 (21)  538 (24) 234 (21)  459 (23) 313 (23)  
> 20 years 873 (39) 294 (31)  779 (35) 388 (35)  785 (40) 382 (28)  
Smoking          
  Never 
Smoker 
1450 (57) 566 (58) =0.32 1348 (60) 668 (61) =0.78 1181 (60) 835 (61) =0.39 
  Former 
Smoker 
588 (26) 204 (24)  539 (24) 253 (23)  483 (25) 309 (23)  
 Current 
Smoker 
375 (17) 155 (18)  352 (16) 178 (16)  305 (15) 225 (16)  
Alcohol 
Use 
         
Never 1407 (59) 545 (60) =0.28 1281 (58) 671 (62) =0.07 1156 (59) 796 (59) =0.93 
<7 
drinks/week 





386 (16) 128 (14)  363 (16) 151 (14)  301 (15) 213 (16)  
BMI  26.2 26.3 =0.45 26.1 26.5 =0.056 26.1 26.4 =0.19 
BRCA1 
status 
         
missing 723 (30) 264 (28) <0.0001 677 (30) 310 (28) <0.0001 576 (29) 411 (30) <0.0001 
positive 18 (1) 67 (7)  18 (1) 67 (6)  11 (1) 74 (5)  





      
missing 913 (38) 323 (35) =0.23 844 (37) 392 (35) =0.44 737 (37) 499 (36) =0.006 
positive 54 (2) 19 (2)  47 (2) 26 (2)  25 (1) 48 (3)  





Table A1-3:  Frequency Table of Risk factors by birth cohort, BCFR Population-based Sites 
 Year of birth 


















N (%) N (%) N (%) N (%) 
Age (µ± s.d.) 60.5±2.9 63.6±3.2 51.8±3.6 53.8±3.0 42.8±3.7 44.9±3.1 32.9±3.7 33.6±4.3 
Study Site     
Australia 85 (14) 96 (21) 302 (20) 222 (23) 336 (28) 191 (20) 206 (28) 159 (25) 
Ontario 193 (31) 274 (61) 443 (31) 518 (55) 315 (26) 586 (61) 137 (19) 328 (51) 
California 350 (56) 80 (18) 701 (48) 211 (22) 554 (46) 181 (19) 389 (53) 151 (24) 
First degree 
family history 
    
  No  364 (58) 400 (89) 980 (68) 851 (89) 905 (75) 879 (92) 637 (87) 602 (95) 
  Yes 263 (42) 50 (11) 462 (32) 100 (11) 294 (25) 78 (8) 92 (13) 35 (5) 
OC Use     
  Never 270 (45) 210 (47) 335 (24) 214 (23) 273 (23) 139 (15) 141 (20) 83(13) 
  ≤ 5 years 201 (33) 139 (31) 594 (42) 382 (40) 440 (37) 384 (40) 241 (34) 212 (26) 
  > 5 years 133 (22) 99 (22) 487 (34) 352 (37) 467 (40) 430 (45) 329 (46) 335 (53) 
mean length OC 
use (yrs) among 
users 
5.78 6.07 6.39 6.30 7.29 7.02 7.24 7.29 
Year of first OC 
use 
    
Never 270 (45) 210 (47) 335 (24) 214 (23) 273 (23) 139 (15) 141 (20) 83 (13) 
Before 1975 312 (52) 231(52) 1008 (71) 697 (73) 478 (41) 505 (53) 1 (0) 2 (0) 
1975 or later 22 (4) 7 (2) 73 (5) 37 (4) 429 (36) 309 (32) 569 (80) 545 (87) 
Age (yrs) at first 
OC use (mean) 
28.9±5.3 29.4±5.4 22.8±4.2 22.5±3.7 20.8±4.6 20.2±4.3 19.8±4.3 19.2±3.8 
% of OC users 
starting after 
first live birth 
266 
(74%) 
198 (83%) 500 (45%) 432 (41%) 315 (34%) (230) 28% 254 (43%) 195 (35%) 
Age at menarche     
 ≤ 11 111 (18) 71 (16) 303 (21) 205 (22) 271 (23) 192 (20) 133 (19) 130 (21) 
  12 145 (24) 91 (20) 314 (22) 216 (23) 290 (25) 245 (26) 200 (28) 159 (25) 
  ≥ 13 352 (58) 284 (64) 795 (56) 519 (55) 615 (52) 509 (54) 376 (53) 341(54) 
Parity     
  Parous 535 (85) 408 (91) 1185 (82) 837 (88) 935 (78) 796 (83) 454 (62) 425 (67) 
  Nulliparous 93 (15) 42 (9) 261 (18) 114 (12) 270 (22) 162 (17) 278 (38) 213 (33) 
Age at first live 
birth 
23.6 24.0 24.5 24.2 26.1 25.4 25.6 25.8 
Breastfeeding  
(among parous) 
    
  Never 193 (36) 116 (28) 425 (36) 285 (34) 227 (24) 198 (25) 80 (18) 68 (16) 
  Ever 337 (64) 292 (72) 754 (64) 552 (66) 704 (76) 598 (75) 370 (82) 357 (84) 
% with 3+ Live 
births, no BF 
33% 25% 29% 27% 19% 19% 12% 10% 
Median dur. BF 
(mos) 
8.5 11.5 9.0 9.0 11.5 11.5 8.5 9.5 
Avg. Parity 
(among parous) 




Smoking     
  Never Smoker 347 (56) 220 (49) 833 (58) 511 (54) 723 (60) 461 (48) 476 (65) 350 (55) 
  Former Smoker 194 (31) 165 (37) 369 (26) 290 (30) 277 (23) 318 (33) 117 (16) 146 (23) 
 Current Smoker 80 (13) 63 (14) 232 (16) 150 (16) 196 (16) 178 (19) 137 (19) 142 (22) 
Alcohol Use     
Nondrinkers 357 (58) 223 (51) 796 (56) 505 (53) 697 (59) 474 (50) 445 (61) 336 (53) 
<7 drinks/week 143 (23) 118 (27) 374 (26) 262 (28) 304 (26) 302 (32) 181 (25) 208 (33) 
≥ drinks/week 113 (18) 98 (22) 257 (18) 179 (19) 182 (15) 171 (18) 99 (14) 93 (15) 
Menopausal 
status 
    
Premenopausal 47 (7) 3(1) 562(41) 216 (14) 1010 (90) 738 (89) 707 (98) 609 (98) 
Postmenopausal 581 (93) 447 (99) 803 (59) 710 (56) 112 (10) 95 (11) 17 (2) 10 (2) 
ER/PR status     
ER+ and/or PR+ 518 (82) 1161 (80) 833 (69) 499 (68) 
ER-PR- 110 (18) 285 (20) 292 (31) 233 (32) 
Tumor Grade     
  1, 2 382 (71) 796 (66) 534  (54) 268 (42) 
  3 156 (29) 408 (34) 452 (46) 368 (58) 
BRCA1 status     
Status missing 195 520 414 135 
BRCA1 positive 4 (1) 19 (2) 31 (4) 41 (7) 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table A1-5: Association among oral contraceptive use, parity and breastfeeding and breast 
cancer classified by molecular status, Breast Cancer Family Registry (compared with Luminal 
A cases, N=470) 






OR (95%CI) OR (95%CI) OR (95%CI) 
OC use    
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  ≤ 5 years 0.85 (0.50-1.46) 1.34 (0.66-2.71) 1.24 (0.72-2.12) 
  > 5 years 0.84 (0.49-1.44) 1.61 (0.81-3.20) 1.73(1.03-2.90) 
Timing of first OC    
Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Before 1975 0.94 (0.54-1.63) 1.11 (0.54-2.28) 1.15 (0.67-1.95) 
1975 or later 0.77 (0.43-1.39) 1.69 (0.78-3.68) 2.17 (1.10-3.94) 
Parity (number of 
live births) 
   
  Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  1-2 1.42 (0.72-2.83) 3.48 (1.30-9.48) 2.08 (1.08-4.01) 
  ≥3  1.29 (0.59-2.80) 2.85 (0.97-8.42) 2.72 (1.33-5.55) 
Breastfeeding 
duration (months) 
   
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 
  <12 0.78 (0.44-1.41) 0.70 (0.35-1.39) 0.48 (0.28-0.81) 
  ≥12 1.10 (0.57-2.09) 0.76 (0.35-1.68) 0.56 (0.31-1.01) 
Breastfeeding and 
parity 
   
  Nulliparous 1.0 (ref) 1.0 (ref) 1.0 (ref) 
1-2 live births, 
never BF 
1.38 (0.66-2.89) 3.37 (1.21-9.40) 2.44 (1.24-4.82) 
≥3 live births, 
never BF 
1.28 (0.42-3.16) 3.01 (0.92-9.86) 2.10 (0.93-4.76) 
1-2 live births, 
some BF 
1.25 (0.67-2.33) 2.61 (1.03-6.61) 0.93 (0.48-1.79) 
≥3 lives births, 
some BF 
1.23 (0.58-2.58) 2.10 (0.93-4.76) 1.80 (0.89-3.62) 
Note: Odds ratios (OR) and 95% confidence interval (CI), adjusted for age, race, study site, and menopausal status. OC findings 
adjusted for breastfeeding and parity; parity findings adjusted for OC use and breastfeeding; breastfeeding findings adjusted for 
OC use and parity, combined parity-breastfeeding findings adjusted for OC use. 




Table A1-6: Demographic and Tumor Characteristics by ER status, PR status, and grade, 





















Age (µ± s.d) 50.5±12.4 44.0±10.3 <0.0001 49.5±12.1 46.1±11.9 =0.002 51.0±12.9 45.6±10.7 <0.0001 
Race           
  White 216 (75) 116 (67) =0.30 205 (75) 127 (68) =0.39 170 (77) 162 (67) =0.005 
  Black 5 (2) 6  (3)  6 (2) 5 (3)  2 (1) 9 (4)  
  Hispanic 51 (18) 36 (21)  45 (16) 42 (22)  30 (14) 57 (24)  
  Asian 7 (2) 7 (3)   7 (3) 6 (3)  6 (3) 7 (3)  
 Other 10 (3) 8 (5)  11 (4) 7 (4)  12 (5) 6 (3)  
Site          
 Philadelphia NA NA =0.082 NA NA =0.13 NA NA =0.82 
  New York 256 (79) 135 (72)  242 (79) 152 (73)  187 (77) 207 (756  
  Utah 70 (21) 54 (28)  65 (21) 56 (27)  56 (23) 65 (24)  
Menopausal 
Status 
         
  Pre 116 (36) 90 (48) =0.007 114 (37) 92 (44) =0.11 88 (36) 118 (44) =0.10 
  Post 210 (64) 99 (52)  193 (63) 116 (56)  155 (64) 154 (56)  
Education          
  High school 79 (26) 42 (22) =0.005 72 (25) 49 (24) =0.012 49 (21) 72 (28) =0.216 
 > High 
school 




         
  None  120 (41) 97 (56) =0.025 116 (42) 101 (54) =0.081 89 (40) 128 (53) =0.025 
  1 FDR 116 (40) 56 (32)  109 (40) 63 (34)  92 (41) 80 (33)  
  2+ FDR 54 (19) 20 (12)  50 (18) 24 (12)  39 (19) 35 (14)  
OC Use          
  Never 126 (49) 42 (28) =0.002 117 (48) 51 (31) =0.002 96 (50) 72 (33) =0.002 
  ≤ 5 years 81 (31) 62 (42)  78 (32) 65 (40)  59 (31) 84 (39)  
  > 5 years 51 (20) 45 (30)  48 (20) 48 (29)  36 (19) 60 (28)  
 
OC Use 1975 
         
Never Used 
OCs 
126 (44) 42 (24) <0.0001 117 (43) 51 (27) <0.001 96 (44) 72 (30) =0.0016 
Used OC 
before 1975 
96 (33) 64 (37)  95 (35) 65 (35)  75 (34) 85 (35)  
Used OC 
1975 or later 
66 (23) 67 (39)  61 (22) 72 (38)  48 (22) 85 (35)  
HRT Use          
  Never 210 (74) 134 (79) =0.0009 201 (74) 143 (78) =0.005
2 
144 (67) 200 (83) =0.0001 
  Former 72 (25) 26 (15)  67 (25) 31 (17)  65 (30) 33 (14)  
  Current 3 (1) 10 (6)  3 (1) 10 (5)  6 (3) 7 (3)  
Age at 
menarche 
         
 ≤11 55 (19) 27 (14) =0.400 56 (20) 26 (14) =0.215 47 (21) 35 (13) =0.280 
  12 90 (31) 59 (31)  84 (30) 65 (34)  63 (29) 86 (32)  
  ≥13 146 (50) 107 (55)  136 (50) 99 (52)  111 (50) 151 (55)  
Parity          





140 (46) 90 (48)  129 (45) 101 (50)  104 (45) 126 (49)  
 3+ Live 
Births 
114 (38) 60 (32)  106 (37) 68 (34)  87 (37) 87 (34)  
Age at first 
birth 
25.4±5.5 25.1±5.0 =0.63 25.1±5.2 24.9±5.1 =0.22 25.1±4.7 25.5±5.6 =0.43 
Breastfeeding 
duration 
         
  Never 125 (44) 84 (49) =0.069 122 (45) 87 (46) =0.166 90 (41) 119 (49) =0.171 
  <12 mos. 95 (33) 64 (37)  88 (32) 71 (38)  78 (36) 81 (33)  
  ≥12 mos. 67 (23) 25 (14)    62 (23) 30 (16)  50 (23) 42 (17)  
Parity and 
Breastfeeding 
         
  Nulliparous 49 (21) 38 (27) =0.224 53 (23) 34 (22) =0.588 42 (23) 45 (23) =0.200 
1,2 live births 
no BF 
45 (19) 33 (23)  41 (18) 37 (24)  30 (17) 48 (24)  
3+ live births 
no BF 
35 (15) 16 (11)  31 (14) 20 (13)  21 (12) 30 (15)  
1,2 live births, 
some BF 
32 (13) 11 (8)  29 (13) 14 (9)  24 (13) 19 (10)  
3+ live births, 
some BF 
77 (32) 44 (31)  73 (32) 48 (31)  64 (35) 57 (29)  
Time since 
last live birth 
         
 Nulliparous 49 (17) 37 (23) =0.054 53 (19) 33 (19) =0.923 42 (19) 44 (19) =0.003 
≤5 years 29 (10) 22 (14)  28 (10) 23 (13)  17 (8) 34 (15)  
>5 yrs, ≤10 
yrs 
30 (11) 24 (15)  34 (12) 20 (11)  20 (9) 34 (14)  
>10 yrs, ≤20 
yrs 
74 (26) 41 (25)  70 (26) 45 (26)  51 (24) 64 (27)  
>20 yrs 104 (36) 39 (24)  88 (32) 55 (31)  86 (40) 57 (24)  
Smoking          
 Never 
Smoker 
167 (57) 110 (62) =0.512 159(57) 118 (61) =0.678 129 (58) 148 (60) =0.922 
 Former 
Smoker 
109 (37) 60 (34)  104 (38) 65 (34)  82 (37) 87 (35)  
 Current 
Smoker 
16 (5) 7 (4)  14 (5) 9 (5)  11 (5) 12 (5)  
Alcohol Use          
Non-drinker 162(56) 105 (60) =0.495 155 (56) 112 (59) =0.586 126 (57) 141(58) =0.428 
Former 
drinker 
53(18) 34 (19)  50 (18) 37 (19)  37 (17) 50 (20)  
Current 
drinker 
75 (26) 37 (21)  71 (26) 41 (22)  58 (26) 54 (22)  
BMI  25.6±5.2 25.9±5.2 =0.496 25.5±5.3 25.9±5.1 =0.482 25.0±4.5 26.3 ±5.8 =0.007 
BRCA1 
status 
         
missing 69 (21) 32 (17) <0.0001 62 (20) 39 (19) <0.000
1 
52 (21) 49 (18) <0.0001 
positive 11 (3) 44 (23)  12 (4) 43 (21)  7 (3) 48 (18)  





      
missing 66 (20) 40 (21) =0.682 59 (19) 47 (23) =0.593 46 (19) 60 (22) =0.076 
positive 23 (7) 17 (9)  23 (7) 17 (8)  13 (5) 27 (10)  





Table A1-7: Sensitivity Analysis: Parity and ER/PR status 
 
*Adjusted for age, center, parity, oral contraceptive use, race, breastfeeding, menopausal status, family history 
 
 ER+PR+ǂ ER-PR-ǂ 
OR (95%CI) OR (95%CI) 
Cases with Age at Interview ≤ 2 years after Diagnosis, vs. 
Controls 
Parity, LOGISTIC, N=210 N=117 
  Nulliparity 1.0 (ref) 1.0 (ref) 
  1-2 live births 1.04 (0.65-1.67) 2.02 (1.11-3.66) 
  ≥3 live births 0.99 (0.58-1.67) 1.78 (0.89-3.56) 
Cases with Age at Interview ≤ 5 years after Diagnosis, vs. 
Controls 
Parity, LOGISTIC  N=304 N=167 
  Nulliparity 1.0 (ref) 1.0 (ref) 
  1-2 live births 1.31 (0.87-1.97) 2.20 (1.32-3.69) 
  ≥3 live births 1.15 (0.73-1.82) 2.22 (1.23-4.00) 
Cases with Age at Interview at any Date after Diagnosis (full 
case sample) 
Parity, LOGISTIC  N=377 N=219 
Nulliparous 1.0 (ref) 1.0 (ref) 
  1-2 live births 1.63 (1.13-2.36) 1.90 (1.20-3.00) 
  ≥3 live births 1.35 (0.90-2.19) 1.85 (1.09-3.13) 
Cases vs. Controls, BRCA1+ and BRCA2+ omitted 
Parity, LOGISTIC  N=334 N=146 
Nulliparous 1.0 (ref) 1.0 (ref) 
  1-2 live births 1.54 (1.05-2.27) 2.18 (1.27-3.75) 
  ≥3 live births 1.32 (0.85-2.04) 1.93 (1.03-3.61) 
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